

















































Cancer& immunotherapy& strategies& based& on& lentiviral& vector& (lentivector)&
transduction& have& recently& been& shown& to& be& safe& and& effective& in& the& clinic.& The&
objective& of& cancer& immunotherapy& is& to& induce& antiFcancer& immune& responses.&
Cytotoxic&T&cell&(CTL)&responses&are&particularly&effective&at&recognizing&and&eradicating&
cancer& cells& and& their& activation& is& the&main&objective&of&most& cancer& immunotherapy&
treatments.& Effective& CTL& responses& depend& on& activation& by& antigen& presenting& cells&
(APCs),&presenting&tumourFassociated&antigens&(TAAs)&in&the&context&of&appropriate&coF
stimulatory& and& cytokine& signals.& In& general,& cancer& immunotherapy& has& largely& been&
ineffective& due& to& tumourFinduced& immune& suppression.& One& immunosuppressive&
mechanism& employed& by& tumours& relies& on& the& accumulation& of& tumourFinfiltrating&
myeloidFderived&suppressor&cells&(MDSCs).&Effective&cancer&immunotherapy&treatments&
therefore& need& to& stimulate& tumourFspecific& CTLs& as&well& as& counteract& the& activity& of&
tumourFinfiltrating&immunosuppressive&cells.&
The& first& part& of& this& thesis& is& based& on& the& construction& and& evaluation& of&
lentivector& vaccines.& The& lentivector& vaccines& simultaneously& expressed& TAAs& and&
cytokines,& combined&with&silencing&of& the&coFinhibitory&molecule&programmed&death&1&
ligand&1& (PDFL1).&A& collection&of& lentivector&vaccines&expressing&an&array&of&different&T&




tumours& in& mice.& Ex# vivo& MDSC& phenotype,& differentiation,& and& immunosuppressive&
activities& were& extensively& studied.& The& novel& ex# vivo& melanoma&MDSCs&were& further&
used& to& evaluate& the& lentivector& vaccines& generated& in& the& first& part& of& this& thesis.&
Simultaneous&delivery&of&IL12&and&a&PDFL1Fsilencing&microRNA&was&the&only&combination&
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Ever& since& immunotherapy& and& vaccination& were& successfully& applied& against&
infectious&diseases&have&immunologists&been&dreaming&of&applying&the&same&strategies&
to& the& fight& against& cancer.& In& this& way,& the& immune& system& could& effectively& and&
specifically& target& cancer& cells,& leading& to& longFterm& immunological& memory& and&
prevention& of& tumour& reFestablishment.& These& hopes& have& largely& been& unfulfilled& as&
cancer&immunotherapy&strategies&and&vaccinations&have&been&rather&unsuccessful&in&the&
clinic,& especially& concerning& nonFvirally& induced& cancers.& Cancer& cells& derive& from& the&
host’s& own& cells& and& thus& cancer& immunotherapy& strategies& have& to& break&
immunological& tolerance& to& selfFantigens& to& raise& cancerFspecific& immune& responses.&





to& effectively& eliminate& tumours& (Rosenberg,& Sherry& et& al.& 2005;& Boon,& Coulie& et& al.&
2006).& Once& cancerFspecific& effector& cells& have& been& raised,& they& are& frequently&




distinct&and&harmful& to& the&organism& they&belong& to.& This& view& is&emphasized&by& such&
statements&as& the&following:&“In&the& last&10&years,& it&has&become&evident&that&a& tumor&









Due& to& the& complexity&of& cancer&and& the&difficulty&of& treating&and&curing& these&
malignancies& there& exists& a& high,& unmet& medical& demand& to& find& more& targeted& and&
effective&therapies.&Current&treatments&are&accompanied&by&serious&adverse&events&and&
more&targeted&therapies&are&needed&to&circumvent&collateral&damage&to&healthy&tissues.&
Cancer& is& such& a& difficult& disease& to& treat& because& cancer& cells& develop& from& normal&
tissues&and&retain&a&high&similarity&to&the&tissue&they&develop&from.&The&difficulty&lies&in&
finding&treatments&that&can&distinguish&such&similar&nonFtransformed&cells.&Our&immune&
system& remains& the& most& effective& and& sophisticated& system& to& distinguish& and& fight&
diseaseFcausing& processes.& However,& in& the& fight& against& cancer& our& immune& system&
needs&some&extra&help.&
Cancer& Immunology& can& be& viewed& as& one& of& the& most& dynamic& fields& of&
biological&research.&At&the&same&time&it&remains&one&of&the&most&controversial&areas&of&
biology,& in& which& even& basic& concepts& are& still& under& debate.& The& exact& role& of& the&
immune& system& in& cancer& remains& controversial& as& the& relationship& between& immune&
cells& and& cancer& cells& are& highly& complex& and& can& lead& to& various& opposing& effects,&
including&antiFtumour&protection,& tumour&promotion,&or&no&visible&effects&at& all& (Ichim&
2005;&Weinberg&2006).&The& immune&system& is& in&a&precarious&situation&because&under&
physiological& conditions& it& is& crucial& to&maintain& peripheral& tolerance& to& prevent& autoF
immunity& and& initiate& mechanisms& terminating& immune& responses& after& pathogen&
clearance.&However,&peripheral& tolerance&and&the&presence&of& immunosuppressive&cell&
types& in& turn& facilitate& tumour& immune& evasion.& There& is& a& thin& line& separating& overF
reactivity&to&selfFtissues&and&tumour&tolerance,&which&explains&the&duality&of&the&immune&
system&in&respect&to&cancer&responses.&&
Nevertheless,& it& is&now&widely&accepted&that& the& immune&system&can&recognize&
and& eliminate& cancer& cells,& supporting& the& theories& of& cancer& immunosurveillance& and&





Traditionally,& the& hallmarks& of& cancer& were& viewed& as& the& accumulation& of&
genetic& and& epigenetic& mutations& in& genes& regulating& cell& cycle& processes,& including&
proliferation,& replication,& and& apoptosis.& Transformed& cells& could& go& on& to& acquire&
further& mutations& leading& to& tumour& invasion,& angiogenesis,& and& metastasis.& The&
accumulation&of&mutations&in&protoFoncogenes&or&tumourFsuppressor&genes&is&a&gradual&
process.& Thus,& tumours& consist& of& a& heterogeneous& group& of& cancer& cells& at& various&
stages& of& transformation.& Cancer& cells& can& be& subcategorized& into& various& types,&
including&cancer&stem&cells,&cancer&cells,&and& invasive&cancer&cells.&Deregulated&growth&
of&cells&and&metastasis& to&other&organs& interfere&with&the&physiological& function&of& the&
invaded&organs,& leading& to&disease& symptoms& (Hanahan&and&Weinberg&2000;&Hanahan&
and&Weinberg&2011).&
Importantly,&it&has&become&increasingly&clear&that&tumours&do&not&only&consist&of&
transformed& neoplastic& cancer& cells.& Tumour& cells& form& complex& tissues&with&multiple&
cell& types& that&have&been& recruited& to& the&nascent& tumour& site.&NonFtransformed&cells&
within& tumour& tissues& are& generally& termed& the& tumour& stroma.& Cells& of& the& tumour&
stroma&interact&with&each&other&and&with&cancer&cells,&leading&to&the&development&of&the&
tumour&microenvironment.&These&interactions&further&enhance&tumour&development&by&
enhancing& tumour& progression,& vascularization,& immune& evasion,& and& eventually&
metastasis.&Pericytes,&for&example,&play&a&role&in&maintaining&tumour&vasculature&while&
myeloid& cells& aid& in& tumour& angiogenesis& and& immunosuppression.& The& tumour&
microenvironment&hence&contains&several&distinct&cell&types,&including&cancerFassociated&
fibroblasts,& endothelial& cells,& pericytes,& and& cancer& cells& at& various& stages& of&
transformation.&The&tumour&microenvironment&is&further&infiltrated&by&various&types&of&
immune& cells,& exhibiting& both& antiFtumour& effector& and& tumourFpromoting& functions&
(Hanahan&and&Weinberg&2011).&
As& tumour& cells& disrupt& normal& tissue& architecture& tumours& trigger& a& “chronic”&
inflammatory& environment.& In& addition,& tumour& cells& secrete& cytokines& and& growth&
factors& abnormally,& leading& to& further& inflammation& and& recruitment& of& leukocytes& to&
the& microenvironment.& These& tumourFsecreted& factors& suppress& antiFtumour& effector&





turn& increases& the& likelihood& of& acquiring& neoplastic& transformations.& The& constant&
activities&of& recruited&phagocytic& cells& lead& to&an&accumulation&of& reactive&oxygen&and&
nitrogen&species&(ROS&and&RNS)&that&can&damage&DNA,&further&enhancing&the&acquisition&
of& mutations& (Fernandes,& DE& Medeiros& Fernandes& et& al.& 2015).& Thus& it& is& generally&
accepted& that& the& tumour& microenvironment& plays& a& key& role& in& promoting& tumour&
progression.& Chromosomal& instability& of& cancer& cells& is& a& major& factor& contributing& to&
tumour&progression,&leading&to&transformation&of&cells&through&accumulation&of&genetic&
and& epigenetic& mutations.& However,& of& equal& importance& is& the& environment,& using&
chronic& inflammation& and& tolerogenic& immune& responses& for& tumour& initiation,&
progression&and&immune&evasion.&
1.1.2.!CANCER!IMMUNOSURVEILLANCE!




take& place& in& cancer& patients& but& these& TAAFspecific& T& cells& are& mostly& anergic& or&
tolerogenic&due&to&thymic&deletion&of&strongly&autoFreactive&T&cells&and&their&inactivation&
by& several& peripheral& tolerogenic& mechanisms& (Bakker,& Schreurs& et& al.& 1994;& Boon,&
Coulie&et& al.& 2006).&Nonetheless,& the&existence&of&TAAFspecific& responses& indicates& the&
ability&of&the&immune&system&to&recognize&and&potentially&fight&cancer&cells,&paralleling&
its&role&in&infectious&disease.&
The& theory&of& cancer& immunosurveillance&was& first&proposed&by&Paul& Ehrlich& in&
1909,&applying&his&knowledge&of&immune&responses&in&infectious&diseases&to&the&field&of&











for& antiFtumour& responses& in& mice& (Shankaran,& Ikeda& et& al.& 2001;& Teng,& Swann& et& al.&
2008).&Further&studies&using&mice&deficient& in&various&immune&effector&cell&populations&
including& NK& (Natural& killer),& Th1& (T& helper& 1)& or& CTL& (Cytotoxic& T& Lymphocyte)& cells,&





of& cancers& in& immunocompromised& individuals.& Many& of& the& cancers& that& arise& in&
immunocompromised& patients& are& virallyFinduced.& However,& it& is& becoming& clear& now&
that& the& incidence& of& nonFviral& cancers& such& as& melanoma& also& increases& upon&
immunosuppression& (Vajdic& and& van& Leeuwen& 2009;& Vajdic,& van& Leeuwen& et& al.& 2009;&
Hanahan& and&Weinberg& 2011).& Similar& to& the& results& observed& in& nude&mice,& patients&
with&chronically&suppressed&immune&systems&do&not&exhibit&a&higher& incidence&of&nonF
viral& cancers.&Again,& these& individuals&may&be&deficient& in&T&and&B&cell&populations&but&
still&exhibit&functioning&NK&cells&and&other& innate&immune&cell&populations.&All&of&these&
observations& have& augmented& the& controversy& of& the& role& of& the& immune& system& in&
cancer.& These& arguments&may&be&overFsimplified&when&discussing& a& topic& as&wide& and&
complex&as&cancer& immunology&(Hanahan&and&Weinberg&2011).& In&addition,&due&to&the&
lack& of& clinical& efficacy& of& tumour& vaccines& and& other& classical& cancer& immunotherapy&
treatments,& the& theory&of& immunosurveillance& remained&controversial& for& a& long& time.&
Recent& clinical& efficacy& of& new& blocking& antibodies& such& as& immune& checkpoint&
modulators&(Brahmer,&Drake&et&al.&2010;&Topalian,&Hodi&et&al.&2012;&Trinh&and&Hwu&2012)&
and& other& novel& immunotherapeutic& approaches& (Porter,& Levine& et& al.& 2011)& have&
revived& the& field& of& cancer& immunology& and& immunotherapy.& As& the& interactions&
between& the& immune& system& and& cancer& are& highly& complex& and& the& immune& system&
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plays&a&dual& role& in& tumour&progression,& the& field&of& cancer& immunology&will& remain&a&
dynamic&one&for&some&time&to&come&(Schreiber,&Old&et&al.&2011;&Escors&2014).&As& I&will&







is& now& widely& accepted& (Dunn,& Old& et& al.& 2004;& Zitvogel,& Tesniere& et& al.& 2006).& As&
tumours&arise&nonetheless,& it& is&evident&that& in&many&instances&tumours&avoid& immune&
detection& or& develop& mechanisms& to& escape& and& limit& detection.& The& antiFcancer&
immune&response&thus&leads&to&the&selection&of&cancer&cells&that&have&adapted&to&survive&
in& an& immunocompetent& host& (Shankaran,& Ikeda& et& al.& 2001).& This& process& has& been&
termed& cancer& immunoediting& and& consists& of& three& phases;& elimination,& equilibrium,&
and& eventually& escape& (Dunn,& Old& et& al.& 2004).& The& initial& phase& of& recognition& and&
elimination&consists&of& innate&and&adaptive& immune& responses,& correlating& to& immune&
system&functions&in&pathogenFrelated&diseases.&As&the&targets&are&transformed&cells&the&
main& adaptive& immune& responses& employed& to& eliminate& them& are& T& cellFmediated&
cytotoxic& responses.& The& following& paragraphs& summarize& the& antiFtumour& immune&
responses& (Fig.& 1.1),& leading& to& recognition,& elimination,& cancer& immunoediting,& and&
eventually&escape.&
Chronic& inflammation& caused& by& tissue& remodelling& and& disruption& attracts&




and&Weinberg& 2011).& Innate& immune& cells& in& turn&produce& chemokines& and& cytokines,&
















The& initial&antiFtumour&attack&of&the& innate& immune&system&releases&TAAs&from&
necrotic&cancer&cells,&which&is&important&for&the&initiation&of&adaptive&immune&responses&
(Fig.&1.1.B).&Effector&cells&of&the&innate&immune&response&(such&as&NK&cells)&do&not&need&
to& be& activated& by& professional& antigen& presenting& cells& (APCs).& On& the& other& hand,&
effector& cells& of& the& adaptive& immune& response& acquire& effector& activities& upon&
activation& in&the&context&of&appropriate&signals&delivered&by&APCs.&Dendritic&cells& (DCs)&
are& nowadays& considered& to& be& the& main& professional& APCs& regulating& adaptive&
immunity.& DCs& are& also& attracted& to& the& tumour& microenvironment& through&
inflammatory&signals& (Matzinger&1994).&Upon&arrival&DCs& take&up&necrotic&cancer&cells,&
process& TAAs,& mature,& and& migrate& to& tumourFdraining& lymph& nodes& (Fig.& 1.1.B).& In&
tumourFdraining& lymph& nodes& DCs& activate& CD4+& T& cells& by& presenting& TAA& peptides&
complexed& to& major& histocompatibility& complex& (MHC)& II& molecules.& DCs& also& crossF
present&TAA&peptides&complexed&to&MHC&I&molecules&to&CD8+&T&cells&(Huang,&Golumbek&
et&al.&1994;&Lipscomb&and&Masten&2002;&Goold,&Escors&et&al.&2011)(Fig.&1.1.C).&While&CD8+&
T& cells& are& viewed& as& the&main& antiFcancer& effector& cells,& activation& of& CD4+& T& cells& is&
needed&to&efficiently&stimulate&CD8+&T&cells&to&obtain&CTL&activities.&CD4+&T&cells&acquire&








expansion,& and& survival,& reflecting& the& selfFregulatory& mechanisms& of& the& immune&
system.&Th1&cells&in&turn&secrete&mainly&IFNγ,&but&also&IL2&and&IL12,&which&are&important&
for& CTL& differentiation,& expansion& and& survival.& Stimulation& by& Th1& aids& in& the& clonal&
expansion& of& activated& effector& CD8+& T& cells.& In& addition,& Th1& cells& are& needed& for&
differentiation&of&CD8+&memory&T&cells&and&their& reactivation&upon&encounter&with&the&
same& TAAs& (Macatonia,& Hosken& et& al.& 1995;& Schmidt& 2002;& Curtsinger,& Johnson& et& al.&
2003;& Curtsinger,& Lins& et& al.& 2003;& Gerloni& and& Zanetti& 2005;& Knutson& and& Disis& 2005;&
Zaidi&and&Merlino&2011;&Liechtenstein,&Dufait&et&al.&2012).&
Activated& CD4+& and& CD8+& T& cells& infiltrate& tumours& and& kill& cancer& cells& in& an&
antigenFspecific& manner& (Fig.& 1.1.D).& Th1& and& CTL& cells& can& kill& directly& by& IFNγ& (and&




of& cellFmediated& immunity,& and& cancer& cell& recognition& and& elimination.& Secretion& of&
IFNγ&by&T&cells&causes&upFregulation&of&MHC&I&molecules&also&on&tumour&cells,&enhancing&
their& immunogenicity& (Miller,&Maher&et&al.&2009;&Zaidi&and&Merlino&2011).&While& these&
CD4+& IFNγ+& cells& exhibit& tumour& cytotoxicity,& CD8+& CTLs& remain& the& main& antiFtumour&






on& their& cell& surface.& Ligation&of&death& receptors& induces& target& cell& death& (Cullen&and&
Martin&2008).&




which& survive& the& attack& of& the& immune& system.& Due& to& the& heterogeneity& and&
chromosomal&instability&of&transformed&cells,&nascent&tumours&contain&a&wide&variety&of&
cancer& cells& with& rapid& mutagenic& potential.& As& immunogenic& cancer& variants& are&
attacked&and&eliminated,&cancer&cells&resistant&or&invisible&to&the&immune&system&escape&
and& expand.& These& escaping& cells& exhibit& reduced& immunogenicity& and& accumulate&
mutations& that& increase& their& resistance& to& immune& responses.& This& immunoediting&
phenomenon& is& supported& by& experiments& transferring& tumour& cells& from&




studies& further& assessed& the& mechanisms& of& cancer& immunoediting,& using& highly&
immunogenic& MCAFinduced& sarcoma& cell& lines& from& immunodeficient& Rag28/8& mice.&
Unedited&sarcoma&cells&from&immunodeficient&mice&resembled&nascent&primary&tumour&
cells&and&could&be&rejected&by&immunocompetent&mice.&Using&cancer&exome&sequencing&
and& in# silico& epitope&prediction& algorithms& the& authors& identified&highly& immunogenic,&
tumourFspecific& mutational& antigens& (neoantigens)& in& unedited& sarcoma& cells.& These&
neoantigens& conferred& high& immunogenicity& to& unedited& sarcoma& cells& and& served& as&
targets& for& the& elimination& phase& of& cancer& immunoediting.& T& cells& mediated&
immunoselection&of& sarcoma&cells& lacking& strong& rejection&antigens,& leading& to& tumour&
outgrowth&(Matsushita,&Vesely&et&al.&2012).&Importantly,&T&cell&reactivity&against&patientF
specific&neoantigens&has&also&been&shown& in&melanoma&patients&and&thus&neoantigens&
can& remain& targets& in& edited& and& established& tumours& (Linnemann,& van& Buuren& et& al.&
2014).&&
Thus,& there&are& two&classes&of& cancer& rejection&antigens.&Neoantigens& form&the&
first& class& and&are&peptides& that& are&not&present& in& the&normal&human&genome.&These&




limited,& for& example& due& to& restricted& tissue& expression& pattern& (Schumacher& and&
 28&
Schreiber& 2015).& TAAFspecific& CD4+& and& CD8+& T& cells& are&mainly& anergic& or& exhibit& low&
affinity&T&cell&receptors&(TCRs),&further&aiding&tumour&escape&from&the&equilibrium&phase.&













mainly& immature& or& tolerogenic& DCs& can& be& found.& DCs& are& not& the& only& deficient&
immune&cell&type&present&within&the&tumour&microenvironment,&and&the&same&applies&to&
other&tumourFinfiltrating&myeloid&and&lymphoid&cells.&Cancer&cells&do&not&only&escape&by&
becoming& less& immunogenic.& Tumour& cells& actively& subvert& the& immune& system& by&
secreting&tumourFderived&growth&factors&and&cytokines,&skewing&the& immune&response&
to&a&tolerogenic&path&(Zitvogel,&Tesniere&et&al.&2006).&The&equilibrium&phase&between&the&
immune& system& and& escaping& cancer& cells& is& viewed& as& the& longest& phase& of&
immunoediting& (Dunn,& Old& et& al.& 2004).& At& the& end,& cancer& cells& with& reduced&






Fig.# 1.1.# Innate# and# adaptive# immune# responses# to# nascent# tumours.# (A)# Tissue#
remodelling8induced# inflammation# attracts# innate# immune# cells,# such# as# NK# cells# and#
macrophages.#NK#cells#induce#tumour#cell#death#through#IFNγ#and#secretion#of#granules#
containing#perforin#(Perf)#and#granzymes#(Grz).#Secretion#of#cytokines#and#chemokines#by#
innate# immune# cells# induce# further# infiltration# of# other# immune# cells,# such# as#DCs.# (B)#
Attack#of#the#innate#immune#system#leads#to#release#of#TAAs#by#necrotic#cancer#cells.#DCs#
phagocytose# TAAs# and# present# them# on# their# surface,# complexed# to# MHC# molecules.#
Recognition# of# danger# signals# lead# to# the# maturation# of# DCs,# up8regulating# co8
stimulatory# molecules.# (C)# Matured# DCs# home# to# the# tumour8draining# lymph# nodes#
where# they# present# TAAs# to# T# cells# in# a# positive# co8stimulatory# context.# Cytokine#
secretion#within#the#immunological#synapse#leads#to#T#cell#polarization#and#acquisition#of#




Depending& on& the& cancer& type,& tumour& cells& secrete& various& factors,& including&
VEGF&(vascular&endothelial&growth&factor)&(Gabrilovich,&Chen&et&al.&1996;&Young,&Kolesiak&
et& al.& 1999;& Ohm,& Gabrilovich& et& al.& 2003),& GMFCSF& (granulocyte& macrophage& colonyF




Uzaslan& et& al.& 2005)& amongst& others.& These& tumourFderived& factors& act& locally& to&
promote& tumour& progression& or& skew& immune& cell& polarization.& In& addition,& many& of&
these&factors&extend&their&suppressive&effects&to&lymph&nodes&and&spleen&and&enhance&
the& recruitment& of& bone& marrow& (BM)Fderived& cells& to& the& tumour.& TumourFsecreted&
factors&that&reach&the&BM&significantly&alter&myelopoiesis,&resulting&in&the&release&of&high&
numbers& of& undifferentiated& and& immature& myeloid& cells& to& the& circulation.& These&
immature&myeloid&cells&get&recruited&into&the&tumour,&where&they&suppress&rather&than&
stimulate&antiFtumour&immune&responses&(Rabinovich,&Gabrilovich&et&al.&2007).&&
Haematopoiesis& is& tightly& regulated& under& physiological& conditions& but& this&
system& is& unhinged& under& the& assault& of& a& strong& influx& of& tumourFderived& growth&
factors.&Haematopoiesis&originates& from&a&pluripotent&haematopoietic& stem&cell& (HSC).&
Successive& differentiation& steps& give& rise& to& progeny& in& two& lineage& branches,& the&
myeloid&and& lymphoid& lineages& (Fig.& 1.2.A).& Each&differentiation& step& restricts& the& cells&
closer&to&one& lineage&and& is&accompanied&by&a& loss&of&selfFrenewal&capacities.&The&HSC&
can&differentiate& into& two&different&progenitor&cells,& the&common& lymphoid&progenitor&
(CLP)&and& the&common&myeloid&progenitor& (CMP).&CLPs&give& rise& to&NK,&T,&and&B&cells,&
while& CMP& progeny& are& divided& into& two& further& branches.& The&
megakaryocyte/erythrocyte& progenitor& and& the& granulocyte/macrophage& progenitors&
give& rise& to& these& two& branches,& leading& to& the& generation& of& megakaryocytes& and&
erythrocytes,& monocytes,& macrophages,& granulocytes,& DCs,& and& mast& cells& (Akashi,&
Traver& et& al.& 2000).& Fig.& 1.2.A& summarizes& the& text& book& view&of& haematopoiesis.& This&
process&is&much&more&complicated&though.&Haematopoiesis&should&not&be&considered&as&
a& strictly& hierarchical& system& but& should& rather& be& viewed& as& a& highly& interconnected&
 31&
system&(Fig.&1.2.B)(Gabrilovich,&OstrandFRosenberg&et&al.&2012).&Other&progenitor&stages&
have& been& identified,& such& as& the& common& macrophage/DC& progenitor& (MDP)& or& the&
common&monocyte&progenitor& (cMoP)& (Hettinger,&Richards&et&al.&2013),&adding& further&
plasticity&to&the&system.&&
During& physiological& steadyFstate& haematopoiesis& myeloid& proliferation& and&
mobilization&from&BM&and&spleen&is&regulated&by&GMFCSF&and&GFCSF&(Demetri&and&Griffin&
1991;&Summers,&Rankin&et&al.&2010).&GFCSF&regulates&granulopoiesis.&Thus,&GFCSF&induces&
proliferation& of& granulocytic& precursors& and& their& release& from&BM.&As&GFCSF& is& also& a&
frequent& tumourFsecreted& factor& it&may& not& be& surprising& that& its& enhanced& secretion&
leads&to&the&accumulation&of&immature&granulocytes&in&tumourFbearing&hosts&(Fig.&1.2.C).&
In&addition,&IL6,&IL13,&and&GMFCSF&also&stimulate&granulopoiesis&(Summers,&Rankin&et&al.&




responses& but& highFdose& GMFCSF& instead& mobilizes& suppressive& myeloid& cells,& thus&
explaining& the& limited& efficacy& of& these& treatments& (Serafini,& Carbley& et& al.& 2004).&
Transferring& tumour& cells& engineered& to& secrete& high& levels& of& GMFCSF& leads& to&
splenomegaly& in&mice& and& increases&myeloid& cell& infiltration& in& tumour& tissue& (Dufait,&
Schwarze&et&al.&2015).&Interestingly,&a&study&showed&that&there&is&a&correlation&between&
the&number&of&splenic&immunosuppressive&myeloid&cells&from&tumourFbearing&mice&and&
enhanced& transcription& of& splenic& GFCSF.& TumourFinfiltrating& immunosuppressive&
myeloid& cell& numbers& on& the& other& hand& directly& correlated& with& enhanced& GMFCSF&
transcription& in& spleen.& In& addition,& tumourFinfiltrating& immature& myeloid& numbers&
correlated&directly&with& tumour&cell&number&and&tumour&burden& (Abe,&Dafferner&et&al.&




mobilization& of& myeloid& progenitors& before& they& can& fully& differentiate.& In& this& way,&
immature&myeloid&cells&disseminate&to&blood&and&peripheral&organs&and&finally&infiltrate&
and& accumulate& in& spleen& and& tumour& tissues& (Gabrilovich,& OstrandFRosenberg& et& al.&
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2012;& Younos,& Dafferner& et& al.& 2012;& Talmadge& and& Gabrilovich& 2013).& Premature&
mobilization&of&immature&myeloid&cells&leads&to&a&decrease&of&functional&DCs&and&other&





myeloid& cell& populations,& accumulation& sites,& and& tumour& infiltration.& In& summary,&
tumourFsecreted&factors&affect&the&macroenvironment&by&altering&myelopoiesis,&leading&
to& immature& myeloid& cell& mobilization,& accumulation,& differentiation,& and& function&







(A)# Scheme# represents# haematopoiesis# in# a# simplified,# text# book# view.# (B)# Scheme#
represents# fluidity# and# interconnectivity# of# haematopoiesis.# Black# frames# highlight# the#
three# main# terminally# differentiated# myeloid# cell# types;# DCs,# granulocytes,# and#
macrophages.# Figure#B#was#designed#according# to# information# from#Gabrilovich#et#al.,#
Nat# Rev# Immunol,# Vol.# 12(4),# 253868,# 2012.# (C)# Tumour8derived# factors# alter#




Tumour& immune& subversion& can& act& systemically& to& flood& the& host& with&
dysfunctional& myeloid& cells.& TumourFinfiltrating& immature& myeloid& cells& are& further&
subjected& to& tumourFsecreted& factors& in& the& tumour& environment,& skewing& their&
polarization& and& function& further.& Tolerogenic& and& immunosuppressive& myeloid& cells&
inhibit& T& cell& and& NK& cellFmediated& antiFtumour& activities& and& contribute& to&
vascularization,& tumour& progression,& and& metastasis& (Gabrilovich& and& Nagaraj& 2009;&
OstrandFRosenberg& and& Sinha& 2009;& Gabrilovich,& OstrandFRosenberg& et& al.& 2012;&
Talmadge&and&Gabrilovich&2013).&Tumours&not&only&alter&the&myelopoietic&compartment&
but&also&subvert&adaptive& immune&responses&by&polarizing&T&cells& to&tolerogenic& types.&





















































CTL& responses,& in& this& way& suppressing& TAAFspecific& immune& responses.& Like& DCs,&
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macrophages& are& also& professional& APCs,& capable& of& phagocytosing& pathogens& and&
presenting& antigen& on&MHC& I& and& II& molecules.&Macrophages& are& tissueFresident& cells&
that&have&differentiated&from&monocytes&and&are&normally&involved&in&the&elimination&of&
infectious& agents,& wound& healing,& and& regulation& of& adaptive& immunity& (Mosser& and&
Edwards&2008;&Gabrilovich,&OstrandFRosenberg&et&al.&2012).&Macrophages&can&be&further&
categorized& into&M1&and&M2&phenotypes,& depending&on& the& signals& they& receive& from&
their&environment.&When&macrophages&are&activated&by&bacterial&products&or&IFNγ&they&
acquire& M1& properties& and& secrete& high& levels& of& IL12.& M1& macrophages& are& also&
associated&with&antiFtumour&activities.&Macrophages&that&get&activated&by&cytokines&IL4,&
IL10,& or& IL13,& on& the& other& hand,& acquire& an& M2& phenotype.& The& M2& phenotype& is&
associated& with& several& tumourFpromoting& properties& such& as& T& cell& suppression& and&
apoptosis,& Treg& attraction& and& activation,& tumour& growth,& and& angiogenesis.&
Macrophages&within&the&tumour&are&frequently&called&tumourFassociated&macrophages&
(TAMs)& and& acquire& an& M2& phenotype& due& to& tumourFsecreted& factors& and& the&
chronically&inflamed&environment.&TAMs&secrete&high&amounts&of&IL10,&TGFβ,&and&PGE2&
and& thus& attract& Treg& cells& to& the& tumour.& As& TAMs& have& lost& IL12& expression& and&
cytotoxic& capabilities,& they& are& unable& to& effectively& stimulate& adaptive& immune&




tumourFinfiltration& is& also& observed.& Neutrophils& are& myeloid& cells& that& contain&
cytoplasmic& granules& with& high& histotoxic& potential.& Due& to& their& cytotoxicity,& the&
processes& of& granulocyte& formation,& mobilization,& and& activation& are& normally& tightly&
regulated.& Under& physiological& conditions& they& are& rapidly& recruited& to& inflammatory&
sites,& where& they& kill& invading& pathogens& thorough& phagocytosis,& release& of& granular&






types& such& as& TAMs& and& TANs& differ& in& frequency,& gene& expression,& and& function,&
depending&on&tumour&type&(Elpkek,&Cremasco&et&al.&2014).&
1.1.6.!! MYELOID+DERIVED!SUPPRESSOR!CELLS!
All& three& terminally& differentiated& myeloid& cell& types,& DCs,& granulocytes,& and&
macrophages,& can& be& polarized& to& acquire& immunosuppressive& activities.& Tumours&
extend&their&activities&to&the&BM&and&alter&myelopoiesis,& leading&to&the&mobilization&of&
high&numbers&of& immature&myeloid&cell& types.&Already& in&the&early&20th&century& it&was&
described&that& tumour&progression&was&associated&with&an& increase& in&extraFmedullary&
haematopoiesis& (EMH)&and&neutrophilia&(Sonnenfeld&1929).& In&the&1960s& it&was&further&
described& that& EMH&was& associated&with& increased& haematopoietic& colonyFstimulating&
factors&and&abnormal&myeloid&cell&differentiation.&These&abnormal&myeloid&cells&induced&
a& leukaemoid& reaction,& which& was& associated& with& tumour& growth& and& myeloid& cell&
infiltration&(Lappat&and&Cawein&1964;&Robinson&1965;&Talmadge&and&Gabrilovich&2013).&
CancerFrelated& NS& (natural& suppressor)& cells& were& first& described& in& 1989& in& tumourF
bearing&mice.&These&NS&cells&suppressed& immune&responses&and&were&unresponsive&to&
mitogens&(Subiza,&Viñuela&et&al.&1989).&Later&it&was&appreciated&that&the&accumulation&of&
immature& myeloid& cells& leads& to& vascularization& and& immune& evasion& of& tumours&
(Talmadge&and&Gabrilovich&2013).&
Nowadays,& these& cancerFinduced& heterogeneous& populations& of& immature& and&
immunosuppressive&myeloid& cells& are& called&myeloidFderived& suppressor& cells& (MDSCs)&
by&most& immunologists,& although& some& continue& to& call& them& immature&myeloid& cells&
(iMCs)&or&myeloid&suppressor&cells&(MSCs)&(Talmadge&and&Gabrilovich&2013).&MDSCs&are&
comprised& of& myeloid& progenitors& and& precursors& of& macrophages,& DCs,& and&
granulocytes& at& various& stages& of& differentiation& (Condamine& and& Gabrilovich& 2011).&
Their& phenotypic& characterization& remains& rather& controversial& due& to& cell&
heterogeneity,& investigatorFdependent& phenotypic& marker& profiles,& and& tumourF
dependent&variability.&TumourFdependent&variability&stems&from&the&fact&that&different&
tumours& secrete& different& growth& factors& and& cytokines& (Peranzoni,& Zilio& et& al.& 2010;&
Talmadge& and& Gabrilovich& 2013).& Thus,& the& most& important& characteristic& of& MDSCs&
remains& their& immunosuppressive& activity.& Although& they& are& mostly& described& in&
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cancerFrelated& studies,& they& also& exist& under& physiological& conditions,& where& their&
function&is&to&limit&damage&to&tissues&by&the&immune&system&(Bronte,&Wang&et&al.&1998)&
(Strober,& Okada& et& al.& 1984;& Youn& and& Gabrilovich& 2010).& For& treatment& of&
autoimmunityFrelated& diseases& it& is& of& interest& to& raise& MDSC& responses& while& they&
obstruct&antiFtumour&immune&responses&in&patients&with&high&tumour&burden&(Poschke&
and&Kiessling&2012).&
In& tumourFbearing& mice& they& are& defined& as& CD11b+& GRF1+& cells& with& T& cell&
inhibitory&activities.&GRF1&consists&of&two&epitopes,&Ly6C&and&Ly6G&(Bronte,&Apolloni&et&al.&
2000;&Youn,&Nagaraj&et&al.&2008).&In&humans,&the&MDSC&phenotype&has&remained&rather&
controversial& and& less& defined& but& can& be& summarized& as& expressing& either& CD33& or&
CD11b& and& low& or& no& HLAFDR.& These& markers& reflect& their& myeloid& lineage& and& low&
antigen&presenting&capabilities&(Almand,&Clark&et&al.&2001;&Poschke&and&Kiessling&2012).&
Murine& and& human& MDSCs& can& be& further& divided& into& two& subsets& according& to&
morphology& and& surface& marker& expression.& MDSCs& exhibiting& a& monocyticFlike&




in&mice& are&CD11b+& Ly6Ghi& LyF6Cinterm/+& and& in&humans&CD33+&HLAFDRF/low& CD15+& (Youn,&
Nagaraj&et&al.&2008;&Ko,&Zea&et&al.&2009;&Poschke&and&Kiessling&2012).&To&this&date&there&
remains& controversy& on& the& recognition& of& MDSCs& as& distinct& cell& lineages.& MDSCs&
express& high& phenotypical& and& functional& plasticity& in& mice& and& humans,& further&
complicating&the&issue.&MDSC&differentiation&and&function&depends&on&the&environment&
they&are&in.&Many&factors,&including&growth&factors,&cytokines,&chemokines,&hypoxia,&and&
glucose& levels& influence& their& differentiation,& accumulation,& and& function& (Gabrilovich,&
OstrandFRosenberg& et& al.& 2012).& This& reflects& the& plasticity& of& the&myeloid& cell& system&
(Fig.& 1.2).& It& should& not& be& forgotten& that& immature& myeloid& cells& with& the& same&
phenotype& exist& in& the& BM&of& naïve&mice,& albeit&without& suppressive& functions.& It& has&
therefore& been& suggested& that& these& immature& myeloid& cells& need& to& be& activated&





Nonetheless,& it& is& now& widely& accepted& that& accumulation& of& MDSCs& strongly&
correlates&with&cancer&progression&(Almand,&Resser&et&al.&2000;&DiazFMontero,&Salem&et&
al.& 2009;& Solito,& Falisi& et& al.& 2011;& Christiansson,& Söderlund& et& al.& 2013;& Markowitz,&
Wesolowski&et&al.&2013;&Jiang,&Guo&et&al.&2014)&and&metastasis&(DiazFMontero,&Salem&et&
al.& 2009)& in& patients.&Murine& tumour&models& also& show& a& direct& relationship& between&
MDSC&numbers& and& tumour&burden&and&progression& (Donkor,& Lahue&et& al.& 2009;&Abe,&
Dafferner&et&al.&2010;&Steding,&Wu&et&al.&2011;&Younos,&Dafferner&et&al.&2012)&as&well&as&







MDSCs&negatively& impact&NK& cell& function&and& induce&NK& cell& anergy,& an&effect&
mediated& by& membraneFbound& TGFβ& (Li,& Han& et& al.& 2009).& Effector& T& cells& can& be&
inhibited& by& MDSCs& in& antigenFspecific& as& well& as& unspecific& ways.& AntigenFunspecific&
inhibition& relies& on& several& mechanisms& including& secretion& of& immunosuppressive&
cytokines& IL10& and& TGFβ,& depletion& of& LFarginine& by& arginaseF1& and/or& iNOS& activity&
(Gabrilovich&and&Nagaraj&2009),&and&secretion&of& reactive&oxygen&and&nitrogen&species&
(ROS&and&RNS)&(Nagaraj,&Gupta&et&al.&2007;&Corzo,&Cotter&et&al.&2009).&AntigenFspecific&T&
cell& suppression& is& initiated& by& secreting& immunosuppressive& cytokines& and& signalling&
through& negative& coFstimulatory& molecules& during& antigen& presentation.& Antigen&
presentation& in& this& context& leads& to& the& expansion& of& T& cells& with& no& or& only& limited&




inhibition& of& antiFtumour& immune& effector& cells.& MDSCs& also& aid& in& promoting&
angiogenesis& (Yang,& DeBusk& et& al.& 2004;& Murdoch,& Muthana& et& al.& 2008)& and&
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metastasis(DiazFMontero,& Salem& et& al.& 2009;& Abe,& Dafferner& et& al.& 2010;& Condamine,&
Ramachandran& et& al.& 2015)& by& secreting& cytokines,& chemokines,& and& matrix&
metalloproteinases& (MMPs)(Yang,& DeBusk& et& al.& 2004;& Gabrilovich& and& Nagaraj& 2009;&
Gabrilovich,&OstrandFRosenberg&et&al.&2012;&Liu,&Lai&et&al.&2012).&For&instance,&MMPs&aid&
in& the& modification& of& the& extracellular& matrix,& thus& aiding& in& tissue& remodelling,&
invasion,& angiogenesis,& and& metastasis& (Yang,& DeBusk& et& al.& 2004;& Gutschalk,&
Yanamandra&et&al.&2012;&Liu,&Lai&et&al.&2012).&The&tumour&microenvironment&is&a&highly&
complex&site&and&tumourFinfiltrating&myeloid&populations&engage&in&crossFtalk&with&other&
cell& types.& Thus,& crossFtalk& between&MDSCs& and& TAMs& exacerbates&myeloidFmediated&
immune& suppression.& IL10& secreted& by& MDSCs& decreases& IL12& and& increases& IL10&
secretion& by& TAMs,& thus& potentiating& suppressive&mechanisms& (Sinha,& Clements& et& al.&
2007).& Close& interactions& also& exists& between& MDSCs& and& tumour& cells.& MDSCs& help&






causing& mutations,& implementation& of& cancerFscreening& techniques,& and& the& study& of&
cancer& immunology& over& the& past& decades,& the& possibility& for& more& effective& and&
targeted& therapies& has& arisen.& Traditional& cancer& therapies& such& as& chemotherapy& are&
characterized& by& high& collateral& damage& and& limited& efficacy& in& the& longFterm.& A&
promising& approach& relies& on& boosting& the& immune& system’s& natural& defences& against&
tumours,& termed& cancer& immunotherapy.& The& aim& of& cancer& immunotherapy& is& to&
stimulate&the&immune&system&to&recognize&and&eradicate&tumour&cells&without&harming&




associated&with& the& induction& of& antiFtumour& immune& responses.& & The& first& one& is& the&
natural& tolerance& of& T& lymphocytes& against& TAAs.& A& cancer& immunotherapy& treatment&
must& therefore& overcome& this& natural& tolerance.& Once& a& treatment& has& resulted& in&
generating&antiFtumour&CTL&responses&it&needs&to&ensure&that&these&effector&cells&are&not&
inactivated&by& the& immunosuppressive& tumour&microenvironment.& This& represents& the&
second&major&barrier&to&efficient&induction&of&antiFtumour&immune&responses.&&
Cancer& immunotherapy& has& classically& focused& on& two& immune& cell& types& for&
manipulation,&as&described&in&previous&sections.&The&first&are&DCs&and&the&second&are&the&




mutations& that& are& reflected& in& the& range& of& altered& antigens& they& present& on& their&
surface.&These&TAAs&make&cancer&cells&susceptible&to&the&attack&of&the&immune&system&
and&can&be&exploited&by&cancer&immunologists&(Zitvogel,&Tesniere&et&al.&2006).&Nowadays&




Summarising,& there& are& six& major& therapeutic& strategies& for& cancer&
immunotherapy:&Cytokine&treatment,&tumour&vaccines,&adoptive&transfer&of&TAAFspecific&
CTLs,& adoptive& transfer& of& TAAFpresenting& DCs,& immune& checkpoint& modulators,& and&
depletion& of& MDSCs& and& Tregs.& Combination& of& several& of& these& immunotherapeutic&
strategies&often&has&synergistic&effects,&boosting&the&immune&response&at&several&levels.&
1.2.1.!! CYTOKINE!TREATMENTS!
Cytokines& are& small& signalling& proteins,& and& major& modulators& in& immune&
processes& and& can& be& divided& into& interleukins& (ILs),& chemokines,& interferons& (IFNs),&
tumour&necrosis&factors&(TNFs),&mesenchymal&growth&factors,&and&adipokines.&Cytokines&
are&characterized&by&their&pleiotropicity,&as&they&possess&multiple&and&various&biological&
functions.& Their& specific& activities& over& target& cells& are& determined& by& the& differential&
expression& of& receptors& on& target& cell& types& (Dinarello& 2007).& Cytokines& can& be&
administered& to& either& activate& the& immune& system& or& to& induce& direct& antiFtumour&
effects.&IL6,&TNFα,&and&IFNγ&exhibit&direct&antiFtumour&cytotoxicity&in#vitro&but&they&show&
strong& toxicity& in# vivo& and& even&promote& tumour& growth&or& exert& immunosuppressive&
effects& through& the& activation& of& negative& feedback& mechanisms& to& dampen&
inflammation& (Disis& 2014).& IL12& also& has& direct& antiFcancer& cytotoxic& effects& but& its&
systemic&administration&is&highly&toxic&(Cohen&1995;&Leonard,&Sherman&et&al.&1997;&Car,&
Eng&et&al.&1999;&Colombo&and&Trinchieri&2002).&Thus,&although&several&cytokines&exhibit&
antiFtumour&activity,& systemic&administration& frequently& leads& to&highly&undesired& side&
effects.&&
Cytokines& that& activate& and& expand&NK& and& T& cells& such& as& IL2& and& IFNα,& have&
been&used&in&patients&more&or&less&successfully&(Atkins,&Lotze&et&al.&1999;&Flaherty,&Othus&
et&al.&2014).& IL2& is&approved& for& treatment& in&cancer&patients&but& its&proFinflammatory&
effects& can& be& problematic& as& these& are& not& easily& tolerated& by& many& patients.& In&
addition,& low& efficacy& has& been& observed& in& metastatic& melanoma& and& renal& cell&
carcinoma&(Fehniger,&Cooper&et&al.&2002;&Dinarello&2007;&Disis&2014).& IFNα& is&approved&
for&malignant&melanoma,&leukaemia,&and&lymphoma&but&its&clinical&efficacy&is&limited&by&
some& immunosuppressive& activities&within& cancer& patients& (Tarhini,&Gogas& et& al.& 2012;&
Disis&2014).&
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GMFCSF& has& been& used& and& approved& in& humans& for& haematopoietic&
reconstitution,& recruitment&of&mature&DCs,&and&DC&maturation&and&activation.&GMFCSF&
administration& in& clinical& trials& has& led& to& promising& results,& for& example& in&melanoma&
patients&(Daud,&Mirza&et&al.&2008).&On&the&other&hand,&GMFCSF&has&recently&been&shown&
to& favour& tumour& invasion& in& mice,& by& elevating& MMP& (matrix& metalloproteinase)&
expression& levels& in& the& tumour& environment& (Gutschalk,& Yanamandra& et& al.& 2012).& As&
discussed&in&the&previous&section,&high&levels&of&GMFCSF&do&not&recruit&mature&DCs&but&
rather& alter& myelopoiesis,& resulting& in& accumulation& of& dysfunctional& DCs& and& other&
immature&myeloid& cells& (Serafini,& Carbley& et& al.& 2004).& IL7,& IL11,& IL12,& IL15,& IL21,& IFNβ,&
and& IFNγ& are& being& evaluated& for& cancer& immunotherapy& (Disis& 2014)& but& their&
pleiotropicity& makes& it& difficult& to& use& cytokines& in& cancer& patients,& especially& when&




Natural& TAAFspecific& CD4& and& CD8& T& cell& responses& take& place& in& patients.& The&
objective& of& tumour& vaccines& is& to& enhance& TAA& presentation& to& immune& cells,& thus&
inducing& their& activation& and& differentiation& to& antiFTAA& effector& T& cells.& There& are& at&
least& three& different& types& of& tumour& vaccines;& protein/peptide& vaccines,& cellFbased&
vaccines,&and&genetic&vaccines.&
Protein/peptide& vaccines& consist& of& either& entire& TAAs& or& various& peptides&
derived& from& them.& As& TAAs& are& poorly& immunogenic,& protein/peptide& vaccines& are&
usually& coFadministered& with& immunostimulatory& adjuvants.& Most& peptideFbased&
vaccines& in& clinical& trials& target& cancerFtestis& antigens,& differentiationFassociated&
antigens,& or& oncofoetal& antigens,& mostly& in& combination& with& adjuvants& and& immune&
modulators.&Peptide&vaccines&induce&TAAFspecific&T&cells&but&clinical&efficacy&remains&low&
(Guo,&Manjili&et&al.&2013).&Nevertheless,&recent&successes&have&validated&this&approach.&A&





this&may& not& sufficiently& stimulate& different& cohorts& of& CD4& and& CD8& T& cells& that&may&
cooperate& in& cytotoxic& activities.& Stimulation& of& CD4& T& cell& responses& is& important& to&
effectively&raise&CD8&T&cell&responses&(Guo,&Manjili&et&al.&2013).&
Tumour&cellFbased&vaccines&are&more&costly&than&peptideFbased&vaccines&but&an&
advantage& is& that&APCs&process& the&TAAs& themselves& into&peptides,& ensuring& that&CD4&
and&CD8&T&cell&responses&are&stimulated.&In&addition,&the&whole&range&of&TAAs&is&supplied&
to&the&patient’s&immune&system&rather&than&a&selected&few.&Tumour&cellFbased&vaccines&
are& either& autologous& (from& patient)& or& allogeneic& (from& allogeneic& tumour& or& human&
tumour&cell&lines).&Autologous&tumour&cell&vaccines&are&produced&by&irradiating&tumour&
cells&from&the&patient.& Immunostimulatory&agents&are&added&to& irradiated&tumour&cells&
and& the& tumour&vaccine& is& then&administered& to& the&patient& (Guo,&Manjili&et&al.&2013).&
Autologous& tumour& cell& vaccines& genetically& modified& to& secrete& GMFCSF& (Gvax)& have&
shown& certain& efficacy& in& the& clinic& (O'Rourke,& Schmidt& et& al.& 1997;& Nemunaitis& 2003;&









highly& important& as& using& the& wrong& adjuvant& can& obstruct& vaccine& efficacy.& IFA&
(incomplete& Freund’s& adjuvant)& analogues&have& frequently&been&used&as& adjuvants& for&
vaccination.& TAA& delivery& in& IFA& has& recently& been& shown& to& cause& sequestration& and&
deletion& of& TAAFspecific& CTLs& at& the& vaccination& site,& rendering& the& tumour& vaccine&
ineffective.&Thus,&delivery&of&TAAs&alone&did&not&cause&antigen&deposits&but&did&not&raise&
strong& CTL& responses& (Hailemichael,& Dai& et& al.& 2013).& Hence,& genetic& vaccines& and&
especially&viralFbased&vaccination&may&represent&a&more&effective&option.&For& instance,&





Genetic& tumour& vaccines& are& based& on& TAA& DNA& transfer& to& patients,& either&
encoding&TAAs&as&full&proteins&or&as&peptides.&APCs&are&the&main&target&of&TAA&DNA,&so&
that& they& can&present&TAAs&and& initiate&antiFTAA& immune& responses.& TAA&DNA&can&be&
transferred&through&several&methods;&through&bacterial&plasmids,&as&RNA,&or&supplied&by&
viral& vector& transduction.& DNA& vaccines& have& shown& promising& results& in& preFclinical&
models,&leading&to&TAAFspecific&CTL&responses&and&tumour&protection&(Bronte,&Apolloni&
et&al.&2000;&Yan,&Tingey&et&al.&2014).&The&use&of&multiple&epitopes&or&mutated&TAA&DNA&
can& further&enhance&antiFtumour& immune& responses& (GuevaraFPatino,&Engelhorn&et&al.&
2006).& Although& preclinical& results& have& been& promising,& translation& to& the& clinic& has&
been& disappointing& (Guo,& Manjili& et& al.& 2013).& There& is& room& for& improvement& and&
current&clinical&studies&are&testing&alternative&strategies&to&enhance&DNA&tumour&vaccine&
efficacy.&A& recent& study& suggested& that& intraFlymph&nodal& delivery& could& enhance& TAA&
uptake&by&APCs&to&enhance&antiFtumour&T&cell&responses&(Ribas,&Weber&et&al.&2011).&
Thus,& due& to& the& lack& of& TAA& immunogenicity,& tumour& vaccines& need& to& be&
combined&with&adjuvants&or&other& immunostimulatory&agents&and& immune&checkpoint&
modulators&(Tarhini,&Leng&et&al.&2012).&ViralFbased&tumour&vaccines&have&the&advantage&
that& virusFspecific& peptide& presentation& could& act& as& an& immunostimulatory& adjuvant&
during& TAA& presentation& (Breckpot,& Escors& et& al.& 2010).& Apart& from& encoding& TAA&




in&prophylactic&and& therapeutic& settings,& success& in& the&clinic&has&been&poor.&Although&
immune&responses&against&TAAs&supplied&by&the&cancer&vaccines&were&observed&in&most&
trials,& it& seldom& leads& to& a& reduction& in& tumour& burden.& This& may& be& due& to& low&
immunogenicity& of& TAAs,& a& lack& of& adequate& coFstimulation,& and& tumourFinduced&
immune&suppression.&In&addition,&immune&selective&pressure&induces&cancer&cell&variants&
with& low& MHC& expression& and/or& TAA& expression,& rendering& TAAFtargeting& immune&






Rather& than& delivering& TAAs& to& the& patient’s& immune& system& to& initiate& TAAF
specific&CTL&responses,&a&different&approach&is&to&generate&activated&TAAFspecific&CTLs&ex#
vivo,& before& transfer& to& the& patient.& The& objective& is& to& generate& activated& CTLs& with&
engineered& receptors& exhibiting& a& high& affinity& towards& TAAs.& Two& strategies& are&
currently&applied&to&engineer&TAAFspecific&CTLs&ex#vivo;&engineering&T&cells&that&express&
highFaffinity& T& cell& receptors& (TCRs)& or& that& express& chimeric& antigen& receptors& (CARs)&
(Fig.&1.3).&Both&transgene&receptors&are& introduced& into&patientFspecific&effector&T&cells&
ex# vivo& using& viral& vectors& as& gene& carriers.& Engineered&T& cells& are& then&expanded&and&
activated& before& transfer& back& into& the& patient& (Coccoris,& Straetemans& et& al.& 2010;&
Thomas,&Stauss&et&al.&2010).&Although&resting&T&cells&are&more&refractory&to&viral&vector&
modification& than& DCs,& this& strategy& remains& viable& (Bobisse,& Zanovello& et& al.& 2007;&






et& al.& 2006).& Thus,& TCR& transgenes& are& introduced& into& autologous& T& cells& ex# vivo,&
activated,&expanded,&and&transferred&back&to&patient&(Coccoris,&Straetemans&et&al.&2010;&
Perro,& Tsang& et& al.& 2010;& Thomas,& Stauss& et& al.& 2010).& Genetically& engineered& T& cells&
recognize& TAAs& in& the& recipient,& expand& upon& encounter,& and& eliminate& tumour& cells.&
There&have&been&promising&results&in&preFclinical&models&(Bobisse,&Rondina&et&al.&2009)&
as& well& as& success& in& human& clinical& trials& (Johnson,& Heemskerk& et& al.& 2006;& Morgan,&
Dudley&et&al.&2006;&Parkhurst,&Yang&et&al.&2011;&Robbins,&Morgan&et&al.&2011;&Phan&and&
Rosenberg&2013).& In&these&trials&TCRs&were& isolated&from&T&cells& isolated&from&patients&
undergoing& remission.& Thus,& TCRs& specific& for& cancer& testis& antigen& NYFESO& and&
melanomaFassociated& antigen&MELANFA& (MARTF1)& and& gp100& (Robbins,&Morgan& et& al.&
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2011;& Phan& and& Rosenberg& 2013)& have& been& cloned.& Poor& persistence& of& adoptively&
transferred& T& cells& in# vivo& has& hampered& clinical& efficacy& and& this& could& be& due& to&
premature& differentiation& ex# vivo& (Perro,& Tsang& et& al.& 2010).& In& addition,& especially& in&
early&clinical&trials,&onFtarget/offFtumour&toxicity&has&been&a&problem&(Lamers,&Seijfer&et&
al.& 2006;& Morgan,& Dudley& et& al.& 2006).& Of& note,& there& are& several& other& problems&
associated&with&this&strategy.&Endogenous&TAAFspecific&T&cells&frequently&do&not&exhibit&
TCRs&with&high&enough&affinity.& This& is&due& to& the& fact& that&highFaffinity&TAAFspecific&T&





immunogenic& cancer& cell& variants& can& still& be& selected& for& tumour&progression& (Escors,&
Lopes&et&al.&2008;&Park,&Rosenberg&et&al.&2011;&Liechtenstein,&PerezFJanices&et&al.&2013).&
To& overcome& some& of& the& aboveFpresented& problems,& CARs& have& been&
developed.&CARs&consist&of&intracellular&T&cell&signalling&domains&(e.g.&CD3&chains)&fused&
to& TAAFbinding& domains& of& antibodies.& This& strategy& confers& a& higher& affinity& of& the&
engineered&T&cells&to&TAAs&and&renders&TAA&recognition&independent&of&MHC&restriction&
(Gross,& Waks& et& al.& 1989).& On& the& other& hand,& problems& related& to& tumour&
immunosuppression&and&selection&of& less& immunogenic&cancer&variants&still& take&place.&
Poor&persistence&of&transferred&CARFT&cells&has&been&observed&due&to&immune&responses&
against&CARFengineered&T&cells&(Jensen,&Popplewell&et&al.&2010;&Lamers,&Willemsen&et&al.&
2011).& CARFT& cell& in# vivo& limited& expansion& leads& to& reduced& efficacy& in& clinical& trials.&
Interestingly,&these&two&clinical&trials&had&not&used&lentivectors&for&T&cell&gene&transfer.&It&
has& been& suggested& that& lentivectorFmediated& TCR& transfer& to& T& cells& may& be& more&
efficient&than&retrovirus&vectorFmediated&transfer.&For&example,&this&was&the&case&for&a&




in& human& patients,& especially& using& CD19Fspecific& CARs& in& leukaemia/lymphoma&
(Kochenderfer,& Wilson& et& al.& 2010;& Kochenderfer,& Yu& et& al.& 2010;& Kalos,& Levine& et& al.&
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2011;& Porter,& Levine& et& al.& 2011).& The& group& of& Dr.& June& has& engineered& CARs& against&
CD19,& containing& the& CD137& coFstimulatory& domain& and& TCR& ζ& chain.& T& cells& were&
engineered& through& lentivector& transduction& and& their& transfer& led& to& complete&
remissions& in& a& high& percentage&of& patients& but& exhibiting& tumour& lysis& syndrome&and&
lymphopenia&(Kalos,&Levine&et&al.&2011;&Porter,&Levine&et&al.&2011).&As&a&consequence&of&




in& immediate&adverse&symptoms&and&death&of&a&patient&only&5&days& later.& In& this&case,&
CARFT& cells& were& engineered& to& be& specific& for& ERBB2,& but& showed& potent& offFtarget&
effects.&It&was&suggested&that&CAR&T&cells&recognized&low&ERBB2&expression&in&the&lung,&
leading&to&a&cytokine&storm&(Morgan,&Yang&et&al.&2010).&&
Thus,& adoptively& transferring& genetically& engineered& T& cells& showed& clinical&









Fig.# 1.3.# Engineering# of# TAAFspecific# T# cells# for# adoptive# T# cell# therapy.# The# figure#
depicts#the#introduction#of#TAA8specific#TCRs#or#CARs#into#T#cells#isolated#from#patients.#
TCR#α#and#β#chains#are#cloned#from#TAA8specific#T#cells#of#patients#undergoing#remission.#
The# TCR# chains# are# amplified# by# PCR# and# inserted# into# viral# vectors,# in# this# case#
lentivectors.#CARs#on#the#other#hand#are#generated#by#fusing#the#TAA8binding#region#of#
an# antibody# with# TCR# signalling# domains.# The# lentiviral# vectors# are# then# used# to#
transduce# autologous# T# cells.# VH# and# VL,# immunoglobulin# variable# regions;# LTR,# long#
terminal# repeat;# Ψ,# packaging# signal;# RRE,# rev# response# element;# cPPT,# central#








activities& but& also& for& inducing& tolerance& in& the& case& of& autoFimmune& disorders.& Upon&
antigen& uptake& and& processing& for& presentation,& DCs& undergo& maturation& and& upF
regulate& coFstimulatoy&molecules,& secrete& proFinflammatory& cytokines,& and&migrate& to&
lymphoid&organs& to& stimulate&naïve&and&antigenFexperienced&T&cells.&There&are&several&
important& strategies& for& the& modification& of& DCs& as& efficient& stimulators& of& CTL&
responses.& The& first& one& is& to& ensure& TAA& presentation;& the& second,& ensuring& full&
maturation& of& DCs;& and& the& third& one& is& to& induce& production& of& immunostimulatory&
molecules&and&cytokines&by&DCs&(Breckpot&and&Escors&2009;&Escors,&Breckpot&et&al.&2012;&
Liechtenstein,& Dufait& et& al.& 2012;& Liechtenstein,& PerezFJanices& et& al.& 2013).& Successful&
strategies& should& combine& all& three& approaches& to& achieve& TAA& presentation& in& the&
correct&context.&
DCs&can&be& loaded&with&TAAs&ex#vivo&by& incubation&with& tumour&cell& lysates&or&
known& TAA& proteins& or& peptides.& In& this& way,& DCs& phagocytose& the& antigens,& process&
them&to&antigen&peptides,&and&load&them&onto&MHC&molecules&for&presentation&on&their&
surface& (Breckpot& and& Escors& 2009;& Escors& 2014)& (Fig.& 1.4).& Alternatively,& DCs& can& be&
modified& to& express& transgenes& encoding& TAAs,& by& viral& vectorFmediated& or& other&
genetic& modification& methods.& Transgenes& are& processed& by& transduced& DCs& and&
presented& on& MHC& molecules.& Of& note,& including& the& entire& transgene& ensures& that&
correct& peptides& are& loaded& on& MHC& molecules& and& circumvents& the& need& to& design&
peptides& specific& for& MHC& genotypes.& As& optimal& antiFtumour& results& are& achieved&
through& activation& of& both& CD4& and& CD8& T& cells,& it& is& beneficial& that& peptides& are&
presented&on&MHC&II&and&MHC&I&molecules&(Collins&and&Cerundolo&2004;&Figdor,&de&Vries&
et& al.& 2004;& Liechtenstein,& PerezFJanices& et& al.& 2013;& Liechtenstein,& PerezFJanices& et& al.&
2014).&&




is& exhibited& by& high& surface&MHC& and& coFstimulatory&molecule& density.& To& ensure& DC&
maturation& intracellular& DC& activatory& signalling& pathways& could& be&manipulated.& The&
use&of&NFFκB&and&p38&activators,&for&example,&can&lead&to&DC&maturation&(Escors,&Lopes&
et& al.& 2008;& Karwacz,& Mukherjee& et& al.& 2009;& Rowe,& Lopes& et& al.& 2009;& Liechtenstein,&
Dufait&et&al.&2012;& Liechtenstein,&PerezFJanices&et&al.&2013).&Expression&of& cytokines&by&







Adoptive& autologous& transfer& of& modified& DCs& is& being& applied& in& human&
immunotherapy.& This& approach& can& lead& to& induction& of& tumourFspecific& immune&
responses& in& cancer& patients& that& correlate& with& clinical& response.& Peripheral& blood&
monocytes& are& isolated& from& the& patient,& differentiated& into& DCs,& and& genetically&
modified&or&loaded&with&TAA&antigens&ex#vivo.&Modified&autologous&DCs&are&then&infused&
into& the&patient.& In&early& clinical& trials&DC&vaccines&used& immature& rather& than&mature&
DCs,& leading& to& immunosuppression& rather& than& immunostimulation& (Dhodapkar,&
Steinman&et&al.& 2001;&Dhodapkar&and&Steinman&2002;&de&Vries,& Lesterhuis&et&al.& 2003;&
Figdor,& de& Vries& et& al.& 2004).& In& more& recent& autologous& DC& clinical& trials,& partial& or&
complete&remissions&are&achieved&(Lesterhuis,&De&Vries&et&al.&2010;&Aarntzen,&De&Vries&et&
al.&2013;&Suehiro,&Hasegawa&et&al.&2015).&As&this&strategy&is&patientFspecific,& it& is&rather&
expensive& and& therefore& represents& a& barrier& for& wideFspread& clinical& application.&
Alternatively,& direct& immunization& with& viral& vectors& (particularly& lentiviral& vectors)&
targeting&DCs& is&an&attractive&alternative.&Viral&glycoprotein&engineering&to&pseudotype&
lentivector& particle& can& achieve& selective& transduction& of& DCs& in# vivo& in& preFclinical&
models&and&prevent&tumour&growth&(Yang,&Yang&et&al.&2008).&A&recent&clinical&trial&used&a&
vaccine&containing&a&human&monoclonal&antibody&specific& for& the&DC&surface&molecule&
DECF205& fused& to& fullFlength& tumour& antigen&NYFESOF1.&DECF205& has& a& role& in& antigen&
processing& and&presentation,& thus& ensuring& that&NYFESOF1& is& processed&and&presented&
 53&




study& combined& autologous& tumourFlysate& loaded& DCs& with& adoptive& TIL& (tumourF







represents# the#modification# of# ex# vivo# differentiated#mouse# and# human# DCs.# DCs# are#
loaded# with# peptides# or# by# genetic# modification.# Peptide8presenting# DCs# are# further#
modified# to# determine# their# activation# and# functional# status.# Activated,# mature# DCs#

















CTLAF4& binding& to& CD80& or& CD86& diminishes& T& cell& activation& by& counterFacting& the&
positive&coFstimulatory&interaction&delivered&by&CD28&binding.&CTLAF4&ligation&thus&leads&
to& inhibition&of&T&cell&activation&and&proliferation&(Chambers,&Kuhns&et&al.&2001;&Peggs,&
Quezada& et& al.& 2009).& In& addition,& it& also& affects& the& Treg& compartment& and& Treg&
inhibitory&activities&(Chambers,&Kuhns&et&al.&2001;&Henson,&Macaulay&et&al.&2008;&Wing,&
Onishi&et&al.&2008;&Peggs,&Quezada&et&al.&2009;&Krummel&and&Allison&2011).&Thus,&CTLAF4&
is& a& crucial& regulatory& receptor& that& controls& immune& responses& and& prevents&
autoreactivity.& Ipilimumab& is& a& monoclonal& antibody& against& CTLAF4& approved& by& the&
FDA&in&2011&for&the&treatment&of&metastatic&melanoma&(Mellman,&Coukos&et&al.&2011).&
Systemic& treatment& with& ipilimumab& enhances& antiFtumour& responses& in& patients& and&
exhibits& prolonged& survival& in& patients& with& melanoma& (Hodi,& Oble& et& al.& 2008;& Hodi,&
O'Day& et& al.& 2010;& Peggs& and& Quezada& 2010)& and& nonFsmall& cell& lung& carcinoma&
(Tomasini,& Khobta& et& al.& 2012).& Not& surprisingly,& systemic& CTLAF4& blockade& is&
accompanied& with& severe& side& effects& due& to& induced& inflammation& that& could& be&
autoimmunityFrelated&(Hodi,&O'Day&et&al.&2010;&Weber,&Dummer&et&al.&2013).&&








inhibiting& antiFcancer& immune& responses.& PDFL1& is& therefore& an& important& target& for&
cancer& immunotherapy& (Blank,& Gajewski& et& al.& 2005;& Zhang,& Gajewski& et& al.& 2009;&





CTLAF4& and& PDF1& regulate& distinct& inhibitory& pathways.& It& has& therefore& been&
suggested& that& combination& therapies& blocking& both&molecules&may& exhibit& enhanced&
efficacy.& Recent& clinical& trials& administering& ipilimumab& (antiFCTLAF4)& in& combination&
with& nivolumab& (antiFPDF1)& were& conducted& in& patients& with& advanced& melanoma&
(Wolchok,&Kluger&et& al.& 2013;&Postow,&Chesney&et& al.& 2015).&CoFadministration&of&both&
antibodies&led&to&greater&objective&response&rate&(61%&versus&11%)&and&progressionFfree&
survival&as&compared&to&treatment&with& ipilimumab&alone.& In&addition,&22%&of&patients&
treated& with& nivolumab& and& ipilimumab& were& reported& to& have& complete& responses&
while& none& of& ipilimumabFtreated& patients& exhibited& complete& responses& (Postow,&
Chesney& et& al.& 2015).& Further& combining& CTLAF4& and& PDFL1/PDF1& targeting& strategies&
with&tumour&vaccines&may&lead&to&enhanced&efficacy,&a&strategy&that&has&already&yielded&
promising&preFclinical& results& (Curran,&Montalvo&et& al.& 2010;&Duraiswamy,&Kaluza&et& al.&







and# APCs# during# antigen# presentation.# Scheme# depicts# antigen# presentation# by# APCs#
(left)# to# T# cells# (right).# Signal# 1# of# T# cell# activation# is# mediated# by# the# binding# of# the#
peptide8MHC#complex#to#the#TCR.#The#depicted#co8stimulatory#and#co8inhibitory#ligands#
on#APCs#bind#to#their#receptors#on#T#cells,#determining#the#activation#status#of#the#T#cell#
in# response# to# the# antigen.# These# interactions# represent# possible# targets# for# cancer#






are& ineffective& as& TAAFspecific& T& cells& are& frequently& inactivated& in& cancer& patients.&
Immunosuppressive& cell& types& therefore&need& to&be& considered& important& targets& and&





patients.& Sunitinib& (multitargeted& tyrosine& kinase& inhibitor),& for& example,& has& been&
shown&to&reduce&Treg&and&MDSC&numbers&in&treated&human&patients,&thus&enhancing&its&
antiFtumour&effects&(Xin,&Zhang&et&al.&2009).&It&is&becoming&increasingly&clear&that&certain&
chemotherapeutic& treatments,& including& gemcitabine,& 5Ffluorouracil,& docetaxel,& and&
doxorubicin,&work&well& in& clinical& practice&because& they& inhibit& cancer& cell& growth& and&
decrease& MDSC& numbers& (Suzuki,& Kapoor& et& al.& 2005;& Kodumudi,& Woan& et& al.& 2010;&
Vincent,&Mignot&et&al.&2010;&Alizadeh&and&Larmonier&2014;&Alizadeh,&Trad&et&al.&2014).&
Therefore,& there& is& a& high& interest& in& developing& strategies& to& specifically& target& these&
immunosuppressive&cell&types.&
Treg& depletion& has& been& approached& through& three& main& strategies;& Treg& cell&
death& induction& through& chemotherapeutic& agents,& Treg& depletion& by& antibodies&
targeting& receptors& (CD25,& CTLAF4,& PDF1,& GITR),& or& targeting& Treg& trafficking& (CCR4&
antagonist)&(Wainwright,&Dey&et&al.&2013).&In&mice,&depletion&of&Tregs&with&CD25Fspecific&
antibodies&leads&to&tumour&regression,&but&only&during&the&early&phase&of&tumour&growth&
(Onizuka,& Tawara& et& al.& 1999).& Similarly,& combining& antiFCTLAF4& antibody& with& CD25F
depleting& antibody& leads& to& tumour& rejection& in& a& B16& mouse& melanoma& model&
(Sutmuller,&van&Duivenvoorde&et&al.&2001).&CTLAF4&and&PDF1&blocking&antibodies&can&be&
combined,&leading&to&inhibition&of&Treg&function&and&tumour&rejection.&This&effect&could&
be& augmented& when& combined& with& a& tumour& vaccine,& demonstrating& again& the&
advantages& of& combination& therapies& (Duraiswamy,& Kaluza& et& al.& 2013).& In& the& clinical&
practice& successes& with& antiFCTLAF4& and& antiFPDF1& antibodies& have& been& shown,& as&
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Treg& cells& are& particularly& important& during& early& phases& of& tumour&
establishment.&This&is&supported&by&the&observation&that&Treg&depletion&is&only&effective&
in&animals&during&early&phases&of& tumour&progression&or&before& tumour&establishment&
(Onizuka,& Tawara& et& al.& 1999;& Elpek,& Lacelle& et& al.& 2007).&As&MDSCs& can&hamper& T& cell&
activities& at& all& levels& using& antigenFspecific& and& unspecific& immunosuppressive&
mechanisms,& they&also& represent&an&attractive& target& to&enhance&antiFtumour& immune&
responses.&&Several&studies&in&mouse&models&have&shown&the&efficacy&of&MDSCFdepleting&
strategies.&Murine&MDSCs&have&been&depleted&in#vivo&by&targeting&GRF1&with&monoclonal&
antibodies.& This& strategy& restored&T& cellFmediated&antiFtumour& immune& responses& and&
prevented& tumour& recurrence.&Of& note,& antiFGRF1& antibodies& also& deplete& neutrophils,&
rendering&the&subject&more&susceptible&to&opportunistic&infections&(Terabe,&Matsui&et&al.&
2003;&MundyFBosse,& Lesinski& et& al.& 2011).& Further&preFclinical& studies&have& shown& that&
targeting&SCF&(stem&cell&factor)&(Pan,&Wang&et&al.&2008),&IL4FRα&(Roth,&De&La&Fuente&et&al.&
2012),& S100& proteins& (Qin,& Lerman& et& al.& 2014),& and& treatment& with& zoledronic& acid&
(Porembka,& Mitchem& et& al.& 2012)& decreases& tumourFinfiltrating& MDSC& numbers.& This&
restores& tumourFinfiltrating& T& cell& proliferation,& decreases& Treg& numbers,& and& inhibits&
angiogenesis.&In&this&way,&these&treatments&limit&tumour&progression.&MDSC&suppressive&
activities& can& be& inhibited& by& administration& of& phosphodiesterase& inhibitors.& This&
reduced& the& immunosuppressive&mechanisms& of&MDSCs& in& tumour&mouse&models& by&
reducing&arginaseF1&and&iNOS&activity&(Serafini,&Meckel&et&al.&2006).&
AllFtransFretinoic& acid& (ATRA)& has& been& successfully& used& to& deplete& MDSCs& in&
tumour&mouse&models& and&patients.& ATRA& reduces&MDSC&numbers& in& tumourFbearing&
mice& and& thus& enhanced& and& prolonged& the& efficacy& of& tumour& vaccines& (Kusmartsev,&
Cheng&et&al.&2003;&Weiss,&Vitacolonna&et&al.&2009;&Lee,&Seo&et&al.&2012).&ATRA&treatment&




transduced&with&p53)& significantly& improved& immune& response& to& vaccination& (Iclozan,&
Antonia&et&al.&2013).&Mechanistically&it&was&shown&that&ATRA&treatment&of&CD33+&MDSCs&
from& patients& with& renal& cell& carcinoma& induced& their& differentiation& into& APC&




Sunitinib,& on& the& other& hand,& does& not& induce& MDSC& maturation& to& APCs& but&
reduces&MDSC&suppressive& function&and&viability& in#vitro.& In&addition,&sunitinib&reduces&
MDSC&and&Treg&numbers&in&peripheral&blood&of&renal&cell&carcinoma&patients&(Ko,&Zea&et&
al.&2009).&Depletion&of&Tregs&and&MDSCs&would&be&favourable&rather&than&depleting&only&
a& single& immunosuppressive& cell& type.& Thus,&one& study& combined&antiFCD25& treatment&
with& ATRA& to& control& Treg& and& MDSC& expansion.& Further& combination& with& an& ILF1α&
vaccine&increased&survival&of&tumourFbearing&mice&(Weiss,&Vitacolonna&et&al.&2009).&
As& the& immune& system&can& recognize,& control,& fight,& and&eliminate& cancer& cells&
(DuPage,&Mazumdar& et& al.& 2012;& Tran,& Burt& et& al.& 2013),& it& is& important& to& overcome&






gene& therapy& approaches& have& become& a& focus& for& cancer& immunotherapy& research.&
Gene&therapy&is&based&on&the&transfer&of&genetic&material&to&target&cells&and&usually&aims&
at&inserting&therapeutic&genes&or&silencing&diseaseFcausing&genes.&Several&techniques&to&
deliver& therapeutic& genes&have&been&developed&over& the&past& decades,& enhancing& the&
field& of& gene& therapy& and& paving& the& way& to& its& use& in& the& clinical& practice& (Escors,&
Breckpot& et& al.& 2012).& The& aim& of& cancer& immunotherapy& is& not& to& correct& a& diseaseF
causing& gene& but& rather& to& boost& or& induce& potent& and& longFlasting& CTL& responses& to&
TAAs.& Hence,& through& the& use& of& gene& carrier& vehicles,& TAAs& can& be& expressed& or&
specifically& targeted.& Additionally,& intracellular& signalling& pathways& of& interest& can& be&
altered& in& various& immune& cell& types.& Many& preFclinical& and& clinical& studies& use&
genetically&modified&DCs&and&T&cells& for&cancer& immunotherapy.&For& this&purpose,&viral&
vectors&are&most&effective,&leading&to&specific,&efficient,&stable,&and&longFterm&transgene&
expression.&&
A& milestone& in& gene& therapy& was& the& clinical& trial& to& correct& XFlinked& severe&
combined& immunodeficiency& (XFSCID)& in& children& using& a&mouse& leukemia& virus& (MLV)&
vector&(CavazzanaFCalvo,&HaceinFBey&et&al.&2000;&HaceinFBey&Abina,&Le&Deist&et&al.&2002;&





regression& and& durable& persistence& of& engineered& cells& in& patients& demonstrated& the&
therapeutic& potential& of& genetically& engineered& cells& for& cancer& immunotherapy&
(Morgan,&Dudley&et&al.&2006).&Nowadays,&the&most&popular&viral&vectors&for&DC&and&T&cell&






advantages&of& using& lentivectors&will& be&discussed,& justifying& the& choice&of& using& these&
vectors&as&gene&transfer&vehicles&in&this&thesis.&
1.3.1.!! HIV!STRUCTURE!AND!LIFE!CYCLE!
RNA& retroviruses,& such& as& lentiviruses,& integrate& a& cDNA& copy& of& their& RNA&
genome& into& host& cell& chromosomes& and& use& the& host& cell’s& machinery& to& replicate&
themselves.&This& is&achieved&through&reverse&transcription&and& integration&by&enzymes&
supplied& by& the& lentivirus& itself.& Lentiviruses& are& part& of& the& retroviridae& family.& The&
retroviridae& are& diploid& ssRNA& (single& stranded& RNA)& viruses,& and& their& genome& is&
organized&from&the&5’&to&the&3’&end&(positive&sense)&as&follows;&Genes&gag,&pol,&and&env&
are&encoded& in&the&genomic&RNA&of&all&members&of&the&retroviridae& family&(Fig.&1.6.A).&
Gag& encodes& the& structural& proteins& of& the& virus,& including& matrix,& capsid,& and&
nucleocapsid&proteins& (Fig.&1.6.B).#The#ssRNA& is&complexed&to&nucleocapsid&proteins& in&
the& viral& particle.& Pol& encodes& the& enzymes& reverse& transcriptase,& integrase,& and&
protease.& These& enzymes& are& used& for& reverse& transcription,& integration,& maturation,&
and& replication.& The&envelope&glycoprotein& is& encoded&by&env&and& it& is& inserted& in& the&
viral& membrane& that& surrounds& the& particle.& In& addition,& the& envelope& glycoprotein&
confers&cell&and&tissue&tropism&to&the&viral&particle.&The&retrovirida#can&be&divided& into&




cisFacting& RNA& elements& to& regulate& gene& expression,& reverse& transcription,& genome&
packaging,& and& particle& assembly& (Escors& and& Breckpot& 2010;& Liechtenstein,& PerezF
Janices&et&al.&2013).&&&








while& it& is& disassembling.& The& core& of& complex& retroviruses& on& the& other& hand& can& be&
actively& transported& into& the& nucleus& and& thus& enter& at& any& time& of& the& cell& cycle&
(Bukrinsky,&Haggerty& et& al.& 1993;& Lewis& and& Emerman&1994).&Once& in& the&nucleus,& the&
virus& dsDNA& is& integrated& into& the& host& cell& chromosomes& as& a& provirus.& The&U3& virus&
promoter&then&directs&gene&transcription&of&the&provirus.&The&virus&mRNA&encoding&the&
structural& and&enzymatic& proteins& is& translated&within& the& cytoplasm&of& the& cell.&Upon&
recognition& of& the& packaging& signal& (Ψ)& by& the& nucleocapsid& domain& of& gag,& the&
untranslated& fullFlength& viral& genomic& RNA& transcript& is& packaged& and& assembled& into&
viral& particles.& The& genomic& RNA& complexed& to& gag& then& assembles& at& the& plasma&
membrane&by& interaction&with&the&CFterminus&of&env.&As&the&viral&particles&bud&off&the&
host& cell,& they& further& mature& by& the& activation& of& the& HIV& protease& within& the& core&
which&processes&gag& into&each&separate&structural&protein.&This& leads&to&the&release&of&














Fig.#1.6.#HIVF1#virion#structure,#genome,#and# life# cycle.# (A)#HIV81#virion# is# represented#
here.#The#lipid#envelope#contains#the#envelope#transmembrane#glycoproteins#(ENV).#The#
matrix# proteins# (MA)# form# a# shell# enclosing# the# nucleocapsid# (NC)# proteins.# The#
nucleocapsid# is#made#of# the#RNA#genome#complexed#to#the#nucleocapsid#proteins.#The#






are# the# genes# Gag8Pro8Pol# and# Env# genes.# The# HIV81# regulatory/virulence# accessory#
genes#vif,# vpr,# vpu,#nef,# rev,#and# tat#are#distributed#along# the#genome.#RRE# represents#
the# rev# response# element.# (C)# The# scheme# depicts# the# retroviral# life# cycle.# R# indicates#
retrovirus# engagement# with# cellular# receptor# on# target# cell# membrane.# This# leads# to#
fusion# and# retrovirus# entry,# either# by# direct# fusion# or# endocytosis.# After# reverse#
transcription,# a# cDNA# copy# is# transported# to# the# nucleus# and# integrated# into# host# cell#
DNA# as# a# provirus.# The# host# cell’s# machinery# is# used# for# provirus# transcription# and#
translation#within# the#cytoplasm.#New#virus#particles#are#assembled#and#released# from#




The& capacity& of& viruses& to& efficiently& deliver& and& transcribe& their& genes& in& host&
cells&has&been&taken&advantage&of&for&gene&therapy&techniques.&Using&recombinant&DNA&
cloning& techniques& pathogenic& and& virulent& genes& are& removed& and& replaced& with&
therapeutic& genes.& For& this& purpose& a& wide& range& of& virus& species& have& been& used,&
including& adenoviruses,& herpes& viruses,& retroviruses,& and& lentiviruses.& Nevertheless,&
vectors&based&on&the&retroviridae&family&are&most&widely&used&nowadays,&as&they&lead&to&
stable& and& longFterm& transgene& expression& in& target& cells,& making& them& ideal& gene&
carriers.&In&the&1980s&retroviruses&were&among&the&first&virus&vectors&to&be&developed&for&
gene& therapy& (Mann,&Mulligan& et& al.& 1983),& leading& to& their& successful& application& for&
human&gene&therapy&in&the&2000s.&The&first&successful&(from&a&therapeutic&point&of&view)&
clinical& trials& using& viral& vectors& were& conducted& with& γFretroviral& vectors.& Due& to&
insertional&mutagenesis&severe&genotoxicity&developed&in&several&patients&indicating&that&
the& biosafety& of& viral& vectors& had& to& be& further& improved& for& use& in& human& therapy&
(CavazzanaFCalvo,&HaceinFBey&et&al.&2000).&&
Lentivectors& were& first& developed& and& applied& in& mouse& models& in& the& 1990s&
(Naldini,&Blomer&et&al.&1996;&Naldini,&Blomer&et&al.&1996)&and&their&biosafety&has&steadily&
increased& since& then.& In& the& beginning& retroviral& and& lentiviral& vectors&were& cloned& as&
fullFlength&infectious&cDNA&clones,&in&which&only&the&env&gene&was&deleted&and&provided&
in& trans& by& a& second& plasmid& during& coFtransfection& (Mann,& Mulligan& et& al.& 1983).&
Biosafety&was& increasingly& improved& by& providing& GagFPol& genes& in& a& third& expression&
plasmid&and&eliminating&nonFessential& virulence&genes& (Fig.&1.7).& Thus,& lentivectors&are&
usually&generated&by&coFtransfection&of& three&plasmids,& leading&to&the&release&of&virusF
like& particles& carrying& the& defective& nonFreplicating& genome.& These& three& plasmids& are&
the&transfer&vector&itself,&the&packaging&plasmid,&and&the&envelope&plasmid&(Fig.&1.7.A).&
The& transfer&vector&plasmid&encodes& the&defective&virus&genome&and& the& transgene&of&
interest,& while& the& packaging& plasmid& encodes& GagFPol& genes.& Finally,& the& envelope&
plasmid&encodes&the&envelope&glycoprotein.&A&widely&used&heterologous&(nonFHIV&env)&
envelope& glycoprotein& is& VSVFG& (vesicular& stomatitis& virus& G& protein),& which& confers& a&
wide& species& and& cell& tropism& to& the& lentivector&particles& (Yee,& Friedmann&et& al.& 1994;&
Akkina,&Walton&et&al.&1996;&Naldini,&Blomer&et&al.&1996;&Naldini,&Blomer&et&al.&1996).&The&
 66&
2nd& generation& lentivectors& still& contain& the& gagFpol,& rev,& and& tat& genes& within& the&
packaging&plasmid&but&the&viral&accessory&genes&(vif,&vpr,&vpu,&nef)&have&been&removed&
(Zufferey,& Nagy& et& al.& 1997)& (Fig.& 1.7.A).& The& 3rd& generation& lentivectors& are& tatF





Breckpot,& Aerts& et& al.& 2007;& He,& Munn& et& al.& 2007;& Escors& and& Breckpot& 2010;&
Liechtenstein,& PerezFJanices& et& al.& 2013)(Fig.& 1.7.B).& 3rd& generation& lentivectors& have&










integrationFdeficient& lentivectors& that& contain& mutations& in& the& integrase& gene,& thus&
transgenes& remain& in& the& nucleus& as& episomes,& circumventing& the& possibility& of&
insertional&mutagenesis&(YanezFMunoz,&Balaggan&et&al.&2006;&Karwacz,&Mukherjee&et&al.&
2009;&Hu,&Dai&et&al.&2010).&
Lentivectors&display& several& advantages&over&other& viral& vectors.&As& lentiviruses&
are& derived& from& complex& retroviruses& they& can& transduce& cells& irrespective& of& their&
division& status& (Bukrinsky,& Haggerty& et& al.& 1993;& Naldini,& Blomer& et& al.& 1996;& Naldini,&
Blomer&et& al.& 1996).& Thus,& these& vectors& can&efficiently& transduce&a&wide& range&of& cell&
types.& They& are& frequently& pseudotyped&with& VSVFG,& which& renders& them& structurally&
stable&and&leads&to&generation&of&relatively&high&titers.&Due&to&stable&genome&integration&
within& transcriptionally& active& chromatin& sites,& lentivector& transduction& leads& to&
prolonged& and& high& transgene& expression& (Mitchell,& Beitzel& et& al.& 2004).& Additionally,&
 67&
lentivectors& can& accommodate& relatively& large& gene& inserts& and& transduce& human& and&
mouse&DCs&with&a&superior&efficiency& than&adenoviral&vectors& (Esslinger,&Romero&et&al.&
2002).& Furthermore,& lentivectors& induce& less& antiFvector& immunity& than& other& viral&
vectors,&such&as&adenoviral&vectors,&a&crucial&asset&for&gene&therapy&(Barouch&and&Nabel&







to& target& them& specifically& is& important& (Dufait,& Liechtenstein& et& al.& 2012;& Dufait,&
Liechtenstein&et&al.&2013).&Targeting&can&be&achieved&by&several&methods,&including&the&
incorporation& of& different& promoters& in& the& transfer& plasmid.& In& this&way& it& is& assured&
that& the& transgene& is& expressed& in& a& cellFspecific&way& (Escors& and&Breckpot&2010).& The&
use& of& various& envelope& glycoproteins& from& different& viruses& with& various& tropisms&
(pseudotyping)&ensures&that&only&some&specific&cell&types&are&transduced&(Morizono,&Xie&
et&al.&2005;&Yang,&Yang&et&al.&2008;&Frecha,&Levy&et&al.&2010).&Further,&antibodies&can&be&
incorporated& that& recognize& specific& surface& receptors& into& the& lentivector& envelope&
membrane,&thus&leading&to&preferential&transduction&of&specific&cell&types&(Yang,&Bailey&
et&al.&2006;&Gennari,&Lopes&et&al.&2009;&Morizono,&Pariente&et&al.&2009).&These&strategies&
can&also&be&combined& to& increase&specificity& (Pariente,&Morizono&et&al.&2007;&Pariente,&
Mao&et&al.&2008;&Yang,&Yang&et&al.&2008).&
As& there& is& increasing& evidence& suggesting& that& lentivectors& are& less& genotoxic,&
they& have& started& replacing& γFretroviral& vectors& in& human& therapy& in& recent& years&
(Hematti,&Hong&et&al.&2004;&Modlich,&Bohne&et&al.&2006;&Bokhoven,&Stephen&et&al.&2009;&
Modlich,&Navarro&et&al.&2009)&(Montini,&Cesana&et&al.&2006;&Howe,&Mansour&et&al.&2008;&
Arumugam,& Higashimoto& et& al.& 2009;& Kustikova,& Schiedlmeier& et& al.& 2009;& Montini,&
Cesana& et& al.& 2009;& Biffi,& Bartolomae& et& al.& 2011;& Cesana,& Sgualdino& et& al.& 2012;&
Liechtenstein,&PerezFJanices&et&al.&2013).&Nevertheless,&there&are&still&more&clinical&trials&




(LIM& domain& only& 2)& (HaceinFBeyFAbina,& Von& Kalle& et& al.& 2003).& MLV& preferentially&
integrate&into&regulatory&sequences&such&as&transcription&start&sites.&Lentivectors&on&the&






any& serious&genotoxicity& in& clinical& trials&using& lentiviral& vectors& (Levine,&Humeau&et&al.&
2006;& Cartier,& HaceinFBeyFAbina& et& al.& 2009;& CavazzanaFCalvo,& Payen& et& al.& 2010;&
DiGiusto,& Krishnan&et& al.& 2010;&Biffi,& Bartolomae&et& al.& 2011;& Kalos,& Levine&et& al.& 2011;&
Porter,&Levine&et&al.&2011;&McGarrity,&Hoyah&et&al.&2013;&Tebas,&Stein&et&al.&2013;&Maude,&
Frey&et&al.&2014).& In&a&clinical&trial&for&βFthalassaemia,& lentivector& integration&led&to&the&
transcriptional&activation&of&HMGA2&in&erythroid&cells&with&further&increased&expression&





note,& genotoxicity&may& in& some& cases& result& from& the& choice& of& vector& transcriptional&
regulatory&elements&rather&than&the&vector& itself& (Maruggi,&Porcellini&et&al.&2009;&Ginn,&
Liao&et& al.& 2010;&Knight,&Bokhoven&et& al.& 2010).& There&are& two&major& fears& concerning&
viral& vector& use& in& patients,& the& first& is& oncogenic& potential& through& insertional&
mutagenesis& and& genetic& instability& while& the& second& is& production& of& replicationF
competent& virus.& Even& though& lentivectors& appear& to& induce& less& insertional&
mutagenesis,& the& use& of& nonFintegrating& lentivectors& can& further& reduce& genotoxicity&
potential&in&human&therapy&(YanezFMunoz,&Balaggan&et&al.&2006;&Karwacz,&Mukherjee&et&









The# figure# depicts# the# second# generation# lentivector# system.# Packaging# and# envelope#
plasmids# contain# a# strong# constitutive# promoter,# such# as# CMV# (Cytomegalovirus)#
promoter.# The# transfer# vector# encodes# a# defective#HIV81# genome#as# lacking#genes# are#
provided#by#the#packaging#and#envelope#plasmids.#Depicted#here#is#a#transfer#vector#with#
two#LTRs# (Long#Terminal#Repeats,#U38R8U5)#and# the#expression# cassette# containing#an#
internal# promoter# and# the# desired# transgene# (gene).# Ψ,# packaging# signal;# RRE,# rev#
response#element.#(B)#This#scheme#depicts#the#third#generation#lentivector#system.#In#this#
generation,#rev#and#tat#genes#are#removed#from#the#packaging#plasmid.#The#5’#HIV#U3#
region# has# been# replaced# by# a# strong# constitutive# promoter,# such# as# CMV# promoter,#
which#is#tat8independent.#(C)#The#third#generation#of#lentivectors#can#be#further#modified#
to# increase#biosafety# and# efficacy.# Further# improvements# are# indicated#as# stars.# These#
include# the# addition# of# the# cPPT# (central# polypurine# flap)# and# the# WPRE# (woodchuck#
post8transcriptional# regulatory#element).#The#removal#of#enhancers# from#the#3’#HIV#U3#
 70&
region# generates# self8inactivating# lentivectors# (ΔEnh).# Introducing# point# mutations# or#
deletions#within#the#integrase#attachment#sites#in#the#5’#U3#region#of#the#transfer#vector#












2007;& Breckpot,& Escors& et& al.& 2010;& Liechtenstein,& PerezFJanices& et& al.& 2013).& Recently,&
the& first& clinical& trials& using& lentivectorFmediated& cancer& immunotherapy& treatments&
showed&clinical&efficacy& (Kalos,& Levine&et&al.& 2011;&Porter,& Levine&et&al.& 2011).& In& these&
clinical& trials&T& cells&were& transduced&with& lentivectors&ex#vivo& to&express&CARs&against&
CD19&and&were&thus&applied& in& leukemia&patients.&Due&to&the&highly&promising&results,&
this&same&strategy&is&now&being&employed&in&a&variety&of&different&leukemias.&In&one&of&
the&most& recent& clinical& trials& complete& remissions& in& 90%& of& relapsed& and& refractory&
acute& lymphoblastic& leukemia& (ALL)& patients& was& achieved.& All& patients& acquired&
cytokineFrelease&syndrome&but&this&could&be&treated&effectively&with&antiFIL6&antibodies&
(Maude,&Frey&et&al.&2014).&&
In& these& recent& antiFcancer& clinical& successes,& T& cells& were& the& target& of&
lentivector& transduction,&but& significant& research& is& also&employed& in& targeting&DCs& for&
cancer& immunotherapy.& Lentivectors,& in& contrast& to& retroviral& vectors,& can& transduce&
nonFdividing& cells& such& as& DCs& (Bukrinsky,& Haggerty& et& al.& 1993;& Naldini,& Blomer& et& al.&






are& not& as& effective& at& transducing& DCs& without& affecting& their& viability& or& antigen&
presenting& capabilities& (He& and& Falo& 2006;& He& and& Falo& 2007;& He,&Munn& et& al.& 2007).&
Lentivector&transduction&was&shown&to&result&in&prolonged& in#vivo&antigen&presentation&
in&mouse&models,& thus& increasing& the&potency&and&duration&of&CTL& responses& (He&and&
Falo& 2006).& Thus,& preFclinical& studies& using& ex# vivo& manipulated& DCs& for& cancer&
immunotherapy& have& yielded& promising& results.& However,& translation& into& clinical&
practice&has&yielded&rather&disappointing&results&so&far&(Escors&2014).&This&may&partly&be&
due& to& the& fact& that& transferred&DCs& are& subjected& to& the& immunosuppressive& tumour&
environment,&once&transferred&to&the&patient.&Nevertheless,&DCs,&as&the&main&regulators&
of&adaptive&immunity,&represent&a&major&gene&therapy&target&for&cancer&immunotherapy&
and& lentivectors&are&an&efficient&tool& for&their&manipulation.& In&addition,&the& increasing&





The& initial& objective& of& this& thesis& was& the& development& and& assessment& of&




the& lentivector& vaccines& to& stimulate&TAAFspecific& T& cell& responses& in# vitro#and& in# vivo.&





development&of& an&ex#vivo&MDSC&differentiation& system.&Ex#vivo& differentiated&MDSCs&
were& extensively& characterized& and& their& T& cell& stimulatory& activities& tested& upon&
lentivector&transduction.&
The&three&main&objectives&of&this&PhD&thesis&can&be&summarized&as&the&following:&

























PCR& reactions& were& performed& using& GoTaqFlexi& DNA& Polymerase& (nonFproofF
reading,&Promega)&or&Phusion&Hot&Start&II&HighFFidelity&DNA&Polymerase&(proofFreading,&
2U/μl,&Thermo&Scientific)&in&a&C1000&thermal&cycler&(Bio&Rad).&PCR&reaction&reagents&and&
cycling& conditions& are& listed& below& (Tables& 2.2& and& 2.3).& Forward& and& reverse& primers&











































Restriction& enzyme& digestion& for& cloning& was& usually& performed& with& 10μg& of&
DNA& in& a& total& volume& of& 30μl.& 3μl& of& 10x& digestion& buffer,& 1μl& of& each& restriction&
enzyme,&DNA,&and&distilled,&autoclaved&H2O&were&incubated&at&37°C&for&2&hours.&Agarose&




1%& agarose& gels& were& prepared& by& dissolving& agarose& (D1& agarose& low& EEO,&
Conda)& in& 1x& TAE& buffer& (Table& 2.1).& After& cooling,& 0.5μg/ml& of& ethidium& bromide&




(BioFRad).& DNA& fragments& were& cut& from& gels& using& a& scalpel.& DNA& fragments& were&
purified&using&the&Gel&Extraction&kit&(Qiagen)&following&the&manufacturers’&instructions.&
2.1.5.!! LIGATION!REACTION!
Ligation& reactions& of& DNA& fragments& was& performed& using& T4& DNA& ligase& (1μl,&
Promega),& 10x& ligation& buffer& (1μl),& DNA& vector& (4μl),& and& DNA& insert& (4μl),& in& a& final&




For& sequencing& of& PCR& products& amplified&with& Taq& polymerase,& PCR& products&







distilled& water& according& to& manufacturer’s& instructions.& Using& a& LBFAgar& plate&
containing& tetracycline& (10μg/ml),& XL1& blue&E.# coli&were& grown&overnight& at& 37°C.& The&
following&day&a&single&colony&was&picked&and&grown&overnight&in&a&shaker&at&37°C&in&10ml&
of& LB& broth& (Lennox& Broth& base,& Invitrogen)& containing& tetracycline& (10μg/ml).& 1ml& of&
overnight&culture&(starter&culture)&was&then&grown&in&100ml&LB&(without&tetracycline)&for&
2&hours&in&a&shaker&at&37°C&without&tetracycline.&The&bacterial&culture&was&then&cooled&
for& 5& minutes& on& ice& and& centrifuged& for& 10& minutes& at& 4°C& and& 3000rpm.& Gentle&
resuspension&of&cell&pellet&in&50mliceFcold&TFBFI&buffer&(Table&2.1)&was&followed&by&a&5F
minute& incubation& on& ice.& The& centrifugation& step& was& repeated,& followed& by& gentle&
resuspension& performed& with& 4ml& of& iceFcold& TFBFII& buffer,& and& left& on& ice& for& 15&
minutes.& The&bacterial& suspension& in& TFBFII& buffer&were& aliquoted& and& stored& at& F80°C&
until&use.&
2.1.8.!! TRANSFORMATION!OF!COMPETENT!BACTERIA!
Competent& bacteria&were& thawed&on& ice& for& 20&minutes.& Purified&plasmid&DNA&




plated& on& LBFAgar& (Invitrogen)& plates& containing& ampicillin& (100μg/ml)& and& incubated&
overnight&at&37°C.&
2.1.9.!! PLASMID!PREPARATION!
Single& colonies& from& transformations& were& grown& overnight& in& LB& medium&
containing& ampicillin& (100μg/ml).& LB& volumes& depended& on& quantity& of& DNA& required,&




using& NanoDrop& (NDF1000;& NanoDrop& Technologies).& As& a& quality& control& for& each&
plasmid& preparation,& a& restriction& analysis& was& performed& usually& with& HindIII.& When&
required,& plasmids&were& cut&with& appropriate& restriction& enzymes& and&DNA& fragments&






Figure& 2.1.& shows& schematic& representations& of& the& lentivector,& packaging,& and&









xenoFantigen&HAFtagged& IiOVA,& or& tumourFantigen&HAFtagged& IiTRP1.&While&HAFtagged&
IiOVA&had&been&previously&constructed&and&used&in&our& laboratory&(Escors,&Lopes&et&al.&
2008;&Arce,&Breckpot&et&al.&2011),&HAFtagged&IiTRP1&was&engineered&for&this&study.&HAF
tagged& IiTRP1& gene&was& engineered& as& a& fusion&between& the& coding& regions&of& the&NF
terminus& of& the& MHC& II& invariant& chain& (Ii)& with& the& fullFlength& HAFtagged& mouse&
tyrosinase&related&protein&(Trp1)&gene,&a&known&melanomaFassociated&tumour&antigen.&!
For& the& generation& of& stable& cell& lines,& the& second& transgene& encoded& an&
antibiotic& resistance&gene&such&as&puromycin& resistance& (puroR).&When& indicated,&dual&
lentivector&plasmids&contained&the&PDFL1Fspecific&shortFhairpin&RNA&(shRNA)&designated&






















with# lentivector# expression# plasmids.# LTR,# Long# terminal# repeat;# RRE,# rev# response#
element;# cPPT,# central# polypurine# tract;# SFFV# p,# spleen# focus8forming# virus# promoter;#
CYTOK,#cytokine#gene;#WPRE,#Woodchuck#hepatitis#virus#post8transcriptional#regulatory#





Lentivectors& were& prepared& by& transient& transfection& of& 293T& cells& using& the&
FugeneF6& transfection& reagent& (Promega).& The& expression& plasmid& (containing& desired&
transgenes,& Fig.& 2.1.A,B)& was& mixed& and& coFtransfected& with& the& packaging& plasmid&
(p8.91,& containing& HIVF1& structural& genes)& and& VSVFG& envelope& plasmid& (pMDF
G)(Fig.2.1.C).&1.5μg&of&each&p8.91&(Plasmid&Factory)&and&pMDFG&(Plasmid&Factory)&were&
mixed&with&3μg&of&expression&vector&plasmid&in&a&final&volume&of&50μl&ultrapure&water.&
25μl& of& FugeneF6& in& 100μl& Dulbecco’s& Modified& Eagle& Medium& (DMEM,& Gibco)& were&
added& to& the& plasmid& mixture,& followed& by& a& 15& minute& incubation& time& at& RT.& The&
transfection& mixture& was& then& added& to& 80%& confluent& 293T& cells& and& supernatant&
containing&lentivector&particles&was&collected&every&24&hours&for&72&hours.&Supernatants&
were& filtered& (45μm& filters)& and& concentrated& 100Ffold& by& ultracentrifugation& (1.5F2&
hours&at&22000rpm)& through&a&20%&sucrose&cushion& in&phosphateFbuffered&saline& (PBS&
1x,& Lonza).& & Lentivectors&were& resuspended& in& PBS& containing&10%&glycerol,& aliquoted,&
and&stored&at&F80°C.&
2.2.3.!! LENTIVECTOR!TITRATION!
3*105& 293T& cells& were& transduced& with& 1μl& of& concentrated& lentivectors& and&
harvested&72&hours&later.&Lentivectors&containing&the&reporter&gene&GFP&were&titrated&by&
flow&cytometry.&The&percentage&of&GFP+&cells&represented&the&percentage&of&transduced&
cells.& In& this&way,& the& lentivector& titer& (infectious& units/ml)& could& be& estimated& by& the&
following&equation:&
Titer&(infectious&units/ml)=Number&of&cells&*&(%GFP+cells/100)*(1000/μl&used)&
Lentivectors& containing& no& fluorescent& reporter& gene& were& titrated& by&
quantitative& PCR& using& a& TaqMan®probe& (fluorescent& reporter& molecule,& Applied&
Biosystems),&as&previously&described&(Towers,&Stockholm&et&al.&1999;&Rowe,&Lopes&et&al.&
 82&
2006).& For& this& purpose,& transduced&293T& cells&were&harvested&and&genomic&DNA&was&
purified&using&the&DNeasy&Blood&and&Tissue&Kit&(Qiagen).&TheTaqMan®&gene&expression&
assay& (Applied& Biosystems)& was& used& to& estimate& the& number& of& integrated& HIVF1F
derived& vectors& in& transduced& cells.& Primer/probe& sequences& used& were& Primer& 1&
(GAGTCCTGCGTCGAGAGAGC),& primer& 2& (TGTGTGCCCGTCTGTTGTGT),& and& probe&
(CAGTGGCGCCCGAACAGGGA)& complexed& to& FAMFTAMRA,& were& used.& Dilutions& of&




Cycling& conditions& were& applied& according& to& manufacturer’s& instructions& and&





293T& and& B16& cell& lines& were& grown& in& Dulbecco’s& Modified& Eagle& Medium&
(DMEM,&Gibco),&supplemented&with&10%&FBS&(Foetal&bovine&serum,&Gibco),&LFglutamine&
(2mM,& Gibco),& penicillin& (100U/ml,& Gibco),& and& streptomycin& (100μg/ml,& Gibco).& Cells&
were&grown&and&maintained&at&37°C&in&a&humified&5%&CO2&incubator&and&split&every&2F3&
days&using& trypsin&EDTA& (Gibco).& The&H1299&human&nonFsmall& cell& lung& carcinoma&cell&
line&was&grown& in& the& same&conditions&but&using& the&RPMI&1640&medium& (Gibco).&The&
293T& cell& line& is& derived& from&human& embryonic& kidney& cells& and& contains& the& large& T&
antigen& from& simian& virus& 40.& 293T& cells&were&primarily& used& for& lentiviral& preparation&
and& titration.&B16&cells&are&mouse&melanoma&cells&and&were&primarily&used& for& in#vivo#
tumour& experiments.& 293T& cells&were& purchased& from& the&American& Type&Cell& Culture&




B16& cells& with& lentivectors& (multiplicity& of& transduction& of& 50)& coFexpressing& genes&
encoding& murine& GMFCSF& and& puromycin& resistance.& Transduced& cells& were& then&
selected& by& addition& of& 3μg/ml& puromycin& (CAYLAFInvivoGen).& H1299FhuIL4FhuGMCSF&
cells& were& generated& by& transducing& H1299& cells& with& two& lentivectors.& The& first&
lentivector& coFexpressed& human& GMCSF& and& puromycin& resistance& while& the& second&





BM&cells&were&collected&by& flushing&tibia&and& femur&with&Hank’s&balanced&salt& solution&
(HBSS,&Gibco),&supplemented&with&2%&FCS,&using&25G&needles&(BD&Microlance)&attached&
to& syringes.& Red& blood& cells& were& lysed& using& the& Red& Blood& Cell& Lysis& Buffer& (SigmaF
 84&
Aldrich).& For& preparation& of& BMFDCs& (Bone& marrowFderived& DCs),& BM& cells& were&
resuspended&in&Iscove’s&Modified&Dulbecco’s&Medium&(IMDM,&Gibco)&and&supplemented&




BMFDCs,& cells&were& treated&with&100ng/ml& LPS& (SigmaFAldrich)& at& least&4&hours&before&
use& in& in# vitro& assays.& For& preparation& of&myeloidFderived& suppressor& cells& (MDSCs)& a&
similar& protocol& was& followed.& Purified& BM& cells& were& cultured& for& 4& days& in& 75%&
conditioning&medium&(CM293T&and&CMB16)&before& transduction&or&use& in& in#vitro& assays.&
CM293T& and& CMB16& were& generated& by& collecting& supernatants& from& confluent& 293TF







The&white& layer& containing& the&white&blood& cells&was& retrieved&and&diluted&with&RPMI&
medium.&FicollFPaque™&PLUS&(GE&Healthcare)&was&added&to&Falcon&tubes&and&the&diluted&
blood& cells& were& added& gently& on& top& (without& disturbing& Ficoll& surface).& Tubes& were&
centrifuged& for& 45& minutes& at& room& temperature& at& 1500rpm,& without& a& brake.& The&
Peripheral&Blood&Mononuclear&Cell&(PBMC)&layer&was&collected&(underneath&plasma&and&
above&Ficoll& and& red&blood&cell& layers)& and&washed&with&RPMI.& Ten&million&PBMCs&per&
well& were& then& plated& in& M6& well& plates& and& left& at& 37°C& for& 4& hours.& Floating& cells&
(lymphocyte& fraction)& and& attached& cells& (monocytes)& were& aliquoted& and& frozen&
separately& at& F80°C.&Alternatively,& the&monocytic& fraction&was&washed&with&PBS& (room&
temperature)&and&cultured&with&CMH1299&for&three&to&five&days.&CMH1299&was&generated&by&





for& 20& minutes& with& mouse& Fc& Block™& (antiFCD16/CD32,& BD& Biosciences)& in& PBS&
supplemented& with& 20%& FBS.& Antibodies& directed& against& surface&markers& (Table& 2.3)&
were& diluted& to& the& required& concentration& in& PBS& supplemented& with& 20%& FBS& and&
mouse&Fc&Block™.&Cells&were&incubated&with&antibody&for&10&minutes&and&washed.&Cells&
could&then&be&used&to&perform&fluorescent&activated&flow&cytometry&(FACS).&To&perform&
intracellular& stainings,& cells& were& fixed& for& 20& minutes& (Cytoperm/Cytofix,& BD&
Biosciences).& For& staining& of& transcription& factors& or& nuclear& proteins& the&
FoxP3/Transcription& Factor& Staining& Buffer& Set& (eBioscience)& was& used.& Cells& were&
washed& and& incubated& with& buffer& from& appropriate& kit& containing& desired& antibody&
concentrations& (Table& 2.4).& Cells& were& washed& and& analysed& by& flow& cytometry& using&




Antibody! Alternate!Name! Fluorochrome! Clone! Company! Dilution!
!
CD11b& MacF1&alpha& PE& M1/70& BD&
Pharmingen&
1:500&
CD11b& MacF1&alpha& PEFCy7& M1/70& BD&
Pharmingen&
1:500&
CD11b& MacF1&alpha& FITC& M1/70& BD&
Pharmingen&
1:500&
CD11b& MacF1&alpha& AF647& M1/70& BD&
Pharmingen&
1:500&
CD11c& & APC& N418& Invitrogen&
&
1:500&
CD14& & PE& Sa14F2& BioLegend&
&
1:100&
IFA/IFE& MHC&Class&II& FITC& M5/114.15.2& BioLegend&
&
1:500&
IFA/IFE& MHC&Class&II& APC& M5/114.15.2& BioLegend&
&
1:500&
H2Kb& MHC&Class&I& Biotin& AF6F88.5& BioLegend&
&
1:100&
CD64a/b& FcgRI& AF647& X54F5/7.1& BD&
Pharmingen&
1:100&
LyF6C& & AF488& ERFMP20& AbDSerotec&
&
1:100&
LyF6G& & PEFCy7& 1A8& BioLegend&
&
1:100&
ICAMFI& & Biotin& YN1/1.7.4& BioLegend&
&
1:100&
CD49d& & Biotin& R1F2& BioLegend&
&
1:100&





Biotin& AFS98& eBioscience& 1:100&
CD34& & PE& HM34& BioLegend&
&
1:100&















CD80& B7F1& APC& 16F10A1& BD& 1:100&
 87&
Pharmingen&
CD86& & PE& GLF1& BioLegend& 1:100&
&




CD117& cFKit& PE& 2B8& BD&
Pharmingen&
1:100&




CD309& FLKF1& Biotin& Avas12a1& eBioscience& 1:100&
&
CD3& & PE& 17A2& BioLegend& 1:100&
&
CD4& & PE& RM4F5& eBioscience& 1:100&
&
CD8& & AF488& GK1.5& eBioscience& 1:100&
&
CD8a& & FITC& 53F6.7& eBioscience& 1:100&
&
CD62L& & PE& MELF14& AbDSerotec& 1:100&
&









& APC& JES5F16E3& eBioscience& 1:100&
FoxP3& & AF647& 150D& BioLegend& 1:100&
&




PE& FAF11& ebioscience& 1:100&












& PE& MP5F20F3& BioLegend& 1:100&





















































Integrin&alphaFX& PEFCy7& BFly6& BD&
Pharmingen&
1:100&

































inhibitors& as& recommended& by& the& manufacturer& (Protease& Inhibitor& Cocktail& tablets,&
Roche& Life& Science)& and& incubated& on& ice& for& 15& minutes.& Nuclei& were& removed& by&
centrifugation&in&a&microfuge&at&maximum&speed&for&1&min,&and&reducing&protein&buffer&
(Laemmli&Buffer)&was&added&to&supernatant.&Samples&were&heated&at&90°C&for&5&minutes&
before& freezing& (F80°C)& or& loaded& in& 10%& polyacrylamide& gels.& Total& protein& was& then&
separated& using& a& 10%& denaturing& SDSFpolyacrylamide& gel& in& SDS& running& buffer.&
Separated& proteins& were& then& transferred& to& a& Hybond& ECL& nitrocellulose& membrane&
(Amersham)& using& transfer& buffer& following& standard& conditions.& Membranes& were&
blocked&for&1&hour&at& room&temperature&with&blocking&buffer&and& incubated&overnight&
with& primary& antibody& (4°C).& Membranes& were& washed& with& washing& buffer& and&
incubated& with& HRPFconjugated& secondary& antibodies.& Membranes& were& washed& and&
developed& using& ECL& (Enhanced& chemiluminescence)& substrate& solution& containing& 1μl&
hydrogen&peroxide.&Western&Blots&were&developed&either& on& radiographic& film&or& in& a&
ChemiDoc&XRS+&System&(BioFRad).&
Transgene& expression& in& transduced& cells& was& detected& using& HA& tagFspecific&
rabbit&antibody&(Sigma).&For&detection&of&tumourFassociated&antigens&in&mouse&tumour&
tissue,& mouse& antiFtyrosinase,& TRP1,& TRP2,& and& Gp100Fspecific& antibodies& were& used&
(Abcam).&In&addition,&we&used&mouse&antiFiNOS&antibody&(Cell&Signaling),&polyclonal&antiF
P450R&antibody&(Abcam),&and&antiFGADPH&(Calbiochem)&for&analysis&of&myeloid&cells&and&
























BD& OptEIA™& Set& Mouse& GMFCSF& and& BD& OptEIA™& Set& Mouse& ILF10& were&
purchased& from& BD& Biosciences& and& mouse& IL12& and& IFNγ& ELISA& kits& were& purchased&
from& eBioscience.& ELISAs& were& performed& according& to& manufacturer’s& instructions.&




standards& and& samples& in& the& corresponding& wells& (diluted& in& assay& diluent)& for& two&
hours.& The& plate&was&washed& and&working& detector& (detection& antibody& and& SAvFHRP&
reagent)& was& added.& After& one& hour& of& incubation,& plate& was& washed& and& substrate&
solution& (TMB& Substrate& Reagent,& BD& Pharmingen)&was& added.& Incubation& time& varied&





ELISpot& 96& well& plates& coated& with& nitrocellulose& membranes& were& coated& with& a&
solution&of& IFNγ& capture&antibody& (1&μg/ml& concentration)&overnight& at& 4°C.& Then,& the&
wells& were& blocked& with& 20%& FCS& in& PBS& and& half& a& million& splenocytes& from& the&
appropriate& treated& mice& were& incubated& overnight& in& complete& IMDM& medium&
containing& 100& ng& class& I& or& class& II& OVA& peptides& per&ml& in& the& corresponding& wells.&







cell& line& (SMADFGFP),& previously& developed& by& our& laboratory& (Arce,& Breckpot& et& al.&






C57BL/6& and& BALB/c& mice& were& used& for& extraction& of& bone& marrow& and&
splenocytes.&C57BL/6&mice&were&used&for&vaccination&and&tumour&experiments.&OTFI&and&
OTFII& mice& were& used& for& ex# vivo& antigenFspecific& assays& as& these& mice& contain& OVAF
specific& CD8& and& CD4& T& cells,& respectively& (Hogquist,& Jameson& et& al.& 1994;& Barnden,&








10%& FBS& (Gibco),& LFglutamine& (2mM,&Gibco),& penicillin& (100U/ml,&Gibco),& streptomycin&
(100μg/ml,& Gibco),& recombinant& ILF2& (10U/ml,& Peprotech),& and& 2FMercaptoethanol&
(50μM,&SigmaFAldrich).&CD4&and&CD8&T&cells&were&purified&using&the&CD4+&T&cell&isolation&




Purified& CD8& T& cells& were& plated& at& 105& cells/well& in& 96Fwell& plates& and& were&




were& added& to& activated& T& cells& at& various& ratios.& When& indicated,& supernatants&
containing&IL12&were&added&at&250pg/well.&Monoclonal&antibodies&against&CTLAF4,&PDF1,&
 94&
and& control& hamster& IgG& (BioXCell,& UC10F4F10F11,& BE0033F2,& BE0091)& were& added& at&
10μg/ml& per& well.& To& evaluate& T& cell& proliferation,& cells& were& stained& with& antiFCD3&
antibody&and&CFSE&dilution&in&CD3+&cells&was&assessed&72&hours&later&by&flow&cytometry.&
Alternatively,& cell& cultures& were& stained& with& CD11b,& CD8,& and& Ki67& FACS& antibodies.&
Supernatants& were& collected& and& IFNγ& concentrations& were& analysed& using& ELISA&
(eBioscience).&
Suppression&assays&were&performed&in&a&similar&way&using&human&H1299FMDSCs.&
For& this& purpose,& Dynabeads®Human& TFactivator& CD3/CD28& (Gibco)& were& used& to&
activate& thawed& human& lymphocytes,& previously& purified& from& whole& blood& and& kept&
frozen& at& –80& degrees& until& use.& After& 4& hours& of& incubation& with& activation& beads,&
H1299FMDSCs&were& added& at& various& ratios.& 72& hours& later& cell& cultures&were& stained&
with&CD4,&CD8,&and&Ki67&FACS&antibodies&and&analysed&by&flow&cytometry.&
2.4.4.!! MIXED!LYMPHOCYTE!REACTION&
Spleens&were& collected& from&BALB/c&mice&and&CD8&and&CD4&T& cells&purified,& as&














2.4.7.!! DIRECT! LENTIVECTOR! VACCINATION! AND! ANALYSIS! OF! IN# VIVO! T! CELL!
RESPONSES&
C57BL/6& mice& were& subcutaneously& (s.c.)& injected& at& the& base& of& the& tail& with&
concentrated& lentivectors& (1*107& infectious&units/mouse).& 5&naïve&mice&were&used&per&
group.& Two&weeks& later& spleens& could& be& harvested& and& isolated& for& analysis& of& T& cell&
responses.& Splenocytes& of& mice& vaccinated& with& IiOVAFcontaining& lentivectors& were&
isolated& and& cultured& overnight& in& the& presence& of& class& I& and& II& OVA& peptides,& as&
previously& described& (Arce,& Breckpot& et& al.& 2011).& Class& I& OVA& peptide& (SIINFEKL)& and&
class&II&OVA323F339&peptide&were&generously&donated&by&Prof.&Mary&Collins.&0.1ng/μl&class&I&
OVA&peptide&and&2μg/ml&class& II&OVA323F339peptide&were&used.&Th1/2/17,&Treg,&and&CTL&
responses& were& assessed& by& flow& cytometry& using& the& appropriate& antibody&
combinations.&!
Splenocytes& from& mice& vaccinated& with& IiTRP1Fcontaining& lentivectors& were&
isolated& and& cultured& overnight& with& BMFDCs& that& were& previously& transduced& with&
IiTRP1Fcontaining&lentivectors&and&activated&with&LPS&(100ng/ml).&Th1&and&CTL&responses&
were& assessed& by& flow& cytometry& using& the& appropriate& antibody& combinations.& All&
vaccination& experiments& were& repeated& independently& at& least& twice,& unless& stated&
otherwise.!
2.4.8.!! TUMOUR!EXPERIMENTS!ASSESSING!LENTIVECTOR!VACCINES&
Prophylactic& experiments&were& performed& by& vaccination& of& healthy&mice&with&
lentivectors& (1*107& infectious& units/mouse).& Two& weeks& later& B16& cells& were&
subcutaneously& transferred& at& the& base& of& the& tail.& Tumour& growth& and& survival& was&




























week& (during& the& following2&weeks)&MDSC&mice&were& s.c.& or& intraFtumourally& injected&
with& 2*106& B16FMDSC& cells.& Tumour& growth& and& survival& was& monitored& and& mice&
sacrificed& when& tumour& sizes& grew& above& 150mm2.& 5&mice& per& group&were& used& and&
experiments& repeated& independently& at& least& twice.& When& indicated,& B16FFluc& cells&
(expressing&the&firefly& luciferase&gene,&kindly&donated&by&Dr.&Frederick&Arce,&UCL)&were&
used.& In& this& way,& we& assessed& tumour& size& also& via& bioluminescence& imaging.& Upon&
intraperitoneal& injection& of& luciferin& (3mg/mouse,& VivoGlo™& Luciferin,& Promega)&
bioluminescence&was& recorded&with& a& Photon& Imager& Optima& bioluminescence& device&
(Biospace&Lab).&Images&were&processed&and&bioluminescence&signal&quantified&using&the&
M3&vision& software& (Biospace& Lab).& Regions&of& interest& (ROIs)&were&defined&as& regions&
 97&








MDSCs,& 293TFMDSCs,& and& conventional& immature&BMFDCs&were& collected&on&day& 8& of&
culture&and&pelleted&by&centrifugation.&Cell&pellets&were&lysed&using&a&buffer&containing&7&
M&urea,&2&M&thiourea,&4%&(v/v)&CHAPS,&and&50&mM&DTT.&Homogenates&were&centrifuged&




The& iTRAQ& system& was& used& to& perform& a& shotgun& comparative& proteomic&
analysis&of&total&cell&extracts(Unwin,&Griffiths&et&al.&2010).&160μg&of&protein&extracts&were&
precipitated&with&methanol/chloroform&and&pellets&dissolved&in&7&M&urea,&2&M&thiourea,&
and& 4%& (v/v)& CHAPS.& iTRAQ& labeling& was& performed& according& to& the& manufacturer’s&
































Peptides&were& then& fractionated& to& increase& proteome& coverage.& Peptide& pool&
was&injected&into&an&Ettan&LC&system&with&an&XFTerra&RP18&preFcolumn&(2.1mm&x&20mm)&
and&a&high&pH&stable&XFTerra&RP18&column&(C18;&21mm&x&150mm;&3.5μm)&(Waters)&at&a&
flow& rate& of& 40& μl/min.& Peptides& were& eluted& with& a& mobile& phase& B& of& 5F65%& linear&
gradient& over& 35&minutes& (A,& 5mM&ammonium&bicarbonate& in&water,& pH&9.8;& B,& 5mM&





Peptide& mixtures& were& separated& by& reverse& phase& chromatography& using& an&
EksigentnanoLC& ultra& 2D& pump,& fitted&with& a& 75μm& ID& column& (Eksigent& 0.075& x& 150).&
Samples&were&desalted&and& concentrated&by& loading& in& a&0.5cm& length&300μm& ID&preF
column& (packed& as& separating& column).&Mobile& phases&were& 100%&water& 0.1%& formic&
acid0.1%& formic& acid& (FA)& (buffer& A)& and& 100%& Acetonitrile& 0.1%& FA& (buffer& B).&
Development& of& column& gradient& was& performed& in& a& 70& minute& two& step& gradient.&
Gradient&was&developed& from&2%&B& to&30%&B& in&60&minutes&and&30%B&to&40%&B& in&10&
minutes.& Column& was& then& equilibrated& using& 95%& B& for& 5& minutes& and& 2%& B& for& 15&
minutes.& Importantly,& preFcolumn& was& always& in& line& with& column& and& flow& was&
maintained&all& along& the&gradient&at&300&nl/min.& Eluting&peptides&were&analysed&using&
the& AB& Sciex& 5600& TripleTOFTM& system.& Information& data&was& acquired& upon& a& survey&
scan&performed&in&a&mass&range&from&350&m/z&up&to&1250&m/z&in&a&scan&time&of&250&ms.&
Top&25&peaks&were& selected& for& fragmentation& and& a&minimum&accumulation& time& for&
MS/MS&was& set& to& 75&ms& giving& a& total& cycle& time& of& 2.1& seconds.& Product& ions&were&





for& database& search& and& ProgroupTM& for& data& grouping.& Each& MS/MS& spectrum& was&
searched& against& a& database& of& murine& protein& sequences& (Uniprot& complete& mouse&
proteome),&as&described&previously&(Liechtenstein,&PerezFJanices&et&al.&2014).&The&search&
parameters& allowed& for& cysteine& modification& by& MMTS& and& biological& modifications&
programed& in& the& algorithm& (i.e.& phosphorylations,& amidations,& semitryptic& fragments,&
etc.).& Reporter& ion& intensities& were& bias& corrected& for& the& overlapping& isotope&
contributions& from& the& iTRAQ& tags& according& to& the& certiﬁcate&of& analysis& provided&by&
the& reagent& manufacturer& (ABsciex).& The& peptide& and& protein& selection& criteria& for&
relative& quantitation& were& performed& as& follows.& Only& peptides& unique& for& a& given&
 101&
protein& were& considered& for& relative& quantitation,& excluding& those& common& to& other&
isoforms&or&proteins&of&the&same&family.&Proteins&were&identified&on&the&basis&of&having&
at& least& one& peptide& with& an& ion& score& above& 99%& confidence.& Among& the& identified&
peptides,& some& of& them&were& excluded& from& the& quantitative& analysis& for& one& of& the&
following&reasons:& (i)&The&peaks&corresponding&to&the& iTRAQ& labels&were&not&detected;&
(ii)&the&peptides&were&identified&with&low&identification&confidence&(<1.0%);&(iii)&the&sum&
of& the& signalFtoFnoise& ratio& for&all&of& the&peak&pairs&was&<6& for& the&peptide& ratios.&The&
protein& sequence& coverage& (95%& conf.)& was& estimated& for& specific& proteins& by& the&
percentage& of& matching& amino& acids& from& the& identified& peptides& having& confidence&
greater& than& or& equal& to& 95%& divided& by& the& total& number& of& amino& acids& in& the&
sequence.&Several&quantitative&estimates&provided&for&each&protein&by&ProteinPilot&were&
utilized:& the& fold& change& ratios& of& differential& expression& between& labelled& protein&












displayed& corresponded& to& those& reporting& a& 1%&Global& False&Discovery& Rate& (FDR)& or&
better.& The& mass& spectrometry& proteomics& data& have& been& deposited& to& the&
ProteomeXchange& Consortium& (http://proteomecentral.proteomexchange.org)&





The& proteomic& information& could& then& be& analysed& using& various& bioinformatic&
tools,&including&DAVID&(Database&for&Annotation,&Visualization&and&Integrated&Discovery)&
Bioinformatics&Resources&(v6.7)&and&PANTHER&(Protein&annotation&through&evolutionary&
relationship)& (http://www.pantherdb.org/)& software& tools& (Huang& da,& Sherman& et& al.&
2009;&Mi,&Muruganujan&et&al.&2013).&These&programs&can&detect&and&infer&differentially&
activated/deactivated&pathways& as& a& result& of& cell& type&differences.&UniProtKnowledge&
base&(Universal&Protein&Resource,&http://www.uniprot.org/)&was&used&to&obtain&protein&
functional&information.&In&addition,&STRING&(Search&Tool&for&the&Retrieval&of&Interacting&
Genes)& software& (v.9.1)& (http://stringdb.org/)(Franceschini,& Szklarczyk& et& al.& 2013)&was&





and& statistical& analyses.& No& data& was& considered& an& outlier.& All& experiments& were&
repeated&independently&at&least&twice,&unless&stated&otherwise.&Means&were&compared&
using&an&unpaired&TFstudent&test&or&oneFway&ANOVA.&Flow&cytometric&data&from&surface&
or& intracellular& staining& from& multiple& groups& were& analysed& by& oneFway& ANOVA&
followed& by& a& Tukey´s&a# posteriori& test.& Percentages& of& T& cells& in& in# vitro& assays&were&
normally& distributed& and& analysed& with& oneFway& ANOVA& followed& by& a& Tukey´s& a#
posteriori& test.& Three& independent& reactions& per& group& were& used& for& most& in# vitro&
assays.& Data& from& independent& experiments& was& pooled& to& increase& statistical&
sensitivity,&unless&stated&otherwise.&
For& in# vivo& experiments,& 5& mice& per& group& were& used& following& the& results& of&
Mead’s& resource& equation& for& power& analysis.& Survival& data& from& tumour& experiments&
was&compared&using&the&LogFRank&test.&Tumour&sizes&and&lifespan&were&compared&with&
the&nonFparametric&tests&U&of&MannFWhitney&or&Kruskall&Wallis.&&
Significant,& very& significant& and& highly& significant& differences& were& indicated& in&
the& figures&with& *,& **& or& ***&when& the& associated&probability&was& P<0.05& (twoFtailed,&





CHAPTER! 3:! IL12! EXPRESSION! AND! PD+L1! SILENCING! INDUCES!





of& cytotoxic&CD8+&T& lymphocytes& (CTLs).&T&cells& specific& for& tumourFassociated&antigens&
(TAAs)& already& circulate& systemically& in& naïve& and& tumourFbearing& individuals& but& are&
mainly& unresponsive& (Novellino,& Castelli& et& al.& 2004;& Boon,& Coulie& et& al.& 2006).&










melanoma& is& still& increasing& (Jemal,& Devesa& et& al.& 2001;& Jemal,& Siegel& et& al.& 2010)& and&
treatment& options& are& limited& when& disease& has& progressed& to& the& metastatic& stage.&
Nevertheless,& several& melanomaFassociated& tumour& antigens& have& been& identified&
(Novellino,&Castelli&et&al.&2004;&Boon,&Coulie&et&al.&2006;&Cipponi,&Wieers&et&al.&2011)&and&
patients& can& raise& autologous& antiFmelanoma& and& tumourFinfiltrating& T& cell& responses&
(Boon,&Coulie&et& al.& 2006;&Cipponi,&Wieers&et& al.& 2011).&MelanomaFassociated&antigens&
can& be& grouped& into& three& categories;& early& melanocyte& differentiation& antigens,& late&
melanocyte& differentiation& antigens,& and& a& group& of& cancerFtestis& antigens.& Early&
 106&
melanocyte&differentiation& antigens& are& represented&by& gp100& (Bakker,& Schreurs& et& al.&
1994;& Kawakami,& Eliyahu& et& al.& 1994)& and& MelanFA/MART1& (Kawakami,& Eliyahu& et& al.&
1994),&while& late&melanocyte&differentiation&antigens& include& tyrosinase& (Brichard,&Van&
Pel& et& al.& 1993),& TRP1& (TyrosinaseFrelated&protein&1)& (Wang,& Johnston&et& al.& 1998)& and&
TRP2&(TyrosinaseFrelated&protein&2)&(Wang,&Appella&et&al.&1996).&The&MAGE&(Melanoma&
antigen&gene)&superfamily&(van&der&Bruggen,&Traversari&et&al.&1991)&and&NYFESOF1&(Chen,&
Scanlan& et& al.& 1997)& antigens& are& cancerFtestis& antigens,& also& overFexpressed& in& other&
cancer& types& (Brasseur,& Marchand& et& al.& 1992;& Duffour,& Chaux& et& al.& 1999;& Gnjatic,&
Nishikawa&et&al.&2006;&Pollack,&Jungbluth&et&al.&2012).&&&&&
Many& preFclinical& (Overwijk,& Lee& et& al.& 1999;& Bronte,& Apolloni& et& al.& 2000;&
GuevaraFPatino,& Engelhorn& et& al.& 2006;& Bobisse,& Rondina& et& al.& 2009;& Liu,& Peng& et& al.&
2009;& Vacchelli,& Martins& et& al.& 2012)& and& clinical& studies& (Marchand,& van& Baren& et& al.&
1999;&Germeau,&Ma&et&al.&2005;&Ribas,&Weber&et&al.&2011;&Vacchelli,&Martins&et&al.&2012;&
Aranda,& Vacchelli& et& al.& 2013;&Wilgenhof,& Corthals& et& al.& 2014;& Rotte,& Bhandaru& et& al.&
2015)& using& melanoma& TAAs& have& been& conducted.& MelanomaFspecific& responses&
initiated&by&vector&vaccination&encoding&TRP2&rejected&established&B16&tumours&in&mice&
and&this&effect&depended&on&CTL&responses&(Bronte,&Apolloni&et&al.&2000).&Genetic&TRP1&
vaccines& on& the& other& hand&were& only& effective& at& inducing& antiFtumour& responses& in&
mice&when&TRP1&was&mutated,&suggesting&that&wildFtype&TRP1&is&a&poorly&immunogenic&
TAA& (GuevaraFPatino,& Engelhorn& et& al.& 2006;& Liu,& Peng& et& al.& 2009).& In& a& different& preF
clinical& study,& vaccination& with& a& recombinant& vaccinia& virus& encoding& TRP1& led& to&
elimination&of&normal&and&malignant&melanocytes&and&could&confer&protection&from&B16&
melanoma.&Interestingly,&while&this&response&depended&on&TRP1Fspecific&antibodies,&no&
TRP1Fspecific& CTLs& could& be& detected& (Overwijk,& Lee& et& al.& 1999).& Ex# vivo& engineered&
TRP1Fspecific&CTLs&slowedFdown&B16&tumour&progression&but&tumours&eventually&grew&
out.&The&authors&suggested&that&T&cell&exhaustion&could&be&a&possible&cause&for&tumour&











used& for& the& preparation& of& melanoma& vaccines& for& use& in& clinical& practice& (Rotte,&
Bhandaru& et& al.& 2015).& Clinical& studies& have& shown& an& increase& in& TAAFspecific& CTL&
numbers&but&responses&have&been&rather&limited&(Ribas,&Weber&et&al.&2011).&Vaccination&
of&melanoma& patients&with&MAGE,&MelanFA,& or& tyrosinase& antigens& can& raise& tumourF
infiltrating&T&cell&responses&against&various&melanoma&TAAs&(including&TAAs&not&included&
in& the& tumour& vaccines)& (Germeau,&Ma&et& al.& 2005;&Ribas,&Weber&et& al.& 2011)& and& can&
cause& stable& disease& or& tumour& regression& in& about& 30%& of& patients& (Marchand,& van&
Baren& et& al.& 1999;& Ribas,& Weber& et& al.& 2011).& Further,& a& recent& clinical& trial& used&
autologous&DC& transfer&where&monocyteFderived&DCs&were&electroporated&with&mRNA&
encoding& fusion&proteins&between&MAGEFA1,&AF3,& FC2,& tyrosinase,&MelanA/MARTF1,&or&
gp100&and&an&HLA&class&IIFtargeting&sequence.&In&combination&with&IFNαF2b&this&resulted&
in&encouraging& longFterm&overall& survival& rates& (Wilgenhof,&Corthals&et&al.&2014).&Thus,&
this& data& confirms& that& natural&melanoma& TAAFspecific& T& cell& responses& exist& but& that&
they&eventually&lose&efficacy.&Thus,&while&tumour&vaccines&have&been&able&to&raise&high&
numbers& of& TAAFspecific& CTLs& in& immunized& patients,& clinical& results& have& been& rather&
disappointing.& Delivery& of& TAAs& alone& is& therefore& not& enough& to& raise& effective& CTL&









To& modulate& T& cell& activation,& it& is& first& necessary& to& understand& the& highly&
regulated& process& of& antigen& presentation& and& T& cell& activation.& DCs& are& the& main&
professional&APCs&and&when&they&encounter&pathogenic&or&tumourFassociated&antigens,&
DCs&mature,&and&migrate&to&secondary&lymphoid&organs&(Rescigno,&Martino&et&al.&1998;&
Gallucci,& Lolkema&et& al.& 1999;&Ardeshna,& Pizzey& et& al.& 2000;& Fong& and& Engleman&2000;&
Lipscomb&and&Masten&2002;&Breckpot,&Escors&et&al.&2010;&Goold,&Escors&et&al.&2011).& In&
secondary& lymphoid& organs&DCs& present& antigen& to& CD4& or& CD8& T& cells,& depending& on&
whether&the&antigens&are&complexed&to&MHC&II&or&MHC&I&molecules,&respectively.&MHC&I&
molecules& are& complexed& to& intracellular& antigens,& such& as& TAAs& or& viral& antigens.&
Intracellular& antigens& are& degraded&by& the& proteasome& and& loaded&onto&MHC& I& in& the&
endoplasmic&reticulum&(ER)&before&transport&to&the&cell&membrane&(Fong&and&Engleman&
2000).&MHC&I&molecules&are&recognized&by&CD8&T&cells,&which&can&be&activated&to&acquire&
CTL& effector& functions& upon& antigen& encounter.& MHC& II& molecules& are& complexed& to&
antigens& that& are& usually& (but& not& always)& phagocytosed& by& APCs& and& degraded& in&
endosomes,&thus&generally&representing&peptides&from&extracellular&pathogens.&MHC&II&










Signal& 1& is& initiated& by& the& specific& binding& of& the& TCR& to& the& peptideFMHC& (pF
MHC)& complex& but& this& is& not& sufficient& for& T& cell& activation.& Quite& the& contrary,& TCR&












2004;& Liang,& Greenwald& et& al.& 2006;& Butte,& Keir& et& al.& 2007;& Karwacz,& Bricogne& et& al.&
2011).&Thus,&the&overall&activation&status&of&T&cells&depends&on&the&integration&of&positive&




such& as& tollFlike& receptors& (TLRs)& on& DCs,& leading& to& upFregulation& of& coFstimulatory&
molecules&and&pFMHC&complexes&(Nurieva,&Thomas&et&al.&2006;&Escors,&Lopes&et&al.&2008;&
Arce,&Breckpot&et&al.&2011).&&
&At& this& stage,& the& T& cell& has& recognized& the& antigen& on& DCs& and& has& received&
sufficient&positive&coFstimulatory&signals&to&be&activated.&However,&T&cell&activation&alone&
is& not& sufficient& for& the& T& cell& to& acquire& appropriate& effector& capacities.& Additional&
signals& have& to& be& provided& in& the& immunological& synapse& to& polarize& T& cell&
differentiation.& Signal& 3& thus& determines& the& differentiation& of& the& activated& T& cell&
through& cytokine& release,& also& called& cytokine& priming& (Fig.& 3.1.A).& Depending& on& the&
context& in& which& DCs& encounter& the& pathogenic& molecules& they& secrete& different&
cytokines&into&the&immunological&synapse.&(Kapsenberg,&Hilkens&et&al.&1999;&Curtsinger,&
Johnson&et& al.& 2003;&Curtsinger,& Lins& et& al.& 2003).& CD4&T& cells& thereby&acquire&effector&
phenotypes&and&functions&(Th1,&Th2,&Th17,&Treg)(Fig.&3.1.A).&For&Th1&polarization&DCs&are&
required& to& secrete& IFNγ& and& IL12& into& the& immunological& synapse.& CD4& Th1& cells& are&
crucial&for&the&effective&activation&of&antiFtumour&CD8&CTL&responses&and&effective&antiF







strong& and& rapid& proFinflammatory& reactions& (Bettelli,& Carrier& et& al.& 2006;& Sutton,&
Brereton&et&al.&2006;&McGeachy,&BakFJensen&et&al.&2007;&Lewkowich,&Lajoie&et&al.&2008;&
Larsen,& Bonefeld& et& al.& 2009;& Ortega,& Fernandez& et& al.& 2009).& Further,& Tregs& can& be&
induced&by& secretion&of& IL10&and&TGFβ& (O'Garra&and&Vieira&2004;&O'Garra,&Vieira&et&al.&
2004;&Rutella,&Danese&et&al.&2006;&Escors,&Lopes&et&al.&2008;&Saraiva&and&O'Garra&2010;&
Arce,&Breckpot&et&al.&2011).&Appropriate&cytokine&secretion&by&APCs&is&thus&crucial&for&the&
acquisition& of& cytolytic& effector& functions.& In& the& absence& of& signal& 3& T& cells& acquire& a&
tolerogenic& phenotype,& unless& antigen& levels& are& high& (Curtsinger,& Lins& et& al.& 2003;&




the& engagement& of& pattern& recognition& receptors& (such& as& TLRs)& on& their& surface.& TLR&
ligation&ensures&the&strong&activation&of&DCs&and&determines&the&type&of&cytokines&that&
are& secreted& into& the& immunological& synapse.& Different& TLR& ligands& will& result& in&
activation& of& differential& signalling& pathways& in& DCs,& thus& determining& their& activation&
status& and& cytokine&production.& TLR4& ligation& for& example& induces&DC&maturation& and&
IL12& secretion,& leading& to& stimulation&of&antiFtumour& immune& responses& (Cisco,&AbdelF
Wahab&et&al.&2004;&BekeredjianFDing,&Roth&et&al.&2006;&Apetoh,&Ghiringhelli&et&al.&2007;&
Breckpot& and& Escors& 2009).& On& the& contrary,& TLR2& stimulation& mainly& activates& ERK&
(Extracellularly& regulated& protein& kinase)& signalling,& prevents& DC& maturation& and&
stimulates& IL10& secretion.& TLR2& stimulation&will& therefore& lead& to& immune& suppression&
rather&than&activation&(Dillon,&Agrawal&et&al.&2006;&Manicassamy,&Ravindran&et&al.&2009).&
DCs& can& indirectly& receive& inflammatory& signals& from& other& immune& cells& within& the&
inflammatory&tissue.&There&is&increasing&evidence&suggesting&that&directly&and&indirectly&
















Fig.# 3.1.# ThreeFsignal# model# of# antigen# presentation# in# the# immunological# synapse.#
Schemes# depict# antigen# presentation# by# DCs# (left)# to# CD4# T# cells# (right).# Peptide8MHC#
complexes#interact#with#TCR#of#T#cell#to#initiate#signal#1.#Co8stimulatory#(CD80/CD86)#or#
co8inhibitory# (CD80/PD8L1)# ligands# on# DCs# bind# to# their# receptors# on# T# cells# (CD28,#
CTLA.4,#PD81),#representing#signal#2.#Furthemore,#cytokine#secretion#(Signal#3)#by#the#DC#
induces# T# cell# differentiation.# (A)# Cytokine# combinations# leading# to# differentiation# of#
several#CD4#T#helper#subtypes#are#depicted.#(B)#Scheme#depicts#indirectly#versus#directly#
activated#DCs.#On#top,#the#directly#activated#DC#provides#all#3#signals#to#the#interacting#T#






be& reFactivated& in& patients& (Novellino,& Castelli& et& al.& 2004;& Germeau,& Ma& et& al.& 2005;&
Boon,& Coulie& et& al.& 2006;& Cipponi,&Wieers& et& al.& 2011;&Mellman,& Coukos& et& al.& 2011),&
targeting& T& cell& reFactivating&mechanisms& represents& an& attractive& strategy& for& cancer&
immmunotherapy.& One& way& to& achieve& this& would& be& through& modulation& of& coF
stimulation& during& TAA& presentation.& Modulation& of& coFstimulation& can& be& achieved&
through&activation&of&signalling&pathways&in&DCs&(Escors,&Lopes&et&al.&2007;&Breckpot&and&
Escors&2009;&Arce,&Breckpot&et&al.& 2011;&Arce,&Kochan&et&al.& 2012;& Franks,&Wang&et&al.&
2013).&Activating&the&appropriate&intracellular&pathways&induces&upFregulation&of&MHC,&
coFstimulatory,&adhesion,&and&cytokine&molecules,&thus&assuring&that&T&cells&receive&the&
appropriate& signals& in& the& immunological& synapse& (Liechtenstein,& Dufait& et& al.& 2012).&
Another&way&to&modulate&coFstimulation&is&to&block&negative&coFstimulatory&interactions&
between& tolerogenic&DCs& and& naïve& or& antigenFexperienced& T& cells.& This& approach& has&











types& including&DCs,&T&cells,&B&cells,&and&macrophages& (Latchman,&Liang&et&al.&2004).& In&














can& inhibit& the& activation,& expansion,& and& differentiation& of& naïve& selfFspecific& T& cells.&
Second,& PDFL1& interaction& can& inhibit& the& reactivation,& expansion,& and& function& of&
effector& and& antigenFexperienced& T& cells& (Ansari,& Salama& et& al.& 2003;& Keir,& Butte& et& al.&
2008;&Francisco,&Sage&et&al.&2010).&
Importantly,& PDFL1& is& highly& expressed& in& many& human& and& mouse& cancers&
(Latchman,&Wood&et&al.&2001;&Blank,&Gajewski&et&al.&2005),&including&melanoma&(Gadiot,&
Hooijkaas&et&al.&2011),&hepatocellular&carcinoma&(Gao,&Wang&et&al.&2009),&and&lymphoma&
(Andorsky,& Yamada& et& al.& 2011;& Chen,& Chapuy& et& al.& 2013).& In& certain& studies,& PDFL1&
expression& was& shown& to& correlate& with& poor& prognosis,& although& this& remains&
somewhat& controversial& and& varies& between& tumour& types& (Gao,& Wang& et& al.& 2009;&
Gadiot,& Hooijkaas& et& al.& 2011).& It& is& clear& though& that& tumours& can& use& PDFL1& to&
 115&
effectively& inhibit& antiFtumour& immune& responses& (Blank,&Gajewski& et& al.& 2005;& Zhang,&
Gajewski&et&al.&2009;&Samimi,&Benoit&et&al.&2010;&Zhou,&Munger&et&al.&2010;&Andorsky,&
Yamada&et&al.&2011).& Interference&with&PDFL1/PDF1&signalling&can& therefore&be&used& to&
enhance&coFstimulation&and&thus& improve&tumour&vaccines.&Several&approaches&can&be&
used& to& target& this& signalling& pathway.& The& simplest& approach& is& to& systemically&
administer& blocking& antibodies& to& PDFL1& or& PDF1& (Hirano,& Kaneko& et& al.& 2005;& Zhang,&
Gajewski&et&al.&2009;&Zhou,&Xiao&et&al.&2010).&Blocking&of&PDFL1/PDF1&leads&to&acquisition&









PDFL1/PDF1& signalling& alone& may& lead& to& limited& efficacy& and& is& therefore& mostly&
combined&with& tumour&vaccines& (Curran,&Montalvo&et&al.&2010;&Zhou,&Xiao&et&al.&2010;&
Karwacz,&Bricogne&et&al.&2011;&Sierro,&Donda&et&al.&2011),&antiFCTLA4&antibodies&(Curran,&
Montalvo& et& al.& 2010;&Mangsbo,& Sandin& et& al.& 2010),& cytokines& (Yu,& Steel& et& al.& 2012),&
chemotherapy& (Sierro,& Donda& et& al.& 2011),& and& DC& intracellular& signalling& pathway&
activators/modulators&(Karwacz,&Bricogne&et&al.&2011;&Liechtenstein,&Dufait&et&al.&2012).&&&&&
Nevertheless,& clinical& trials& have& been& performed& using& systemic& antiFPDFL1&
(Brahmer,&Tykodi&et&al.&2012)&or&PDF1&(Brahmer,&Drake&et&al.&2010;&Topalian,&Hodi&et&al.&
2012;&Ansell,&Lesokhin&et&al.&2015)&antibodies&as&monotherapy.&Patients&in&these&clinical&
trials& had& a& wide& range& of& advanced& cancer& types,& including& melanoma,& lymphoma,&
breast,&lung,&pancreatic,&colon,&renal,&and&gastric&cancers.&But&objective&responses&could&
only& be& achieved& in& patients& with& nonFsmallFcell& lung& cancer,& melanoma,& renalFcell&
cancer,& colorectal& cancer,& and& ovarian& cancer.& Although& these& clinical& trials& showed&
objective& responses& with& durable& tumour& regression& (between& 6F20%& of& patients)&
serious&immuneFrelated&adverse&events&were&observed&(in&9F14%&of&patients)&(Brahmer,&
Tykodi& et& al.& 2012;& Topalian,& Hodi& et& al.& 2012).& A& recent& and& still& ongoing& clinical& trial&
 116&
using& antiFPDF1& antibodies& in& patients& with& refractory& Hodgkin’s& lymphoma& reported&
complete& response& in& 17%& of& patients& while& 70%& exhibited& partial& responses.& Again,&




mouse&DCs& leads& to& decreased& TCR& downFregulation& in& activated& T& cells& upon& antigen&
presentation.& This& suggests& that& PDFL1& silencing& enhances& signal& 1& and& thus& leads& to&
proliferation&and&hyperactivation&of&TCRhigh&CD8&T&cells.&These&hyperactivated&CD8&T&cells&
expressed& high& levels& of& IFNγ& and& IL17.& Vaccinating& mice& with& PDFL1Fsilenced& DCs&
inhibited&tumour&growth&and&prolonged&survival&(Karwacz,&Bricogne&et&al.&2011;&Escors,&
Bricogne& et& al.& 2012;& Karwacz,& Arce& et& al.& 2012).&Of& note,& overall& cure& rates&were& not&
improved&in&a&thymoma&mouse&model&and&PDFL1&silencing&had&to&be&combined&with&ERK&
inhibition&or&p38&activation&in&DCs&to&improve&cure&rates&(Karwacz,&Bricogne&et&al.&2011).&
Thus,& PDFL1& silencing& can& enhance& activation,& expansion,& and& cytokine& secretion& of&
tumourFspecific& T& cells& but&other& signals& are&needed& to&enhance& their& cytotoxicity& and&
effector& activities.& To& efficiently& induce& effector& activities& in& activated& CD8& T& cells,& we&
hypothesized& that& a& signal& 3& (cytokine& signal)& needs& to& be& supplied.& Importantly,& this&
signal&has&to&be&provided&in#cis&by&the&APC&itself&(Liechtenstein,&Dufait&et&al.&2012).&
3.1.4.!! CYTOKINES!USED!IN!THIS!STUDY!
The& cytokines& provided& during& antigen& presentation& by& DCs& determine& T& cell&
polarization.& Different& combinations& induce& differentiation& of& various& CD4& T& helper&
subtypes.&In&addition,&cytokines&are&pleiotropic&molecules&and&therefore&induce&various&




not& only& induce& various& functions& but& can& even& initiate& opposing& functions& in& certain&
conditions.& Thus,& it& is& particularly& difficult& to& use& cytokines& as& monotherapy& through&
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systemic& administration.& Local& delivery& in# cis& to& T& cells&will& avoid& toxicities& and& enable&
targeted&application&for&the&enhancement&of&antigen&presentation.&
IFNγ,& IL12,& and& IL15& are& among& the& most& effective& stimulators& of& antiFtumour&
immune&responses&in&preFclinical&studies&(Waldmann,&Dubois&et&al.&2001;&Kishida,&Asada&
et&al.&2003;&Weiss,&Subleski&et&al.&2007;&Zaidi&and&Merlino&2011).&The&crucial&role&of&IFNγ&
in& antiFtumour& immune& responses& and& in& cancer& immunosurveillance& was& already&
discussed&in&chapter&1&(Dighe,&Richards&et&al.&1994;&Dunn,&Old&et&al.&2004;&Schreiber,&Old&
et&al.&2011).&Briefly,& IFNγ& is&vital& for& the&maturation&and& function&of&most& immune&cell&
types,& activates& innate& immune& cells& to& acquire& cytotoxic& activities,& polarizes& Th1&
differentiation,&and&suppresses&Th2&differentiation&(Miller,&Maher&et&al.&2009;&Zaidi&and&
Merlino&2011).&Thus&IFNγ&represents&an&attractive&candidate&to&polarize&T&cell&responses&
with& antiFtumour& activities.& In& addition,& it& displays& direct& antiFangiogenic,& antiF
proliferative,& and& proFapoptotic& effects& on& tumour& cells& and& enhances& tumour& cell&
immunogenicity,&detection,&and&elimination&(Miller,&Maher&et&al.&2009;&Zaidi&and&Merlino&
2011).&Recombinant&IFNγ&has&been&used&in&the&clinic&but&due&to&its&limited&efficacy&and&





cancer& immunotherapeutic& strategies& (Wigginton,&Gruys&et&al.&2001;&Weiss,&Subleski&et&
al.&2007).&But&IFNγ&does&not&only&play&a&role&in&immunoediting/elimination&but&also&in&the&
equilibrium/subversion&stages&of&tumour&development&(Zaidi&and&Merlino&2011).&Thus,&it&
may& not& be& surprising& that& systemic& administration& of& IFNγ& leads& to& limited& efficacy.&
Local&IFNγ&secretion&during&antigen&presentation&may&have&other&effects.&&
IL6&has&also&been&associated&with&antiFtumour&effects& in#vitro&and&in&preFclinical&





in& Th17& differentiation& (McGeachy,& BakFJensen& et& al.& 2007;& Zhou,& Ivanov& et& al.& 2007).&
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However,&response&rates&of&recombinant&human&IL6&in&cancer&patients&have&been&rather&
low&(Veldhuis,&Willemse&et&al.&1996).& IL6& is& involved& in&haematopoiesis&and&thus& it&may&
not& be& surprising& that& increased& MDSC& accumulation& is& associated& with& IL6& levels& in&
tumour&models& and&patients& (Kopf,&Baumann&et& al.& 1994;&Chen,&Kuan&et& al.& 2014).& IL6&
also&inhibits&DC&differentiation&through&STAT3&signalling&(Park,&Nakagawa&et&al.&2004).&&
Another&attractive&cytokine&for&this&study&is&IL15.&IL15&induces&NK&and&activated&T&
cell& proliferation,& aids& in& the& expansion& of& effector& T& cells,& and& induces& expansion& of&
memory&CD8&T&cells&(Fehniger,&Cooper&et&al.&2002;&Waldmann&2006).&IL15&administration&
was& shown& to& enhance& CD8& T& cell& antiFtumour& activities& in& preFclinical& models,& when&
combined&with& other& cytokines& (such& as& IL21)(Kishida,& Asada& et& al.& 2003),& secreted& by&




development& of& Th17& cells& (Katstelein,& Hunter& et& al.& 2007).& In& addition,& IL23& can&
stimulate&T& cell& and&memory&T& cell&proliferation,& IFNγ& secretion& from&activated&T& cells,&
and& CTL& activity.& IL23& secreted& by& tumour& cells& was& shown& to& enhance& splenocyte&
proliferation,&CTL&activity,&DC&numbers,&and&production&of& IFNγ,& IL12,&and&TNFα& (Shan,&




IL23& supplied& in# cis& by& activated& DCs& may& enhance& antiFtumour& immune& responses,&
making&it&an&attractive&cytokine&for&this&study.&&
IL12& is& structurally& related& to& IL23&as& they& share& the&p40& subunit.& IL23&binds& to&
IL12R&beta&1&but&not&to&IL12R&beta&2&(Oppmann,&Lesley&et&al.&2000).&IL12&is&a&heterodimer&
of&p40&and&p35,&connected&through&a&disulfide&bond.& IL12&was& initially&purified&by& two&
different&groups& (Kobayashi,& Fitz&et& al.& 1989)& (Stern,&Podlaski& et& al.& 1990).&As& IL12&was&
found& to& synergize& with& IL2& to& induce& CTLs& and& augment& NK& cytotoxicity,& it& was& first&
called&cytotoxic& lymphocyte&maturation&factor&and&natural&killer&cell&stimulatory&factor,&
respectively& (Kobayashi,& Fitz& et& al.& 1989;& Stern,& Podlaski& et& al.& 1990).& IL12& is& generally&
viewed&as&a&hallmark&proFinflammatory&cytokine&and&it&is&mainly&produced&by&activated&
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2011;& Kerkar,& Leonardi& et& al.& 2013).& IL12& secretion& elicits& potent& innate& and& adaptive&
immune& responses& and& it& is& an& important& connector& of& the& two& responses& (Weiss,&
Subleski& et& al.& 2007;& Vignali& and& Kuchroo& 2012).& IL12& further& augments& effector& cell&
functions& of& NK,& CD4,& CD8,& and& NKT& cells,& thus& enhancing& their& capacity& to& eliminate&
tumour&cells& (Trinchieri&2003).& In& the&context&of&a& strong&antigen&signal,& IL12&secretion&
leads& to& T& cell& proliferation& and& thus& amplifies& antigenFspecific& T& cell& responses&
(Bertagnolli,&Lin&et&al.&1992).&Recently&it&has&been&suggested&that&IL12&plays&a&role&in&the&
recovery&of&APC&functionality&within&the&tumour&microenvironment&(Kerkar,&Muranski&et&
al.& 2010;& Kerkar,& Goldszmid& et& al.& 2011;& Kerkar,& Leonardi& et& al.& 2013).& Apart& from& its&
immunostimulatory& effects,& IL12& is& also& involved& in&direct& tumour& cytotoxicity& and&has&
antiFmetastatic&and&antiFangiogenic&effects&in&various&tumour&mouse&models&(Hendrzak&
and&Brunda&1996;&Trinchieri&1998;&Colombo&and&Trinchieri&2002;&Trinchieri&2003;&Airoldi,&
Di&Carlo&et&al.&2007;&Chinnasamy,&Yu&et&al.&2012).& It& is&evident& that& IL12&administration&
can& have& significant& adjuvant& activities& for& cancer& immunotherapy& treatments.& Clinical&
application& has& been& limited& as& systemic& administration& is& highly& toxic& (Cohen& 1995;&
Leonard,& Sherman& et& al.& 1997;& Car,& Eng& et& al.& 1999),& possibly& due& to& enhanced& IFNγ&
production&and&toxicity& (Leonard,&Sherman&et&al.&1997).&Thus,&more& targeted&and& local&
delivery& of& IL12& is& necessary.& Several& studies& have& been& conducted& using& either&
engineered& DCs& or& fibroblasts& to& locally& deliver& IL12& to& the& tumour,& delaying& tumour&
growth&in#vivo&through&enhanced&priming&of&CD8&T&cell&responses&(Zitvogel,&Tahara&et&al.&
1995;& Zhao,& Bose& et& al.& 2011).& In& addition,& there& are& several& preFclinical& studies& using&
TAAFspecific&or&CARFengineered&T&cells&with&enhanced&IL12&expression&that&show&efficacy&





a& proFinflammatory& cytokine& it& exhibits& significant& proFtumourigenic& activities.& In&
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colorectal&cancer&IL17A&is&associated&with&rapid&tumour&progression&as&well&as&resistance&
to& therapy& (Wang,& Kim& et& al.& 2014).& IL17A& exhibits& significant& tumourFpromoting&
functions& in& a& wide& variety& of& cancer& types& and& promotes& angiogenesis& and&
granulopoiesis&in&preFclinical&tumour&models&(Zhang,&Weng&et&al.&2014).&
While& the&previously& listed&cytokines&are&generally& viewed&as&proFinflammatory&
cytokines,&we& also& included& IL4,& TGFβ,& and& IL10& in& this& study& as& comparative& controls.&
While&IFNγ&and&IL12&are&generally&viewed&as&Th1&polarizing&cytokines,&IL6&and&IL4&induce&
Th2& differentiation& (Rincon,& Anguita& et& al.& 1997).& But& IL4& is& not& only& involved& in& Th2&
differentiation&(Serre,&Mohr&et&al.&2010).& IL4&also&exhibits&pleiotropic&effects&on&various&
immune&cell& types.& In&addition,& it&can&enhance&the& immunogenicity&of&cancer&cells&and&
possesses&antiFtumour&effects&in#vitro&and&in&preFclinical&mouse&models&(Hoon,&Banez&et&
al.&1991).&TGFβ&is&a&highly&regulated&and&pleiotropic&cytokine.&Its&regulatory&effects&affect&
many& different& immune& cell& types,& although& T& cells& seem& to& be& crucial& targets.& T& cell&
differentiation& status& plays& a& role& in& determining& whether& TGFβ& acts& in& an&
immunostimulatory& or& Fsuppressive& way.& TGFβ& is& involved& in& the& regulation& of& T& cell&
development,& homeostasis,& differentiation,& and& tolerance.& Differentiation& of& Th1& and&
CTLs&can&be&inhibited&by&TGFβ,&and&in&combination&with&other&factors&TGFβ&induces&Th17&
and& inducible& Treg& responses& (Oh& and& Li& 2013).& Apart& from& Treg& induction,& TGFβ& is&
known&to&have&various&effects&in&cancer&progression.&Depending&on&the&stage&of&tumour&
progression&TGFβ&plays&differential&roles.&Thus,&TGFβ&can&inhibit&cancer&cell&proliferation&
and& induce& apoptosis& before& tumours& are& established.& Once& tumours& have& developed&
further,& TGFβ& promotes& cancer& cell& motility,& invasion,& and& metastasis.& (Inman& 2011).&
Thus,&TGFβ& is&generally&viewed&to&contribute& to& tumour&progression&and& inhibitors&are&
being&used&in&preFclinical&and&clinical&studies&(Rodon,&Carducci&et&al.&2015).&
IL10&is&another&pleiotropic&cytokine&that&is&generally&viewed&to&contribute&to&the&
immunosuppressive& tumour& microenvironment,& by& regulating& and& terminating&
inflammation.& IL10& is&produced&by&Tregs,&MDSCs,&and&tumour&cells,&affects&growth&and&
differentiation& of& many& immune& cell& types,& and& exerts& various& other& effects& on& most&
haematopoietic& cell& types.& IL10& affects& APCs& by& inhibiting& expression& of& MHC& II&
molecules,&coFstimulatory&molecules,&and&proFinflammatory&cytokines.&Further,&IL10&can&
inhibit&the& in#vitro&activation&of&CD4&T&cells&and&macrophages&(Moore,&de&WaalFMalefyt&
et& al.& 2001).& Depending& on& their& activation& status,& IL10& exhibits& differential& effects& on&
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CD8& T& cells& and& can& enhance& their& cytotoxic& potential& (Santin,& Hermonat& et& al.& 2000).&
Similar& to& TGFβ,& IL10& exhibits& both& tumourFpromoting& (Fuji,& Shimizu& et& al.& 2001)& and&
tumour& growthFinhibiting& (Dorsey,& Kundu& et& al.& 2002)& activities& in& mouse& tumour&
models.&In&addition,&the&timing&of&IL10&administration&is&highly&important&as&it&can&impair&
vaccination&when&simultaneously&administered&or&enhance&vaccination&when&given&at&a&





Th2,& Th17,& and& Treg& Fpromoting& cytokines.& As& cytokines& are& highly& pleiotropic& their&
activity& is& contextFdependent& and& thus& of& interest& to& study& in& the& context& of& tumour&
vaccination&and&therapy.&As&all&three&signals&need&to&be&provided&in#cis#for&optimal&T&cell&
activation&and&differentiation,&I&hypothesized&that&lentivector&transduction&providing&all&
three& signals& at& the& same& time& could& enhance& tumourFspecific& T& cell& responses.&
Furthermore,&I&propose&that&local&PDFL1&silencing&by&direct&lentivector&transduction&only&
occurs&in&a&limited&number&of&target&cells&and&thus&reduces&toxicities&observed&following&
systemic&PDFL1&blockade.& In& this&way,&PDFL1/PDF1& signalling& is& inhibited&during&antigen&
presentation&and&thereby&enhances&the&potential&of&cytokines&to&steer&TAAFspecific&T&cell&



























































In& this& chapter& lentivectors& for& the& use& in& melanoma& immunotherapy& were&








tested& in& healthy& mice& as& well& as& tumour& growth& in& prophylactic& and& therapeutic&
settings.&For&these&tumour&experiments&autologous&syngeneic&B16&melanoma&cells&were&
used,&which&did&not&express&model&antigens.&Further,&mechanistic&studies&assessing&the&






Previous& results& of& our& laboratory& demonstrated& that& PDFL1& silencing& in&
transferred&OVAFspecific&DCs&was&not&enough&to&confer&potent&antiFtumour&activities&in&a&
thymoma&mouse&model&(Karwacz,&Bricogne&et&al.&2011;&Karwacz,&Arce&et&al.&2012).&Since&
PDFL1& silencing& hyperactivated& OVAFspecific& CD8& T& cell& responses,& we& reasoned& that&
further&signals&such&as&adequate&cytokine&priming,&would&improve&antiFtumour&effector&
activities& of& these& CD8& T& cells& (Karwacz,& Arce& et& al.& 2012;& Liechtenstein,& Dufait& et& al.&
2012;&Liechtenstein,&Dufait&et&al.&2012).& I& therefore&engineered& lentivectors&that&would&
not& only& silence& PDFL1& by& including& a& shRNA& within& a& microRNA30& context& sequence&




was& introduced& in& the& coding& sequence& between& their& two& constituent& chains,& as&
described& in& chapter& 2.& Dual& lentivector& plasmids& used& to& deliver& the& constructs&were&
previously&used& in&our& laboratory& (Arce,&Breckpot&et&al.& 2011;&Karwacz,&Bricogne&et&al.&
2011).& The& second& transgene& was& expressed& under& the& control& of& the& ubiquitin& (UBI)&
promoter&(Fig.3.2.A).&




as& well& as& the& reporter& gene& green& fluorescent& protein& (GFP)& into& the& lentivector&
backbone&(Fig.&3.2.A).&I&tested&PDFL1&silencing&activity&of&p1&in&B16&mouse&melanoma&and&
in& bone& marrowFderived& DCs& (BMFDCs).& To& ensure& high& baseline& levels& of& PDFL1&
expression,&B16&cells&and&BMFDCs&were&treated&with&IFNγ&and&LPS,&respectively,&as&these&
treatments& enhance& PDFL1& expression.& Transduction& with& p1Fcontaining& lentivectors&
decreased& PDFL1& expression& in& both& cell& types& (Fig.& 3.2.A).& Furthermore,& cytokine&
expression& was& measured& by& transducing& 293T& cells& with& the& lentivectors& and&
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performing& flow& cytometric& analyses& after& intracellular& staining& using& cytokineFspecific&




cytokines,# and# an# antigen# of# interest.# (A)# Above:# Schematic# representation# of# the#





BM8DCs# with# LPS.# Percentages# and# mean# fluorescent# intensities# (MFI)# are# indicated.#
 126&
Horizontal# lines#within#the#histograms#were#drawn#to# include#no#more#than#5%#of#non8
transduced# (GFP8)# cells.# LTR,# long8terminal# repeat;# SFFVp,# spleen# focus8forming# virus#




Western#blot#of#293T#cells# transduced#with#a# lentivector#encoding# IL15.#Golgi#Plug#was#
added# overnight# to# ensure# accumulation# of# IL15# prior# to# protein# extraction.# UT,#
untransduced#293T#cells.#
3.2.2.! TRANSDUCTION! OF! BM+DCs! IN# VITRO! WITH! LENTIVECTORS! MODULATING!
ANTIGEN! PRESENTATION! DOES! NOT! SIGNIFICANTLY! UP+REGULATE! MATURATION!
MARKERS.!
The&purpose&of& the&engineered& lentivector& constructs&was& to&modulate&antigen&
presentation&to&T&cells,&polarizing&T&cell&differentiation&towards&a&cytotoxic&effector&type.&
Initially&the&main&target&cell&types&for&the&lentivector&vaccines&were&APCs,&especially&DCs.&
Hence,& before& analysing& T& cell& responses& to& transduced& APCs,& I& investigated& whether&
lentivector& transduction&with& the& constructs&would& affect& the& phenotype& of& immature&
BMFDCs& themselves.& For& these& experiments& the&GFPFcontaining& constructs&were& used,&
which& would& allow& the& assessment& of& marker& expression& in& transduced& cells& by& flow&
cytometry&in&GFP+&DCs.&Previous&data&from&our&laboratory&indicated&that&PDFL1&silencing&
slightly&increased&maturation&of&BMFDCs&(experiments&previously&performed&by&Dr.&Kasia&









The& ultimate& goal& in& this& study& is& to& modulate& antigen& presentation& to& T& cells&
using& lentivectors& expressing& cytokines& in& combination& with& PDFL1& silencing.& It& may&








expressing#different# cytokines,#p1,#and#GFP.#DCs#differentiated#ex# vivo# from#BM#were#
transduced# with# lentivectors# at# day# 5# of# culture.# The# lentivector# containing# only# GFP#
served#as#a#control.#After#72#hours#transduced#cells#were#stained#and#analyzed#by#flow#
cytometry.# Bar# graphs# represent# percentages# of# marker8expressing# cells# within# the#




3.2.3.! TRANSDUCTION! OF! BM+DCs! WITH! CONSTRUCTED! LENTIVECTORS! INDUCES!
OVA+SPECIFIC!CD8!T!CELL!RESPONSES!IN#VITRO!
As&stimulation&of&antigenFspecific&effector&T&cell& responses& is&crucial& in& inducing&
antiFtumour& immune&responses,&we& further& tested&whether& transduced&BMFDCs&would&
efficiently& stimulate& antigenFspecific& T& cell& responses.& To& measure& antigenFspecific&
responses& in# vitro& I& used& the&model& antigen& ovalbumin& (OVA).& The& reporter& gene&GFP&
was& replaced& in& the& lentivector& plasmids& with& IiOVA.& To& facilitate& MHC& class& II& OVA&




the&expression&of&OVA& in& transduced& cells& could&be&easily& tested&by&western&blot& (Fig.&
3.4.B).& After& transduction& of& BMFDCs&with& the& IiOVAFexpressing& constructs,& these& cells&
were&coFcultured&with&CD8&T&cells&from&OVAFspecific&transgenic&OTFI&mice.&Interestingly,&
only& the& combination& of& IL12& expression& and& PDFL1& silencing& elicited& a& strong& OVAF
specific&CD8&T&cell&response,&in&comparison&with&IFNγ&levels&elicited&by&the&transduction&






Fig.#3.4.#BMFDCs# transduced#with# lentivectors#expressing# the#model#antigen# IiOVAha#
induce#OVAFspecific#T#cell#responses#in#vitro.#(A)#Above:#Schematic#representation#of#the#
lentivector# construct,# containing# the# model# antigen# OVA# fused# to# the# invariant# chain#
(IiOVA).# Below:# Western# Blot# of# 293T# cells# transduced# with# the# IiOVA8containing#
lentivectors,# using# an# antibody# against# the# haemagglutinin# (HA)8tag# of# IiOVA.# Anti8
GADPH#antibody#was#used#as# loading#control.#LTR,# long8terminal#repeat;#SFFVp,#spleen#








vivo.& Mice& were& subcutaneously& (s.c.)& vaccinated& at& the& base& of& the& tail& with& the&
lentivectors&containing& the&different&cytokines,& the&microRNA&p1,&as&well&as& the&model&
antigen& IiOVA& (Fig.& 3.4.A).& Two&weeks& later& splenocytes& were& isolated& and& stimulated&
overnight& with& OVA& peptides& before& analysis& by& flow& cytometry.& Compared& to&
vaccination&with& a& nonFcytokine& containing&GFPFcontrol,& increased&OVAFspecific& CD8& T&
cell&responses&were&observed&using&various&lentivector&vaccines&(Fig.&3.5.A).&CD8&T&cells&
were& induced& to&produce& IFNγ&by& the& lentivector& constructs& containing& the& IFNγ,& IL23,&
IL12,&and& IL15&genes.& IL17&production&by&CD8&T&cells&was&enhanced&by& IFNγF&and& IL23F
containing& lentivectors.&The&most&effective& lentivector&vaccine&was&the& IFNγFexpressing&
lentivector,& as& vaccinated& mice& showed& splenocytes& containing& CD8& T& cells& with&
enhanced& IFNγ& and& granzyme& B& production.& Interestingly,& all& lentivector& vaccines&
exhibited& low& Foxp3+& regulatory& T& cell& (Treg)& numbers& in& splenocytes& after& OVA&
restimulation& compared& to& the& GFPFIiOVA& vaccination& control.& Importantly,& Treg&
numbers& also&decreased&when& cytokines&were& included& in& the& vectors& that& are& known&
Treg& inducers,& such& as& TGFβ& (Fig.& 3.5.A).& Thus,& PDFL1& silencing& in& healthy& mice& may&
override& TGFβF& and& IL10Fmediated& signals.& Although& IFNγFbased& lentivectors&were& the&




exerts& in& the& context& of& proFinflammatory& and& antiFinflammatory& cytokine& induction&






Fig.# 3.5.# Subcutaneous# vaccination# with# lentivectors# expressing# cytokines,# a# PDFL1F
targetd#microRNA,#and#the#model#antigen#IiOVA#induces#OVAFspecific#T#cell#responses#
in#mice.#(A)#Mice#were#injected#subcutaneously#(s.c.)#at#the#base#of#the#tail#with#indicated#





peptide# negative# control.# (B)# Same# as# in# A,# but# experiment# performed# only# once.# Bar#
graphs#represent#percentage#of#marker#positive#CD8#splenocytes.#no,#no#OVA#peptide#as#
negative#control.&





I& used& the& lentivectors& containing& the&model& antigen& IiOVA& and& nonFcommercial& B16F
IiOVA&cells&that&express&OVA&as&a&surrogate&tumour&antigen.&For&this&purpose,&B16&cells&
were&transduced&with&a& lentivector&encoding&the&OVA&gene&fused&to& Ii& (IiOVA)&and&the&
puromycin&resistance&cassette.&Following&transduction&B16FIiOVA&cells&were&selected&by&
puromycin&treatment&(Fig.&3.6.A).&A&similar&approach&with&OVAFB16&tumour&cell& lines&is&
frequently& used& to& assess& cancer& immunotherapy& treatments& as& it& ensures& strong&
antigen&recognition& in#vivo& (Escors,& Lopes&et&al.&2008;&Karwacz,&Mukherjee&et&al.&2009;&
Fraser,& Lousberg& et& al.& 2010;& Aranda,& Llopiz& et& al.& 2011;& Arce,& Breckpot& et& al.& 2011;&
Karwacz,&Bricogne&et&al.&2011;&Bouwer,&Saunderson&et&al.&2014).&Mice&were&s.c.&injected&
at&the&base&of&the&tail&with&a&selection&of&lentivector&constructs,&including&IL12Fp1FIiOVA&
and& IFNγFp1FIiOVA.& Two& weeks& after& prophylactic& vaccination& with& lentivectors,& mice&
were& s.c.& challenged& with& B16FIiOVA& melanoma& cells.& In& this& experimental& setting&
delayed& tumour&growth&and&prolonged& survival&was&achieved& in&all& vaccinated&groups,&
compared& to&unvaccinated&control.&Even&GFPFIiOVAFvaccinated&mice&displayed&delayed&
tumour&growth&(Fig.&3.6.B).&Of&note,&both&GFP&and& IiOVA&are&not&endogenous&proteins&
and& could& therefore& have& synergistic& adjuvant& effects& on& the& host& immune& system.&
Nonetheless& tumours& from& vaccinated&mice& eventually& escaped.& After& sacrificing&mice&
with&large&tumour&burden,&tumours&were&harvested&and&it&was&found&that&tumour&tissue&
from& certain& vaccination& groups& had& lost& melanine& expression& (Fig.& 3.6.C).& Mice& that&





tissue,& protein& was& extracted& and& IiOVA& and& common& endogenous& melanoma& TAA&
expression& was& analysed.& IiOVA& expression& was& lost& in& almost& all& tumours& from&
vaccinated&mice& while& it& was& still& expressed& in& tumours& from& unvaccinated&mice& (Fig.&
3.6.D).& As& B16FIiOVA& cells& were& selected& by& puromycin& treatment& without& further&
clonogenic&selection,&B16FIiOVA&cells&expressed&various& levels&of& IiOVA.&Thus,&B16&cells&
expressing&no&or&only&low&IiOVA&were&selected&within&the&tumour.&Importantly,&some&of&

















to#be# sacrificed#due# to#high# tumour#burden)# (left)# and# time#of#death# (right)# after#B168
IiOVA# challenge.# Experiments# were# performed# with# 5# mice# per# group.# 1# indicates#
melanine# rich# tumours,# 2# indicates# melanine# poor# tumours.# (C)# Tumour# tissue# was#
harvested#when#a#volume#of#150mm2#was#reached.#Only#photographed#tumour#samples#
from#unvaccinated#and#IL128p18IiOVA#vaccinated#mice#are#represented#here#as#examples.#
Samples# from#escaping#tumours# from#each#mouse#are# labelled#T18T5.# (D)#Western#Blot#




TAAs.# Shown# are# the# tumour# samples# analysed# from# unvaccinated# and# IL128p18IiOVA#
vaccinated#mice.#&
 137&
3.2.6.!! PROPHYLACTIC! VACCINATION! WITH! LENTIVECTORS! CO+DELIVERING! IL12,! p1!
AND! ENDOGENOUS! MELANOMA! ANTIGEN! TRP1! ENHANCES! SURVIVAL! IN! A! B16!
MELANOMA!MODEL!WHICH!DOES!NOT!EXPRESS!THE!XENOANTIGEN!OVA!
As& all& IiOVAFcontaining& lentivector& vaccines& delayed& B16FIiOVA& tumour& growth,&
we&sought&to&establish&a&more&realistic&setting&in&which&to&test&the&lentivector&vaccines.&
Using&OVA,&which&is&an&immunogenic&xenoantigen,&might&have&masked&the&antiFtumour&
activities& of& cytokine& induction& and& PDFL1& silencing.& IiOVA& was& therefore& replaced& in&
selected& lentivector&constructs&with& the&endogenous&melanoma&TAA&TRP1.& Lentivector&
vaccination& with& wildtype& TRP1& antigen& does& not& lead& to& protective& or& therapeutic&
activities& (GuevaraFPatino,& Engelhorn& et& al.& 2006;& Liu,& Peng& et& al.& 2009)& and& would&
therefore&not&mask&adjuvant&activities&as& I& suspected&OVA&had&(Fig.&3.6.B).& In&addition,&





fullFlength& HAFtagged& TRP1& was& fused& to& the& NFterminal& half& of& the&MHC& II& invariant&
chain&(Ii)&(Fig.&3.7.A).&Mice&were&s.c.&vaccinated&with&the&IiTRP1Fcontaining&lentivectors,&
and&B16&melanoma&cells&were& transferred& two&weeks& later& to& vaccinated&mice.& In& this&
experimental& setting& only& vaccination& with& IL12Fp1FIiTRP1& strongly& delayed& tumour&
growth& and& significantly& increased& survival& (Figs.& 3.7.BFD).& In& the& first& experiment& I&
vaccinated& mice& with& the& IiTRP1Flentivectors& containing& IFNγFp1,& IL15Fp1,& IL12Fp1,& ILF
10p1,& and& TGFβFp1& (Figs.& 3.7.BFD).& The& combination& of& IL12& expression& and& PDFL1&
silencing&showed&the&best&antiFtumour&responses,&in&which&one&mouse&never&developed&
a&tumour&after&regression&(Fig.&3.7.B,C).&Therefore&a&second&experiment&was&performed&
where&only& IiTRP1Flentivectors& containing& IL12Fp1,& IFNγFp1,& and& IL10Fp1&were&used& for&
vaccination.& In& addition,& IL12FIiTRP1& (without& the& PDFL1& silencing& microRNA)& was&
included& in& this& experiment.& Similar& results& were& achieved& as& in& the& first& experiment,&
confirming& the& enhanced& antiFtumour& activity& of& the& IL12Fp1& lentivectors.& Vaccination&














survival# in# a# B16# mouse# melanoma# model.# (A)Western# Blot# analysis# of# 293T# cells#
transduced# with# indicated# IiTRP18containing# lentivectors,# using# anti8HA# antibody# and#





growth#of# tumours# in#mice#vaccinated#with# the# indicated# lentivectors.# (E)#Repetition#of#
previous# experiment# (B8D)# but# with# inclusion# of# IL128IiTRP1# (without# p1)# as# control.#
Graphs# represent# tumour# sizes# on# day# 13# after# B16# inoculation# and# survival# of# mice#




3.2.7.! THERAPEUTIC! INTRA+TUMOUR!VACCINATION!WITH! IL12+p1+IiTRP1! CONTROLS!
TUMOUR!GROWTH!IN!A!B16!MELANOMA!MODEL!!
IL12Fp1Fcontaining&lentivectors&elicited&promising&results&in&prophylactic&therapy,&
particularly&when&considering& that&animals&were&only&vaccinated&once&prior& to& tumour&
inoculation.& I& further& assessed& whether& these& lentivector& vaccines& would& have&
therapeutic&efficacy,&in&which&tumours&are&first&allowed&to&grow&followed&by&lentivector&
inoculation.& Mice& were& intraFtumourally& injected& with& lentivectors& GFPFIiTrp1,& IL12F
IiTrp1,& IL12Fp1FIiTrp1& or& PBS& (12& days& after& B16& transfer).& Single& lentivector& injections&
were&performed&in&rapidly&growing&tumours&when&a&mean&tumour&volume&between&50&
and&200&mm3&was& reached.&As& in& the&prophylactic&experiments,& IL12FIiTrp1&or& IL12Fp1F
IiTrp1& lentivector& injection&significantly&delayed& tumour&growth&and&prolonged&survival&










Fig.#3.8.# IntraFtumour#vaccination#of#mice#with# IL12F(p1F)IiTRP1# lentivectors# increases#
survival# in#a#B16#mouse#melanoma#model.# (A8D)#3*105#B16#cells#were#subcutaneously#
injected# into# C57Bl/6#mice# (n# =#min# 5#mice# per# group).#When# tumours# reached#mean#
tumour#volume#between#508200mm3#(12#days#later),#mice#were#injected#intra8tumourally#
with#the# indicated# lentivectors#(1*107# lentivector#particles/tumour)#or#PBS#as#a#control.#
(A)# Kaplan8Meier# survival# plot# representing# pooled# data# from# two# independent#
experiments.# (B)#Time#of#death#after#B16# inoculation.#Pooled#data# from#2# independent#
experiments#are#plotted.#(C)#Tumour#volumes#are#represented#on#the#day#of#intra8tumour#
lentivector# injection#(day#12)#and#5#days#later#(day#17).#One#of#two#similar#experiments#
represented.# (D)#Tumour#growth#of# individual#mice,# vaccinated#with# control# lentivector#
GFP8IiTRP1# or# IL128IiTRP1# (above)# and# IL128p18IiTRP1# (below)# lentivectors.# One# of# two#
similar#experiments#represented.#
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3.2.8.! IL12+(p1+)IiTRP1! LENTIVECTORS! INDUCE! TRP1+SPECIFIC! CD4! AND! CD8! T! CELL!
RESPONSES!IN#VIVO!IN!HEALTHY!MICE.!!
My& results& suggested& that& the& inclusion& of& the& PDFL1Fsilencing&microRNA& p1& in&
the& IL12FIiTRP1& lentivector& vaccines& played& a&more& important& role& in& the& prophylactic&
setting& than& in& therapeutic& experiments.& Thus,& further& experiments& to& elucidate& the&
mechanism&exerted&by&the&IL12F&and&p1Fcontaining&lentivector&vaccines&were&performed.&
First,& I& tested&whether& the& IL12FIiTRP1Fbased& lentivector&vaccines&could& indeed&elicit& in#
vivo#expansion&of&IFNγ+&TRP1Fspecific&T&cells&in&healthy&mice&and&whether&inclusion&of&p1&
would& enhance& T& cell& activation.& Breaking& natural& tolerance& to& the& endogenous& TAA&
TRP1& is&particularly&challenging&(GuevaraFPatino,&Engelhorn&et&al.&2006;&Liu,&Peng&et&al.&
2009)(Fig.&3.6.E).&It&would&therefore&be&an&important&achievement&to&raise&TRP1Fspecific&
Th1& and& CTL& responses& with& a& single& lentivector& vaccination& of& healthy& mice.& To& this&
purpose&mice&were&s.c.& injected&with& IL12FIiTRP1&and& ILF12Fp1FIiTRP1& lentivectors.&Two&
weeks&later,&isolated&splenocytes&were&coFcultured&overnight&with&TRP1Fpresenting&BMF
DCs& (by& lentivector& transduction&with&GFPFIiTRP1)&and&the&expression&of& IFNγ& in&T&cells&
was&assessed&by&flow&cytometry.&To&ensure&that&TRP1Fpresenting&BMFDCs&were&activated&
for& this& assay,& immature& transduced& BMFDCs& were& incubated& with& lipopolysaccharide&
(LPS)& prior& to& coFculture.& A& single& vaccination& with& the& IL12Fcontaining& lentivectors&
induced&systemic&TRP1Fspecific&CD8&and&CD4&T&cell&responses&(Fig.&3.9).&Inclusion&of&the&
microRNA&p1&in&the&IL12FIiTRP1&lentivector&vaccines&did&not&increase&TRP1Fspecific&T&cell&
responses& in& vaccinated& mice.& This& suggested& that& in& combination& with& IL12,& PDFL1&
silencing&may&not&play&a&crucial&role&in&enhancing&MHC&I&and&MHC&II&TRP1Fspecific&T&cell&
responses& at& the& priming& stage.& Alternatively,& our& assay& may& not& have& sufficient&
sensitivity& to&discriminate&any&enhancing&effect&by&p1.&Mice&were&also&vaccinated&with&
control& GFP& and& GFPFIiTRP1& lentivectors,& which& did& not& elicit& significant& TRP1Fspecific&






Fig.# 3.9.# Single# injection# of# healthy# mice# with# ILF12F(p1F)IiTRP1# lentivectors# induces#
TRP1Fspecific# CD8# and# CD4# T# cell# responses.# C57Bl/6# mice# were# s.c.# injected# with#
lentivectors# GFP,# GFP8IiTRP1,# IL128IiTRP1,# IL128p18IiTRP1,# and# IL108p18IiTRP1# (1*107#






3.2.9.! PD+L1! SILENCING! IN! NON+HAEMATOPOIETIC! CELLS! AT! THE! INJECTION! SITE!
AMPLIFIES!T!CELL!NUMBERS!AND!COOPERATES!WITH!CYTOKINE!PRIMING!
Subcutaneous& delivery& of& several& cytokines& (namely& IFNγ,& IL23,& IL12,& and& IL15)&
and&the&PDFL1&silencing&microRNA&p1&enhanced&OVAFspecific&CD8&T&cell&responses&in#vivo&
in&healthy&mice&(Fig.&3.5).&Additionally,&expression&of& IL12&alone&was&sufficient&to&break&




et& al.& 2003;& Breckpot,& Escors& et& al.& 2010;& Arce,& Breckpot& et& al.& 2011).& I& therefore&
characterized&the&role&cytokine&expression&and&PDFL1&silencing&in&nonFprofessional&APCs&
would& play& in& the& overall& induction& of& T& cell& responses.& To& specifically& exclude& cells&
derived& from& the& haematopoietic& system& from& the& target& cell& population,& the& target&




macrophages& as& well& as& lymphocytes& will& not& express& transgenes& that& contain& the&
microRNA&142&3p&target&sequence&(Brown,&Sitia&et&al.&2006;&Brown,&Gentner&et&al.&2007;&
Annoni,& Brown& et& al.& 2009;& Gentner,& Visigalli& et& al.& 2010;& Goudy,& Annoni& et& al.& 2011;&
Matsui,&Hegadorn&et&al.&2011).&








the& cytokine& IL12,& p1& and& IiOVA& (IL12Fp1FIiOVA142& 3p)& (Fig.& 3.10.BFC).& The& lentivector&
construct& containing& IL12& was& selected& for& this& experiment& as& the& IL12Fp1Fbased&
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lentivector& was& the& highest& inducer& of& OVAFspecific& CD8& T& cell& responses& in# vitro& and&
exhibited& potent& antiFtumour& efficacy& in# vivo.& In& addition& to& the& constructs& containing&
the&microRNA&142& 3p& target,& control& constructs&without& the&microRNA&p1& (IL12FIiOVA&
and& IL12FΔp1FIiOVA142& 3p)&were& s.c.& injected& into&healthy&mice.& IL12FIiOVA&would& allow&
expression& of& IL12& and& IiOVA& in& all& target& cells&while& IL12FΔp1FIiOVA142& 3p&would& allow&
IL12&and&IiOVA&expression&only&in&nonFhaematopoietic&cells&(Table&3.2).&Two&weeks&later,&
splenocytes& were& isolated& and& reFstimulated& with& OVA& peptide& before& analysis.& OVAF
specific&responses&were&assessed&by&IFNγ&expression&of&CD8&T&cells.&&
Vaccination& with& IL12FIiOVA& and& IL12Fp1FIiOVA& constructs& induced& similar&
percentages& of& OVAFspecific& CD8& T& cells,& representing& similar& “specificity”& of& the&
response.&The&introduction&of&the&142&3p&target&in&ILF12Fp1FIiOVA,&abrogating&transgene&
expression&in&cells&of&the&haematopoietic&lineage&at&the&injection&site,&led&to&significantly&
lower& percentages& of& OVAFspecific& CD8& T& cell& responses& (Fig.& 3.10.B).& Removal& of& p1&
(Δp1)&from&this&142&3pFcontaining&vector&ensures&normal,&unmodified&PDFL1&expression&
at&the&injection&site&and&vaccination&with&this&construct&decreased&CD8&T&cell&responses&
close& to& background& levels& (Fig.& 3.10.B).& Surprisingly,& the& results& were& quite& different&
when& total& numbers& of& OVAFspecific& CD8& T& cells& were& quantified,& representing& the&
“strength”& of& the& response.& In& this& context& the& lentivector& construct& IL12Fp1FIiOVA&
elicited&a&stronger&response&than&IL12FIiOVA.&Removal&of&transgene&expression&from&the&
haematopoietic& lineage&by& vaccination&with& IL12Fp1FIiOVA142& 3p& induced& the& same& total&
number&of&OVAFspecific&CD8&T&cells&as&vaccination&with&IL12FIiOVA.&Unmodified,&normal&
PDFL1& expression& at& the& injection& site& through& vaccination& with& IL12FΔp1FIiOVA& 142& 3p&
reduced& total& number& of& OVAFspecific& CD8& T& cells& close& to& background& levels& (Fig.&
3.10.B).&















microRNA# target# 142#3p.# (A8B)# C57Bl/6#mice#were# injected# s.c.# at# the#base#of# the# tail#
with# indicated# lentivectors.# Two#weeks# later# splenocytes#were# isolated# and# stimulated#
overnight# with# OVA# peptides.# Analysis# was# performed# via# flow# cytometry.# 5#mice# per#
group#were#used#and#pooled#into#two#groups#for#in#vitro#analysis.#(A)#Above,#schematic#
representation# of# the# lentivector# constructs# containing# GFP,# IiOVA,# and# the#microRNA#
142#3p#target#sequence.#Below#left,#western#blot#of#transduced#293T#and#BM8DCs,#using#
the#anti8HA#antibody.#On#the#right,#bar#graphs#represent#OVA8specific#CD4#and#CD8#T#cell#
responses# in# vaccinated# mice,# as# assessed# by# ELISpot.# (B)# Same# as# in# A# but# using#





healthy& mice& and& thus& gave& us& insight& into& the& prophylactic& mechanisms& of& the&
lentivectors& in& priming& immune& responses.& I& further& investigated& the& mechanisms&
underlying& the& therapeutic& activity& of& the& lentivectors& after& intraFtumour& injection.&
During& intraFtumour& lentivector& injection& the& majority& of& transduced& cells& are& cancer&
cells&themselves&(Emeagi,&Van&Lint&et&al.&2012).&To&evaluate&the&effects&over&cancer&cells&
only,& lentivector& transduction&was& limited& to&B16& tumour&cells&by& transducing& them&ex#
vivo&prior&to&in#vivo#transfer.&B16&cells&were&transduced&ex#vivo&with&GFPFIiOVA,&IL12Fp1F
IiOVA,& IFNγFp1FIiOVA,& and& IL10Fp1FIiOVA.& Lentivector& transduction& did& not& affect& B16&
growth& in# vitro,& with& the& exception& of& IFNγFp1FIiOVA,& which& strongly& inhibited& B16&
growth& in# vitro& (data&not& shown).&While&B16FGFPFIiOVA& inoculated&mice&exhibited& fast&
tumour& growth,& it& was& significantly& delayed& in&mice& inoculated& with& B16FcytokineFp1F




immune& responses.& As& melanoma& cells& use& PDFL1& to& escape& from& immune& responses&
(Blank,&Gajewski& et& al.& 2005)& I& further& assessed& the& contribution& of& PDFL1& silencing& on&
cancer&cell&growth&in&the&absence&of&any&other&immunostimulating&agent.&B16&cells&were&
transduced& ex# vivo& with& GFPFIiOVA& or& GFPFp1FIiOVA& before& transfer& to& mice.& To& test&
transduction&efficiency,&transduced&B16&cells&were&analysed&by&flow&cytometry.&B16FGFPF
IiOVA&cells&expressed&50%&GFP&while&B16FGFPFp1FIiOVA&cells&expressed&only&29%&of&GFP&
(data&not&shown).& Interestingly,& silencing&of&PDFL1& in&only&29%&of& transferred&B16&cells&


















This& study& demonstrates& that& modulating& coFstimulation& during& antigen&
presentation& by& manipulating& cytokine& priming& and& PDFL1& silencing& is& an& effective&
approach& to& enhance& antiFtumour& immune& responses.& Assessing& a& wide& range& of&
cytokines& we& found& that& IL12& was& the& most& effective& at& raising& antiFtumour& immune&
responses,&when&combined&with&a&PDFL1& silencing&microRNA& (p1)&and& fullFlength&TRP1&
expression& fused& to& the& NFterminal& half& of& Ii.& CoFculture& experiments& with& different&
lentivector& constructs& showed& that& IL12Fp1FIiOVA& expression& within& BMFDCs& induce&
potent& OVAFspecific& CD8& responses& in# vitro& (Fig.& 3.4.B).& Interestingly,& this&
immunostimulatory& capacity& was& not& accompanied& by& BMFDC&maturation,& at& least& as&





Thus,& secretion& of& IL12& and& a& decrease& in& PDFL1/PDF1& signalling& may& be& sufficient& to&
effectively& stimulate& antigenFspecific& CD8& T& cell& responses& and& thus& upFregulation& of&
other& coFstimulatory,& MHC,& and& adhesion& molecules& may& not& be& necessary,& at& least&
initially.&




Janices&et&al.&2013).&Thus,& it&might&not&be&surprising& that& I& could&not& see&a&phenotypic&
change& in& transduced& BMFDCs& ex# vivo,& with& the& exception& of& the& IFNγFcontaining&








DCs&are& transferred&back& into& the&patient.&Autologous&DCs&have&been& transduced&with&
adenoviral&vectors&encoding&IL12&but&clinical&efficacy&was&somewhat&limited&in&patients&
with&metastatic&gastrointestinal& carcinomas& (Mazzolini,&Alfaro&et&al.&2005).& In&addition,&




but& this& strategy& may& even& be& more& effective& than& autologous& DC& adoptive& transfer&
(Esslinger,& Chapatte& et& al.& 2003).& Direct& lentivector& vaccination& has& been& shown& to&
initiate&CTL&responses& that&are& less&dependent&on&CD4&Th1& induction&and&nevertheless&
lead&to&memory&T&cells&(Chapatte,&Colombetti&et&al.&2006;&Dullaers,&Van&Meirvenne&et&al.&
2006;& Goold,& Escors& et& al.& 2011).& Further& supporting& direct& lentivector& vaccination&
strategies& with& broadFtropism& lentivectors& is& recent& data& showing& that& APCFtargeting&
lentivector& vaccines& are& less& effective& than& broadFtropism& lentivector& vaccines&
(Goyvaerts,&Lienenklaus&et&al.&2015).&








Vitale& et& al.& 2013)& and& data& previously& generated& in& our& laboratory& (experiments&
performed&by&Dr.& Kasia& Karwacz)& confirmed& that& PDFL1& silencing& alone& in&DCs& reduces&
Treg&levels&(Liechtenstein,&PerezFJanices&et&al.&2014).&Interestingly,&silencing&PDFL1&downF
regulated&Treg&cells& in#vivo& also&when&combined&with& IL10&expression.&While& the& IFNγF
containing& lentivector& elicited& the& highest& OVAFspecific& GzmB+& IFNγ+& CD8& T& cell&
responses,& it& was& not& as& effective& at& inhibiting& Treg& responses.& The& IL12Fcontaining&
lentivector&on&the&other&hand&raised&IFNγ+&CD8&T&cell&responses&but&not&GzmB+&IFNγ+&CD8&




various& cytokineFexpressing& lentivectors& initiated& effector& CD8& T& cell& responses.& As&




eventually& grew& out& and& escaping& tumours& from& vaccinated& mice& had& lost& OVA&
expression& (Fig.& 3.6.D).& This& data& suggested& that& through& antiFOVA& immune& selective&
pressure,&tumour&cell&variants&with&reduced&or&without&OVA&expression&escaped.&Certain&
tumours& from& IL12Fp1FIiOVAFvaccinated& mice& also& downFregulated& other& melanoma&
TAAs,& such& as& TRP2& and& gp100,& while& TRP1& remained& expressed& by& all& tumours& from&
IL12Fp1FIiOVAFvaccinated& mice& (Fig.& 3.6.E).& The& B16FOVA& model& is& frequently& used& in&
research&(He,&Zhang&et&al.&2005;&Fraser,&Lousberg&et&al.&2010;&Aranda,&Llopiz&et&al.&2011)&
but& I& used& a& slightly& different&model,&which& I& engineered& for& this& thesis.& In& this&model&
OVA&was& fused& to& the& invariant& chain& (Ii).& As&OVA& is& highly& immunogenic& its& use& likely&
overshadowed& the& adjuvant& effects& of& the& cytokines& and& PDFL1& silencing.& Thus,& using&
OVA&models&is&not&ideal&for&the&evaluation&of&cancer&vaccines.&&
In& the&B16&experimental& system,&TRP1& itself&was&not&an& immunogenic&TAA& (Fig.&
3.6.E).&In&agreement&with&results&presented&in&this&thesis,&TRP1&has&been&shown&by&other&















silencing&on& its&own&does&not&enhance&CTL&or&Th1&responses&and&that& IL12& is& the&main&
driver&for&breaking&tolerance&(Fig.&3.9).& In&stark&contrast&to&these&results&we&found&that&
silencing& of& PDFL1& during& prophylactic& vaccination& with& IL12Fcontaining& lentivectors&
enhanced& protective& immunity& against&melanoma& (Fig.& 3.7.E).& As& vaccinations& in& both&
experiments&were&performed&in&healthy&mice,&additional&factors&(apart&from&raising&CTL&
and& Th1& responses)& may& play& a& role& in& inducing& antiFTRP1& immune& responses& in& this&
experimental&model.&&
Direct& lentivector&vaccination& induces& transduction&of&multiple&cell& types&at& the&
injection&site.&An&experiment& silencing& transgene&expression& in&haematopoietic& cells&at&
the&injection&site&was&conducted.&While&antigenFspecific&T&cell&responses&were&reduced,&
there&was& still& a& significant& antigenFspecific& T& cell& response& elicited& by& transduction& of&
cells& of& nonFhaematopoietic& origin& (Fig.& 3.10.B).& Expression& of& only& IL12& and& IiOVA&
without& p1& in& cells& of& nonFhaematopoietic& origin& (which& includes& professional& APCs)&
reduced&the&T&cell&responses&to&background&levels,&thus&highlighting&the& importance&of&
PDFL1& silencing& in& “nonFimmune”& cells.& These& results& were& confirmed& in& a& recently&
submitted&study&by&Goyvaerts&et&al..&In&this&study,&introduction&of&the&microRNA&142&3p&
target&into&the&lentivector&construct&containing&the&IL12&and&IiOVA&genes&reduced&OVAF
specific& CTL& lytic& activity& in# vivo& close& to& background& levels.& Interestingly,& they& further&
found&that&lentivector&vaccines&specifically&targeting&APCs&were&inferior&to&broad&tropism&
lentivector& vaccines,& further& confirming& the& role& of& nonFAPCs& in& antiFtumour& immune&
responses& (Goyvaerts,& Lienenklaus& et& al.& 2015).& My& data& correlates& with& data&
demonstrating&that&PDFL1&expression&in&endothelial&cells&regulates&CD8&T&cell&activation,&
cytolytic&activity,&and&extravasation&(Rodig,&Ryan&et&al.&2003).&Further,&PDFL1&silencing&in&
both& cells& of& haematopoietic& and& nonFhaematopoietic& origin& at& the& injection& site&
enhances&the&strength&of&the&CD8&T&cell& response&as&the&absolute&numbers&of&antigenF
specific& CD8& T& cells& is& enhanced& as& compared& to& IL12& expression& alone& (Fig.& 3.10.B).&
While& local&delivery&of&a&PDFL1Fsilencing&microRNA&amplified&T&cell& responses,& it&would&





in& the&B16& tumour&model.&While& IFNγFp1FIiOVA&was&particularly& successful& at& inducing&
OVAFspecific& CTL& responses& in& mice,& BMFDCs& transduced& with& IFNγFp1FIiOVA& did& not&
induce&potent&OVAFspecific&CD8&T&cell& responses& in#vitro,&although& this& result& could&be&
due&to&IFNγFmediated&cytotoxicity.&As&IFNγFp1FIiOVA&was&not&effective&at&inhibiting&Treg&
responses& in& vaccinated& mice& (Fig.& 3.5),& earlyFelevated& IFNγ& expression& may& initiate&
regulatory&mechanisms& that& reduce& responses& against& cancer& cells& (Zaidi& and&Merlino&
2011).& Ex# vivo& transduction& of& B16& melanoma& cells& with& IFNγFp1FIiOVA& was& not& as&
effective& as& IL12Fp1FIiOVA& at& delaying& tumour& growth& (Fig.& 3.11.A).& This&was& observed&
despite& direct& B16& cell& cytotoxicity& in# vitro& by& IFNγFp1FIiOVA& transduction,& before&
transfer& to& mice.& Further,& IFNγFp1FIiTRP1& did& not& delay& tumour& growth& or& prolong&
survival& in& B16& melanomaFbearing& mice,& confirming& the& limited& efficacy& of& IFNγ& for&
cancer& immunotherapy&strategies& (Meyskens,&Kopecky&et&al.&1990;&Meyskens,&Kopecky&
et&al.& 1995;& Schiller,&Pugh&et&al.& 1996;&Wigginton,&Gruys&et&al.& 2001;&Zaidi& and&Merlino&
2011).&This&may&be&somewhat&surprising&as&endogenous& IFNγ& is&necessary&for&the&antiF
tumour&activity&of& IL12& (Wigginton,&Gruys&et&al.& 2001;&Weiss,& Subleski&et&al.& 2007)&and&
maintenance& of& high& systemic& endogenous& IFNγ& in& patients& correlates& with& tumour&
regression&in&patients&treated&with&IL12&(Gollob,&Mier&et&al.&2000).&Zaidi&et&al&proposed&a&
“dark& side”& for& IFNγ.& IFNγ&does&not&only&play& a& role& in& immunoediting/elimination&but&
also& in& the& equilibrium/subversion& stages& of& tumour& development& (Zaidi& and&Merlino&
2011).& As& IFNγ& is& involved& in& inflammatory& responses& it& also& protects& tissues& from&
inflammation.& IFNγ&attracts&macrophages& for& tissue& repair& and& induces&Treg& to& control&
inflammatory&processes&(Zaidi&and&Merlino&2011).&Further,& IFNγFactivated&myeloid&cells&
can&induce&CTL&and&Th&suppression&by&IDOFdependent&mechanisms&and&control&myeloid&
cell& tumour& infiltration& by& induction& of&MDSCs& (Fallarino,& Vacca& et& al.& 2002;& OstrandF
Rosenberg& and& Sinha& 2009).& Thus,& it& may& not& be& surprising& that& IFNγ& did& not& show&
efficacy&in&this&study.&
In&prophylactic&experiments&using&B16&melanoma&cells&without&OVA&expression,&
vaccination& with& IL12Fp1FIiTRP1& exhibited& the& strongest& antiFtumour& activities.&
Prophylactic&vaccination&depends&on&the&priming&of&T&cell&responses&and&single&injections&
were& administered& to& avoid& boosting& primary& T& cell& responses.& Although& only&modest&
protective&effects&might&be&achieved&these&responses&could&highlight&relevant&activities&
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that& would& be& missed& otherwise.& Further& testing& of& IL12Fp1FIiTrp1& lentivectors& in&
therapeutic& experiments& by& intraFtumour& administration& showed& that& this& treatment&
slowed& down& tumour& growth.& Importantly,& in& these& experiments,& TAAFindependent&
mechanisms&may&contribute&to&therapeutic&activities,&such&as&IL12Fmediated&cancer&cell&
cytotoxicity.&PDFL1&silencing&also&played&a&differential&role&between&the&prophylactic&and&
therapeutic& settings.& PDFL1& inhibition& in& a& prophylactic& setting& clearly& enhanced&
protective& immunity& combined&with& IL12FIiTRP1Fbased& lentivectors& (Fig.& 3.7.E)&while& it&
was&not&as&pronounced&in&the&therapeutic&setting&(although&statistically&significant)&(Fig.&
3.8).& PDFL1& acts& as& a& break& for& T& cell& activation& at& two& different& levels.& First,& during&
antigen& presentation,& blocking& PDFL1& enhances& T& cell& activation& and& differentiation.&
Second,&during&antigen&recognition&on&target/tumour&cells,&PDFL1&acts&as&a&T&cell&brake&
by& inhibiting& the& activity& of& tumourFspecific& CTL& responses& (Liechtenstein,&Dufait& et& al.&
2012).&Our&group&previously&showed&that&silencing&of&PDFL1&alone&in&antigenFpresenting&
DCs& hyperactivates& TCRhigh& CD8& T& cells& with& enhanced& IFNγ& production.& Thus,& in& the&
prophylactic&protocol,&cells&of&haematopoietic&and&nonFhaematopoietic&origin&present&at&
the&injection&site&present&TRP1&in&the&context&of&IL12&and&reduced&PDFL1.&In&this&way&they&
can& hyperactivate& T& cells& specific& for& TRP1& while& at& the& same& time& inducing& effector&







of& transduced& cells& will& be& tumour& cells,& impairing& their& capacity& to& inactivate& TAAF
specific&CTL&responses.&The&PDFL1Fmediated&T&cell&brake& is&removed&within&the&tumour&
environment,& thus& reFactivating& already& present& infiltrating& effector& CD8& T& cells.& In&
addition,&PDFL1& silencing& in&B16& tumour& cells&ex# vivo& led& to&delayed& tumour&growth& in#
vivo,& thus& directly& contributing& to& inhibition& of& cancer& cell& growth& (Fig.& 3.11.C,D).& The&




The& exact& role& of& IL12& in& antiFtumour& therapeutic& efficacy& (Macgregor,& Li& et& al.&
2006;& Chmielewski,& Kopecky& et& al.& 2011;& Steding,&Wu&et& al.& 2011;& Zhang,& Kerkar& et& al.&
2011;& Zhao,& Bose& et& al.& 2011)& has& not& been& established.& IL12Rb2& knockout& mice&
spontaneously&develop&cancer,&including&BFcell&and&lung&tumours&(Airoldi,&Di&Carlo&et&al.&
2005).& However,& IL12& knockout&mice& do& not& seem& to& spontaneously& develop& tumours&
but& are& more& susceptible& to& tumour& growth& when& treated& with& carcinogens& or&
inoculated& with& tumour& cells.& IL12& deficiency& was& associated& with& greater& risk& of&
photocarcinogenesis& and& the& authors& suggested& that& this&may& be& due& to& reduction& in&
damaged&DNA& repair&ability& (Meeran,&Mantena&et&al.& 2006).& Inoculating& IL12&knockout&
mice& with& syngeneic& bladder& cancer& reduced& survival,& as& compared& to& wildtype& mice&
(Riemensberger,& Böhle& et& al.& 2002).& It& has& been& suggested& that& IL12& appears& to& elicit&
more& potent& antiFtumour& responses& when& present& in& the& tumour& microFenvironment&
rather& than& systemically& (Lasek,& Zagozdzon& et& al.& 2014).& Nevertheless,& IL12& expression&
affects&stromal&and&endothelial&cells&in&the&tumour&environment&(Kerkar,&Leonardi&et&al.&
2013).&IL12&has&direct&antiFtumour&effects&(Hendrzak&and&Brunda&1996;&Airoldi,&Di&Carlo&






2011).& Adoptive& transfer& of& DCs& engineered& to& secrete& IL12& has& been& shown& to& slow&
down&B16&tumour&growth&in#vivo&in&mice&through&priming&of&CD8&T&cell&responses&(Zhao,&
Bose&et&al.&2011).&The&effects&of&IL12&may&therefore&mask&the&adjuvant&effects&of&PDFL1&
silencing& in& the&rapidly&growing&B16&tumour&model.&Testing& its&efficacy& in&spontaneous&
tumour&models&may&be&beneficial&to&better&understand&the&effects&of&the&IL12Fp1FIiTRP1&
lentivector& vaccine.& Further,& assessing& the& effect& of& the& IL12FIiTRP1Fbased& lentivector&
vaccines& on& the& composition& of& tumourFinfiltrating& immune& cells& could& be& of& value.&
Several& studies& have& already& evaluated& the& effect& of& IL12& on& immune& cells& within& the&
tumour&environment.&These&studies&used&several&methods&to&deliver&IL12&to&the&tumour&




(Broderick,& Yokota& et& al.& 2005),& reactivated& resident& impaired& effector& and&memory& T&
cells&(Kilinc,&Aulakh&et&al.&2006),&caused&infiltration&of&activated&and&nonFapoptotic&CD8&
effector& T& cells& (Kilinc,& Aulakh& et& al.& 2006;& Steding,&Wu& et& al.& 2011),& increased&NK& cell&
numbers&(Zhang,&Kerkar&et&al.&2011),&decreased&percentage&of&MDSCs&(Steding,&Wu&et&al.&
2011;& Thaci,& Ahmed& et& al.& 2014),& and& increased& DC& (Thaci,& Ahmed& et& al.& 2014)& and&
macrophage& (Chmielewski,& Kopecky& et& al.& 2011)& numbers& in& the& tumour&
microenvironment.&&
Escaping& B16FIiOVA& tumours& downFregulated& OVA& and& endogenous& TAA&
expression&(Fig.&3.6),&further&confirming&the&immune&selective&pressure&on&cancer&cells.&




effective& activation& of& TRP1Fspecific& Th1& and& CTL& responses.& Prophylactic& vaccination&
with& IL12Fp1FIiTRP1& delayed& tumour& growth,& with& IL12& expression& and& p1& delivery&
exhibiting& clear& synergistic& effects.& Clear& but& rather& modest& therapeutic& effects& were&
achieved& using& IL12FIiTRP1Fbased& lentivector& vaccines.& This& may& be& due& to& the&
administration& of& only& a& single& intraFtumour& lentivector& injection& into& already& rapidly&
growing&tumours&(50F200mm3).&It&was&hypothesized&that&this&was&a&more&realistic&setting&
and& that& even&a&modest& increase& in& therapeutic& activity& could&be&of& relevance.& PrimeF
boost,&multiple& intraFtumour& injections,&and& inclusion&of&multiple&or&mutated&TAAs&are&
all&strategies&that&will&likely&improve&the&efficacy&of&IL12Fp1FbasedF&lentivector&vaccines.&
While& the& role& of& IL12& on& T& cells& is&well& characterized,& its& role& on& immunosuppressive&
myeloid& cell& types& within& the& tumour& environment& has& only& recently& being& studied.&








interactions& that& lead& to& immune& cell& accumulation& and& antiFtumour& activity& will& be&
useful& for& future& improvement& of& cancer& immunotherapy& strategies& that& include& IL12&
induction&and&PDFL1&silencing.&
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CHAPTER! 4:! DEVELOPMENT! OF! AN! EX# VIVO!MYELOID+DERIVED!
SUPPRESSOR!CELL!DIFFERENTIATION!SYSTEM!!
4.1.!! INTRODUCTION!
Cancer& immunotherapy& strategies& are& based& on& the& theory& of&
immunosurveillance,& claiming& that& the& immune& system& can& recognize& and& eliminate&
cancer&cells.&Stimulating&endogenous&antiFcancer&effector&cells&to&fight&against&cancer&is&
an& elegant& approach& to& antiFcancer& treatment,& with& the& promise& of& low& offFtarget&
toxicities.& While& this& strategy& will& appeal& to& any& immunologist,& cancer&
immunotherapeutic& strategies&have&been& largely&unsuccessful& in& the& last&decades.&This&
was&likely&due&to&inactivation&of&antiFcancer&effector&cells&by&immunosuppressive&cells&in&




In& the& previous& chapter& the& combination& of& IL12& induction& and& PDFL1& silencing&
was& most& effective& at& delaying& tumour& growth& in# vivo.& This& lentivector& vaccine& can&
induce& immature& BMFDCs& to& activate& CTL& responses& in# vitro.# However,& as& DCs& are&
dysfunctional& in& tumours,&evaluation&of&cancer&vaccines&on&BMFDCs& from&healthy&mice&
may& not& be& an& appropriate& study& system.& Tumour& progression& is& accompanied& by&
extensive&MDSC& infiltration& and& the&majority& of& cells& that& express& the& ILF12Rb2&within&
B16&tumours&are&not&only&DCs&but&also&MDSCs& (Kerkar,&Leonardi&et&al.&2013).&Recently&
MDSCs& have& been& recognized& as& one& of& the& main& cell& types& responsible& for& tumourF
induced& immune&suppression,& thus& inhibiting& immunotherapy&approaches& (Gabrilovich,&
OstrandFRosenberg&et&al.&2012;&Escors&2014).&TumourFinfiltrating&MDSCs&strongly&inhibit&
CTLs& and& their& accumulation& in& tumourFbearing&hosts& favours& tumour&progression& and&
metastasis&(Talmadge&2007;&OstrandFRosenberg&and&Sinha&2009;&Chen,&Kuan&et&al.&2014).&
Counteracting&MDSC& activities& strongly& enhances& antiFcancer& treatments& and& prolongs&
survival&(Qin,&Lerman&et&al.&2014).&The&capability&of&generating&large&numbers&of&tumourF
infiltrating& MDSCs& ex# vivo& would& significantly& facilitate& the& discovery& of& antiFMDSC&
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treatments&and& improve&research& in&MDSC&biology&and&function.& I& therefore&set&out&to&




Evidence& for& the& correlation& of& MDSC& accumulation& and& cancer& progression,&
invasion,& and& metastasis& was& discussed& in& Chapter& 1& (OstrandFRosenberg& and& Sinha&
2009;& Chen,& Kuan& et& al.& 2014;& Condamine,& Ramachandran& et& al.& 2015).& MDSCs& are& a&
heterogeneous& population& of& immature& myeloid& cells,& arrested& at& various& stages& of&
lineage&development& (Almand,&Clark&et&al.&2001;&Gabrilovich,&OstrandFRosenberg&et&al.&
2012).&MDSCs&accumulate& in&circulation,& lymphoid&organs,&and&tumours&due&to&altered&
myelopoiesis& and& alteration& of&myeloid& cell& differentiation& by& tumourFsecreted& factors&
(Gabrilovich& and& Nagaraj& 2009).&MDSCs& infiltrate& tumours& where& they& strongly& inhibit&
CTL&(Kusmartsev,&Nefedova&et&al.&2004;&Talmadge&2007),&Th1&(Kusmartsev,&Li&et&al.&2000;&
Talmadge& 2007),& and& NK& cell& (Hoechst,& Voigtlaender& et& al.& 2009;& Li,& Han& et& al.& 2009)&
responses.&MDSCs& strongly& impair&NK& cell& function& and& induce&NK& cell& anergy.&MDSCs&
achieve& this&by& inhibiting& cytotoxicity,& activating& receptor&NKG2D&expression,&and& IFNγ&
production&by&NK&cells& in#vitro&and& in&vivo.&NK&cells& lost& their&capacity&to&produce& IFNγ&
after& incubation& with& MDSCs,& and& MDSCFmediated& NK& suppression& depended& on&
membraneFbound&TGFβ& (Li,&Han&et&al.&2009).&MDSCs&can& inhibit&T& cell& responses& in&an&
antigenFspecific& way& but& they& also& inhibit& T& cell& and& other& immune& cell& responses& in&
antigenFindependent& ways.& Antigen& presentation& in& combination& with& secretion& of&
immunosuppressive&cytokines&(or&even&IFNγ)&induces&Treg&differentiation&(Huang,&Pan&et&
al.& 2006).& Antigen& presentation& without& positive& coFstimulation& on& the& other& hand&
expands&T&cells&with&no&or&only&limited&effector&capabilities.&If&these&cells&encounter&the&
same&antigen&T&cell&anergy&is&induced.&In&the&spleen,&MDSCs&associate&with&memory&CD8&
T&cells,& crossFpresenting& tumour&antigens&and&thus& inducing& their& tolarization& (Nagaraj,&
Schrum& et& al.& 2010;& Ugel,& Peranzoni& et& al.& 2012).& Unspecific& inhibition& of& immune&




TGFβ& secreted&by&MDSCs& inhibits&T& cell&proliferation& (Filipazzi,&Valenti&et&al.& 2007)&and&
IL10& skews& macrophages& and& DCs& towards& a& M2& or& tolerogenic& DC& function,& with&
decreased& IL12& production& (Gabrilovich,& OstrandFRosenberg& et& al.& 2012).& MDSCs& also&
secrete& CCR5& ligands,& CCL3,& CCL4,& and& CCL5,& to& attract& Treg& cells& to& tumour& sites&
(Schlecker,&Stojanovic&et&al.&2012).&Lymphocyte&nutrients&are&depleted&or&sequestered&by&
MDSCs& in& various&ways.& LFarginine& depletion& is&widely& accepted& to& be& linked& to&MDSC&
suppressive& activities& (Bronte& and& Zanovello& 2005).& LFarginine& is& depleted& by& ArgF1&
(arginaseF1)&and/or&iNOS&(inducible&nitric&oxide&synthase/NOS2)&activity.&ArgF1&and&iNOS&
use& LFarginine& as& a& substrate,& but& while& ArgF1& produces& urea& and& LFornithine,& iNOS&
produces&nitric&oxide&(NO).&NO&can&suppress&T&cell&proliferation&and&function&by&blocking&
the& ILF2R& pathway& through& dephosphorylation& of& Jak3/Stat5& (janus& kinase& 3/signal&





Gabrilovich,& OstrandFRosenberg& et& al.& 2012).& IDO& (Indoleamine& 2,3Fdeoxygenase)& also&
acts& similarly& to& ArgF1& in& tolerogenic& DCs& and& MDSCs.& IDO& catalyzes& tryptophan& and&






(Talmadge& 2007;& Gabrilovich,& OstrandFRosenberg& et& al.& 2012).& Production& of& NO,& for&
example,&decreases&the&responsiveness&of&T&cells&and&NK&cells&to&IFNα&and&IFNγ&(MundyF
Bosse,& Lesinski& et& al.& 2011).& The& reaction& of& NO& and& superoxide& anion& (O2F)& produces&
peroxynitrite.& Peroxynitrite& nitrates& TCRs& thus& altering& the& recognition& of& the& pFMHC&
complex&(Condamine&and&Gabrilovich&2011).&&








the&extracellular&matrix,&tumour& invasion& into&tumour&stroma&is&promoted.& In&addition,&







Fig.# 4.1.# Mechanisms# used# by# MDSCs# to# suppress# immune# cell# responses.# Scheme#
represents# the# various# effects#MDSCs#have#on# the# function#of# immune# cell# types.# ROS,#
reactive# oxygen# species;# RNS,# reactive# nitrogen# species;# IDO,# Indoleamine# 2,38






According& to& their& Ly6CFLy6G& expression,&mouse&MDSCs& can& be& further& classified& into&







infiltrating& myeloid& cells& with& phenotype& CD11b+& Ly6G+& F4/80low& expression,& tumourF
associated&neutrophils& (TANs,&or&N2)(Fridlender,& Sun&et&al.&2009;&Fridlender,& Sun&et&al.&
2012),&while& others& call& these& cells& tumourFinfiltrating&GFMDSCs& (Youn,& Collazo& et& al.& ;&
Liechtenstein,& PerezFJanices& et& al.& 2014).& Thus,& MDSC& phenotype,& origin,& and& role& in&
cancer&remain&controversial&(Albeituni,&Ding&et&al.&2013).&&
Both& MFMDSCs& and& tumourFassociated& macrophages& (TAMs)& can& suppress&
immune& responses,& exhibit& similar& histological& distribution,& and& express& MCSFFR&
(Macrophage& colony& stimulating& factor& receptor),& making& it& challenging& to& distinguish&
between& the& two& cell& types.& TAMs& are& defined& as& mature& macrophages& with& F4/80&
expression,& while& MFMDSCs& are& immature& myeloid& cells.& TAMs& have& been& shown& to&
differentiate& from& monocyte& populations& resembling& tumourFinfiltrating& MFMDSCs&
(Movahedi,& Laoui& et& al.& 2010)& and& the& hypoxic& tumour&microenvironment& can& induce&
MDSC&differentiation&into&TAMs&(Corzo,&Condamine&et&al.&2010).&As&MFMDSCs&comprise&
a& mixture& of& immature& myeloid& cells& at& various& stages& of& differentiation,& it& may& be&
intuitive& that& they& can& differentiate& into& macrophages,& be& it& in& a& suppressive& or&
immunostimulatory&form&(Movahedi,&Laoui&et&al.&2010;&Talmadge&and&Gabrilovich&2013).&
As&myeloid&cells&are&responsive&to&tumourFderived&factors,&it&may&be&argued&that&
circulating& MDSCs& differentiate& into& tumourFpromoting& macrophages,& neutrophils,& or&
DCs&within&the&tumour&microenvironment.&In&this&line&of&thought,&studies&have&claimed&
that&MDSCs&can&differentiate& into&TAMs&and&TANs&within& the&tumour& (Kusmartsev&and&
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compared& the& transcriptomes& of& TANs,& splenic& GFMDSCs,& and& neutrophils& from& naïve&
mice.&It&was&shown&that&TANs&exhibited&lower&expression&of&cellFcytotoxicity&genes,&thus&
exhibiting&impaired&antiFtumour&efficacy.&MDSCs&and&especially&TANs&upFregulated&many&
immuneFregulated& genes& and& pathways& as& exhibited& by& higher& expression& of&
inflammatory&cytokines&(TNFα,&IL1α/β)&and&MHC&II&complex&genes.&In&addition,&they&upF
regulated& T& cell,& B& cell,& neutrophil,& and& macrophage& chemoattractants.& As& TANs&

























the& tumour& or& lymphoid& organs.& While& MDSCs& accumulate& in& human& patients& and&
tumourFbearing&mice&not&only&in&the&tumour&itself,&but&also&in&peripheral&blood,&tumourF
draining&lymph&nodes,&and&liver,&these&MDSCs&in&different&locations&are&not&equivalent.&
Nonetheless,& increased& MDSC& numbers& correlate& with& disease& progression& and&
metastasis&(DiazFMontero,&Salem&et&al.&2009;&Ilkovitch&and&Lopez&2009;&Lechner,&Liebertz&
et&al.&2010).&Several&studies&have&shown&that&tumourFinfiltrating&and&splenic&MDSCs&are&
not&equivalent,&neither&phenotypically&nor& functionally& (Corzo,&Condamine&et&al.& 2010;&
Maenhout,&Van&Lint&et&al.&2013;&Liechtenstein,&PerezFJanices&et&al.&2014).&In&a&pancreatic&
adenocarcinoma& mouse& model& splenic& MDSCs& were& less& suppressive& than& tumourF
infiltrating&MDSCs& (Porembka,&Mitchem&et&al.&2012).&MDSCs& from&a&mammary& tumour&
model& showed&differential& transcription& levels& of& several& genes,& including&ArgF1,& iNOS,&
Flt3L&(FmsFlike&tyrosine&kinase&3&ligand),&and&VEGFFA&(vascular&endothelial&growth&factor&
A),& between& splenic& and& tumour&MDSCs& (Abe,& Dafferner& et& al.& 2010).& Further,&MDSCs&
from&the&periphery&were&shown&to&suppress&T&cells&only&by&antigenFspecific&mechanisms&
while& tumourFinfiltrating& MDSCs& could& also& suppress& T& cells& in& unspecific& ways.&
Interestingly,&this&functional&change&was&dependent&on&hypoxia&(Corzo,&Condamine&et&al.&
2010).& Hypoxia& was& also& shown& to& recruit& various& BMFderived& myeloid& cell& types& to&
tumour&tissues,&where&they&promoted&tumour&neovascularization&and&invasion&(Du,&Lu&et&
al.& 2008).& Similar& to& hypoxia,& inflammation& also& regulates& MDSC& function& (OstrandF
Rosenberg&and&Sinha&2009).&Prostate&tumours&in&a&prostateFspecific&inflammatory&mouse&
model& showed& that& only& MDSCs& found& at& inflammatory& sites& or& in& tumour& tissues&
exhibited& T& cell& suppressive& function.& MDSCs& found& in& peripheral& tissues& acquired&
suppressive&capacities&only&upon&stimulation&by&IFNγ,&thus&activating&iNOS&(Haverkamp,&
Crist& et& al.& 2011).& It& has& become& clear& that& peripheral& and& tumour&MDSCs& as& well& as&
immature&myeloid&cells& from&healthy&mice&all&exhibit& the&same&phenotype&overall,&but&
not& the&same& immuneFregulatory& functions.&Thus,&Talmadge&et&al&proposed&the& theory&
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and& TANs& similarly& differ& in& frequency,& gene& expression,& and& function,& depending& on&
tumour& type& (Elpkek,& Cremasco& et& al.& 2014).& Tumours& secrete& various& factors& to& alter&
myelopoiesis,&mobilization,&and&accumulation&of&MDSCs&in&spleen,&peripheral&blood,&and&
tumours.& Various& factors& are& known& to& be& involved& in& stimulating&MDSC& proliferation,&
including& VEGF& (Gabrilovich,& Ishida& et& al.& 1998;& Donkor,& Lahue& et& al.& 2009),& GMFCSF&
(Bronte,&Apolloni&et&al.&2000;&Serafini,&Carbley&et&al.&2004;&Dolcetti,&Peranzoni&et&al.&2010;&




subsets& (Dolcetti,& Peranzoni& et& al.& 2010)& and& studies& using& GMFCSF& or& GMCSFFR&
neutralizing&antibodies&have&confirmed&that&this&haematopoietic&growth&factor&is&crucial&
for& MDSC& accumulation& in& tumourFbearing& mice.& In& fact,& it& is& believed& that& tumourF
secreted&GMFCSF&may&also&be&sufficient&to&drive&MDSC&development&(Morales,&Kmieciak&
et& al.& 2010;& Bayne,& Beatty& et& al.& 2012).& Under& physiological& circumstances& GMFCSF& is&
crucial& for& the& recruitment& of& monocytes& and& granulocytes& from& the& BM& to& sites& of&
inflammation.& GMFCSF& also& helps& in& migration& and& proliferation& of& splenic& monocyte&
precursors,&which&subsequently&expand&to&myeloid&cells&at&the&inflammation&site&(Cook,&
Turner& et& al.& 2011;& Robbins,& Chudnovskiy& et& al.& 2012;& Trikha& and& Carson& 2014).& An&
important& factor& is& the& concentration& of&GMFCSF,& as& depending& on&GMFCSF& levels& this&
cytokine&induces&inhibitory&or&stimulatory&immune&effects&(Bronte,&Chappell&et&al.&1999;&
Bronte,&Apolloni&et&al.&2000;&Hansen,&Hercus&et&al.&2008;&Trikha&and&Carson&2014).&Low&
GMFCSF& concentrations& enhance& antigen& presentation& by& DCs,& while& high& GMFCSF&
concentrations& induce& MDSC& differentiation& and& accumulation,& and& hence& immune&
suppression&(Dranoff&2003;&Serafini,&Carbley&et&al.&2004).&GMFCSF&is&frequently&used&as&a&
vaccine& adjuvant& in& clinical& trials& but& with& mixed& success.& Thus,& using& GMFCSF& as& a&
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vaccine&adjuvant&has&been&shown&to&increase&a&highly&suppressive&population&of&CD14+&
HLAFDRlow& myeloid& cells& in& patients.& In& addition,& increased& production& of& TGFβ& was&
observed& and& patients& with& higher& MDSC& numbers& tended& to& be& unresponsive& to&
treatment& (Filipazzi,& Valenti& et& al.& 2007).& A& study& reviewing& clinical& trials& and& animal&
studies& suggested& that& repeated& lowFdose& administration& of& GMFCSF& has&




For& use& in& research,& MDSCs& are& frequently& isolated& from& spleens& or& tumour&
tissues& of& tumourFbearing&mice& (Youn,& Collazo& et& al.& 2012;& Schouppe,&Mommer& et& al.&
2013;& Aliper,& FriedenFKorovkina& et& al.& 2014).& This& is& due& to& a& lack& of& efficient& ex# vivo&
MDSC& differentiation& systems,& unlike& their& immunogenic& counterparts,& DCs.& Mouse&
MDSC& isolation& from& tumour& tissues& is& cumbersome&and&prone& to& contamination&with&
other&myeloid&cell&types.& In&addition,&tumourFinfiltrating&MDSCs&do&not&proliferate&well&




tumourFbearing& mice& (Peranzoni,& Zilio& et& al.& 2010;& Alizadeh,& Trad& et& al.& 2014;&
Chakraborty,&Das&et&al.&2014;&Mao,&Sarhan&et&al.&2014).&While&splenic&MDSCs&may&exhibit&
certain& suppressive& activities,& they& are& not& equivalent& to& tumourFinfiltrating& MDSCs&
(Maenhout,&Van&Lint&et&al.&2013;&Dufait,&Schwarze&et&al.&2015).&&
To& circumvent& this& drawback,& several& ex# vivo& murine& MDSC& differentiation&
systems&have&been&developed&toFdate.&MDSCs&have&been&differentiated&from&stem&cell&
types&but&with& limited&success&(Zhou,&French&et&al.&2010).& & Interestingly,&a&recent&study&
has&shown&that&NK&cells&can&differentiate& into&MDSCs& in& the&presence&of&GMFCSF&or& in&
tumourFbearing& hosts& (Park,& Song& et& al.& 2013).& If& these& results& are& confirmed& it&would&




CSF& plays& a& key& role& in& MDSC& accumulation& in# vivo,& it& is& applied& in& most& ex# vivo#
differentiation& studies& (Lutz,& Kukutsch& et& al.& 2000;& Dolcetti,& Peranzoni& et& al.& 2010;&
Morales,& Kmieciak& et& al.& 2010).& One& of& the& first& ex# vivo& differentiated& MDSCs& were&
generated& by& diverting& BMFDC& differentiation& (through& addition& of& GMFCSF)& to&MDSC&
differentiation& by& the& addition& of& LPS& and& IFNγ.& The& resulting& immature&myeloid& cells&








remained& low.& GMFCSF& in& combination& with& IL6& alone& led& to& accumulation& of&
immunosuppressive&myeloid&cells&but&without&proliferative&capabilities&(Marigo,&Bosio&et&
al.& 2010).& Addition& of& IL13& increased& the& suppressive& capacities& of& immature& myeloid&
cells&generated&with&GMFCSF&and&MFCSF,&but&MDSCs&only&comprised&40F50%&of&culture&
cells& (Highfill,& Rodriguez& et& al.& 2010).& Addition& of& GMFCSF& to& tumourFconditioned&
medium& rendered& up& to& 45F60%& of& CD11b+& GRF1+& cells,& although& certain& subtypes&
showed&no&suppressive&capacities&(Morales,&Kmieciak&et&al.&2010;&Michels,&Shurin&et&al.&
2012).& Addition& of& GMFCSF,& IL4& and& cancer& cell& lineFconditioned& medium& to& BM& cells&
induced& immunosuppressive& myeloid& cells& that& were& comparable& to& in# vivo& MDSCs,&
albeit&without&high&(about&30%)&proliferative&capacities&(Youn,&Nagaraj&et&al.&2008).&Thus,&
current&protocols&can&differentiate&immature&myeloid&cells&equivalent&to&MDSCs& in#vivo&
in& tumourFbearing& mice.& However,& several& problems& remain& unresolved& in& most&
strategies.& Important& for& effective& ex# vivo&MDSC& differentiation& strategies&would& be& a&
high& percentage& of& MDSCs& in& cultures,& prolonged& viability& and& proliferation,& and&




myeloid& cell& types& at& various& stages& of& development,& allowing& precursors& to& replenish&
apoptotic&MDSCs.&
4.1.5.! CURRENT!PROTOCOLS!FOR!THE!EX#VIVO!DIFFERENTIATION!OF!HUMAN!MDSCs!
Similar& to& the&murine& system,& human&MDSCs& are& still& frequently& isolated& from&
blood&of&patients.&However,&circulating&MDSCs&are&not&equivalent&to&tumourFinfiltrating&
MDSCs& and& may& skew& experimental& results.& Researchers& have& used& peripheral& blood&
monocytes&(PBMCs),&CD34+&haematopoietic&precursors,&BM&aspirates,&and&umbilical&cord&
precursors& as& starting&material.& Several& studies& compared& various& protocols& to& induce&
MDSC& differentiation& from& PBMCs,& as& they& can& be& easily& obtained.& Adding& various&
combinations&of&recombinant&cytokines&to&PBMCs,&the&combination&of&GMFCSF&and&IL6&
most& effectively& produced& suppressive& CD33+& immature& myeloid& cells& that& were&
consistent&with& human& CD33+&MDSCs& (Lechner,& Liebertz& et& al.& 2010).& Addition& of& high&
GMFCSF& concentrations& was& sufficient& in& another& study& to& convert& CD11b+& cells& from&
healthy& donors& (De& Santo,& Salio& et& al.& 2008),& while& PGE2,& GMFCSF,& IL4,& and& LPS& were&
combined& in& a& more& recent& study& (Obermajer,& Muthuswamy& et& al.& 2011).& Culturing&
human& monocytes& from& healthy& donors& with& IL4& differentiated& a& fibrocytic& subset& of&
MDSCs&that&was&equivalent&in&phenotype&and&function&to&this&immunosuppressive&MDSC&
subset&found&in&cancer&patients&(Zhang,&Maric&et&al.&2013).&Alternatively,&PBMCs&can&be&








myeloid& cells& shared&markers& of& DCs,&MDSCs,& and& fibrocytes,& the& authors& called& them&
fibrocytic&MDSCs.&These&cells&suppressed&CD4&and&CD8&T&cells&and&induced&Tregs&in#vitro.&
Interestingly,&MDSC& suppression&was& not& dependent& on& iNOS& or& ArgF1& but& on& cellFcell&
interactions&and&IDO&(Zoso,&Mazza&et&al.&2014).&&
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Different& tumours& secrete& varying& factors,&mobilizing&myeloid& cells& from&BM&or&
other&tissues.&The&variety&of&MDSC&ex#vivo&differentiation&protocols&and&differentiation&
of& MDSCs& with& various& characteristics& reflects& their& tumourFdependency& in# vivo.&
Nonetheless,&GMFCSF&remains&a&key&factor&for&the&differentiation&of&human&and&mouse&
MDSCs.& In& addition,& IL4& and& IL6& seem& to& be& additional& key& factors& for& human& MDSC&
differentiation&and&suppressive&function.&This&correlates&with&data&showing&that&IL6&and&
MDSC& levels& predict& prognosis& of& patients& with& squamous& cell& carcinoma& of& the&
esophagus&(Chen,&Kuan&et&al.&2014).&Similarly,&there&exists&a&positive&correlation&between&
IL4&mRNA&in&PBMCs&and&plasma&ArgF1&enhancement,&which&correlated&with&MDSC&levels&




















4.2.1.! SIMULATION! OF! TUMOUR! ENVIRONMENT! FOR! THE! INDUCTION! OF! EX# VIVO!
MYELOPOIESIS!USING!CONDITIONING!MEDIUM!GENERATED!BY!GM+CSF! EXPRESSING!
CANCER!CELLS.!
High& tumour& burden& and& circulation& of& tumourFderived& factors& in& mice& and&
patients&perturbs&physiological&myelopoiesis& in& the&BM.&Altered&myelopoiesis&prevents&
proper& myeloid& differentiation& and& leads& to& the& expansion& of& MDSCs.& MDSCs& then&
distribute& systemically& and& infiltrate& tumours,& where& they& actively& suppress& TILs&
(tumourFinfiltrating&lymphocytes)&(Talmadge&2007;&Gabrilovich&and&Nagaraj&2009;&Raber,&





MDSC& development& and& function& and& thus& I& hypothesized& that& cancer& cell& line&
supernatants,& in& addition& to& GMFCSF,& would& be& important& in& recreating& the& tumour&
environment.&B16&mouse&melanoma&cells&were&genetically&modified&with&a& lentivector&
expressing&murine&GMFCSF&and&a&puromycin&resistance&gene&(Fig.&4.2.A).&Simultaneously,&
293T& cells& were& transduced& with& the& same& lentivector& as& a& control& cell& line.& Culture&
supernatants& were& collected& for& use& as&MDSCFconditioning&media& (CM293T& and& CMB16)&
and& GMFCSF& concentration& was& assessed& by& ELISA.& GMFCSF& concentration& in&
conditioning& medium& (CM)& of& both& lentivectorFmodified& cell& lines& (CM293T& and& CMB16)&
was& found& to& be& similarly& high& (2.9±0.2& and& 2.6±0.1& µg/ml,& n=6)(Fig.& 4.2.B).& Of& note,&





Fig.# 4.2.# Simulation# of# tumour# environment# for# the# ex# vivo# differentiation# of#MDSCs#
from#BM#cultures.# (A)#Above:#Schematic#representation#of#the# lentivector#construct#co8
expressing# murine# GM8CSF# and# puromycin# resistance# genes.# Below:# Schematic#
representation# of# the# generation# of#MDSCs.# Cancer# cell# lines# are# transduced# with# the#
lentivector# LV8GMCSF8puroR.# Conditioning# medium# (CM)# is# collected# from# GM8CSF8
expressing# cells# to# simulate#myelopoiesis#within# a# tumour# environment.# BM# cells# from#
healthy#C57/Bl6#mice#were#cultured#in#the#presence#of#CM#for#minimum#5#days.#(B)#Bar#
graphs# represent# concentration# of#murine# GM8CSF# within# CM# collected# from# GM8CSF8
expressing#293T#and#B16#cells.#Concentration#of#recombinant#GM8CSF#(rec#GMCSF)#used#
for# conventional# immature# DC# differentiation# is# also# represented.# LTR,# long# terminal#







the& optimal& concentration.& Using& increasing& CM& concentrations& led& to& strong&
proliferation& of& immature& myeloid& cells& (Fig.& 4.3.A).& The& use& of& 75%& of& CM& routinely&
yielded&immature&myeloid&cell&numbers&that&ranged&from&40&to&70&million&cells&from&the&
BM&of&a& single& tumourFfree&mouse.&These&numbers&were& comparable& to& immature&DC&
numbers& differentiated& from& BM& (BMFDCs)& with& recombinant& GMFCSF& (Fig.& 4.3.A).&
Increasing& concentrations& of& CM& correlated& with& decreased& expression& of& majorF
histocompatibility& molecule& II& (MHCII),& coFstimulatory& marker& CD86,& and& intercellular&
adhesion& molecule& 1& (ICAMFI),& indicating& poor& antigen& presenting& capacity.& Myeloid&
marker& CD11b& and& coFstimulatory&marker& CD80& remained&highly& expressed.& Immature&
BMFDCs& generated& simultaneously& with& recombinant& GMFCSF& exhibited& high& ICAMFI,&
MHCII,&and&CD86&expression&(Fig.&4.3.A).&In&addition,&the&conventional&DC&lineage&marker&
CD11c&was&highly&expressed&by&immature&BMFDCs&on&day&8&of&culture,&which&correlated&








of# recombinant# GM8CSF# (GM8CSF)# in# standard# protocols# differentiated# conventional#











Hence,& I& first& examined& the& Ly6CFLy6G& (GRF1)& expression& profile& of& myeloid& cells&
differentiated& with& CM293T& and& CMB16.& Immature& myeloid& cells& cultured& for& 5& days& in&





MDSC& phenotype& with& the& same& efficiency& as& by& using& CM293T.& Interestingly,& this&
approach& differentiated& cells& with& a& similar& phenotype,& albeit& at& lower& efficiency& (Fig.&
4.4.B).&In&addition,&as&the&transduction&of&the&293T&and&B16&cell& lines&yielded&such&high&
concentrations&of&GMFCSF&in&the&CM293T&and&CMB16&(Fig.&4.2.B),&it&was&tested&whether&a&










Fig.# 4.4.# Ex# vivo# differentiation# of# myeloid# cells# using# CM293T# and# CMB16# results# in#
immature#myeloid# cells# with# phenotypes# consistent# with#MFMDSC# and# GFMDSC.# (A)#
Flow#cytometry#density#plots#showing#Ly6C8Ly6G#expression#profiles#on#day#5#and#day#8#
of#culture.#Percentages#of#Ly6C#and#Ly6G#expressing#cells#are#indicated#within#the#plots.#
(B)# Flow# cytometry# density# plots# showing# GR81# profiles# of# myeloid# cells# on# day# 8# of#
culture.#BM#cells#were#differentiated#using#conventional#DC#culture#protocols# (GM8CSF,#
recombinant# GM8CSF# 100# ng/mL),# supernatant# from# unmodified# 293T# cells#
supplemented# with# GM8CSF# 100# ng/mL# (293T# sup# +# GM8CSF),# and# CM293T.# (C)# Flow#
cytometry#density#plots#showing#CD11c#and#Ly6G#expression#on#day#8#of#culture.#BM#cells#




4.2.4.! 293T+MDSCs! and! B16+MDSCs! EXHIBIT! A! CD11b+! GR+1+PROFILE! AND! ARE!
DISTINCT!FROM!IMMATURE!BM+DCs!AND!OTHER!MYELOID!LINEAGE!PRECURSORS!
I& further& examined& several& markers& of& different& populations& of& the& myeloid&
lineage&to&discard&that&these&cells&were& immature&versions&of&other&myeloid&cell& types,&
such& as& DCs& and& macrophages.& In& addition,& haematopoietic& progenitor& markers& were&
evaluated.& Immature& myeloid& cells& cultured& for& 5& days& in& CM293T& (293TFMDSCs)& and&
CMB16& (B16FMDSCs)& were& CD11clow/neg,& MHC& I/IIlow/neg,& CD34neg,& FLt3neg,& and& F4/80neg,&
indicating& that& they& were& not& immature& DCs,& haematopoietic& progenitors,& or&
macrophages&(Fig.&4.5.A).&In&addition,&these&ex#vivo&MDSCs&expressed&low&or&no&MHC&I/II,&
CD86,& and&CD40,&which&are& characteristics&of&nonFefficient&APCs.& The& surface& levels&of&
molecules&involved&in&antigen&presentation&remained&well&below&those&of&immature&BMF
DCs&after&8&days&of&culture&(Fig.&4.5.B).&&
An& important& question& to& answer& was& whether& these& immature& myeloid& cells&
would& mature& and& upFregulate& antigen& presenting& molecules& upon& TLR& ligation,& as&
immature& DCs& do.& & Addition& of& the& TLRF4& ligand& LPS& to& BM& cultures& on& day& 5& caused&
maturation&of&immature&BMFDCs&while&the&phenotype&of&myeloid&cells&differentiated&in&
CM293T& and& CMB16& remained& largely& unaltered& (Fig.& 4.5.C,D).& The& only& significantly& upF
regulated&marker& in&B16FMDSCs& in& response& to&LPS&was&Ly6G.& Ly6G&expression& in&BMF
DCs&on&the&other&hand,&was&not&affected&(Fig.&4.5.D).&Taken&together,&this&data&suggested&
that& the& immature& myeloid& cells& differentiated& in& the& presence& of& CM& exhibited&
phenotypes&and& responses&consistent&with&MDSCs&and&not& immature&DCs.& In&addition,&









Bar# graphs# represent# the# percentage# of#marker# positive# cells# in# day# 5# cultures# of# BM8
derived#DCs,#293T8MDSCs,#and#B168MDSCs.#Cell#markers#are#indicated#within#the#graph.##
(B)#Same#as#in#A,#but#on#days#788#of#culture.#(C)#BM8DC#and#MDSCs#were#treated#on#day#5#
of# culture# with# 100ng/mL# LPS.# After# 72h# cells# were# stained# with# indicated# surface#
markers.#Unstained,#untreated,#and#LPS8treated#cells#are#represented#in#flow#cytometry#
histograms.# Percentages# of# marker# positive# cells# and# MFI# are# indicated# within# the#









CD62L,& also& known& as& LFselectin,& is& a& homing& receptor& to& secondary& lymphoid&
organs,& selectively&expressed&on&MDSCs&within& the&myeloid& lineage& (Highfill,&Rodriguez&
et&al.&2010).&We&found&CD62L&to&be&highly&expressed&in&ex#vivo&MDSCs&(Fig.&4.5.A,B).&B16F
MDSCs& exhibited& enhanced& Ly6GFCD62L& coFexpression,& as& compared& to& 293TFMDSCs&
(Fig.&4.6.A).&While&CD62L&surface&expression&decreased&over&time&in&BMFDC&cultures,&the&
opposite& was& true& for& MDSC& cultures& (Fig.& 4.6.B).& CD62L& proved& to& be& a& consistently&
reliable&marker& for&MDSCs& in&our& experimental& system.&CD49d& is& a& subunit& of& integrin&
α4β1,& another& lymphocyte& homing& receptor& that& has& recently& been& described& to& be&
predominantly& expressed& by& a& highly& immunosuppressive& MFMDSC& subpopulation&
(Haile,&Gamrekelashvili&et&al.&2010;&Tsiganov,&Verbina&et&al.&2014).&In&agreement&with&this&
data& CD49d& was& expressed& mainly& by& the& MFMDSC& population& of& our& ex# vivo&
differentiated& MDSCs& (Fig.& 4.6.C).& Similar& results& were& obtained& with& the& marker&
CD64a/b,& also& known& as& FcγRI& receptor,&mainly& present& in& the&MFMDSC&population& of&
B16FMDSCs& (Fig.& 4.6.C).& Immature&BMFDCs&expressed&higher& levels& of& CD64a/b&on&day&


















Fig.# 4.6.# Ex# vivo# MDSC# phenotypes# are# consistent# with# further# MDSCFassociated#
markers.# (A)# Flow# cytometry# density# plots# showing# CD62L8Ly6G# expression# profiles# on#
day#8#of#culture.#Percentages#of#CD62L#and#Ly6G#expressing#cells#are#indicated#within#the#
plots.#(B)#Flow#cytometry#histograms#representing#CD62L#expression#in#day#5,#8,#and#10#
of# cultures# of# BM8derived# immature# DCs# (iDCs)# and#MDSCs.# (C)# Bar# graphs# represent#
CD49d# (left)# and# CD64a/b# (right)# expression# within# the# M8MDSC# and# G8MDSC#
populations# of# 293T8# and# B168MDSCs.# Cells# were# stained# and# analysed# on# day# 7/8# of#





4.2.6.! M+MDSCs! WITHIN! EX# VIVO! MDSC! CULTURES! CONSERVE! THEIR! ABILITY! TO!
PROLIFERATE!AND!DIFFERENTIATE!
The&data&suggested&that&MFMDSCs&and&GFMDSCs& in& the&ex#vivo& cultures&do&not&
only& express& different& surface&markers& but& also& react& differently& to& stimuli.& The& exact&
relationship&between&the&two&subpopulations&remains&unclear&but&it&has&been&suggested&
that& intraFtumour& GFMDSCs& represent& the& terminal& differentiation& stage& of& the& intraF
tumour&MFMDSC&population&(Youn,&Kumar&et&al.&2013;&Condamine,&Kumar&et&al.&2014).&
Alternatively,& intraFtumour& GFMDSCs& have& been& described& as& pathologically& activated&
precursors& of& neutrophils& that& are& recruited& to& the& tumour& by& secreted& factors& (Youn,&
Collazo& et& al.& 2012).& Another& hypothesis& is& that&GFMDSCs& are& recruited& to& the& tumour&
where& they& differentiate& into& TANs& (Fridlender,& Sun& et& al.& 2012).&While& there& remains&




MFMDSC& population& was& purified& on& day& 5& of& culture& using& a& magnetic& beadFbased&
system&(Miltenyi&MACS&MDSC&purification&kit).&Purified&MFMDSCs&were&cultured& in&CM&
for& additional& 72h,&when& they&were& reFanalysed&by& flow& cytometry.& Immediately& after&
purification&MFMDSCs&did&not&express&Ly6G.& In&contrast,& these&cells&strongly&expressed&
Ly6G& after& 72h& of& culture& (Fig.& 4.7.B).& This& suggested& that& ex# vivo& differentiated& MF
MDSCs&differentiate&into&GFMDSCs&and&can&hence&act&as&GFMDSC&precursors.&Assessing&
overall& proliferation& of& MDSCs& versus& immature& BMFDCs,& I& found& that& while& BMFDCs&
continued& proliferating,& MDSC& numbers& remained& stable& after& day& 5& (Fig.& 4.7.C).&
Interestingly,& this& loss& of& proliferation& coincided& with& the& increased& presence& of& GF
MDSCs& (Fig.& 4.7.A,C).& Further,& the& viability& of& the& two& MDSC& subpopulations& was&
assessed.&The&GFMDSC&population&was&less&viable&(Fig.&4.7.C),&in&agreement&with&reports&
demonstrating&impaired&GFMDSC&viability&in#vivo&(Condamine,&Kumar&et&al.&2014).&
In& contrast& to&MFMDSCs,& GFMDSCs& do& not& proliferate&well& (Youn,& Kumar& et& al.&




that& MFMDSCs& could& act& as& precursors& of& GFMDSCs& but& also& that& this& differentiation&
process& was& accompanied& by& a& loss& of& proliferation& and& viability.& There& is& evidence&

















relative# proportion# of# M8# and# G8MDSCs# in# 293T8MDSC# and# B168MDSC# cultures# of#
indicated# days# of# culture.# Relevant# statistical# comparisons# are# shown.# (B)# Ly6C8Ly6G#
expression#profiles#of#purified#M8MDSCs#from#293T8MDSC#and#B168MDSC#cultures#on#day#
5#(density#flow#cytometry#plots#on#the#left).#On#the#right#the#same#cells#but#incubated#in#
CM293T# and# CMB16# for# three# additional# days.# The# percentages# of# G8MDSCs# are# shown#
within#the#graph.#(C)#Bar#graph#on#the#left#represents#the#ratio#of#the#number#of#cells#on#
day# 8# versus# 5# in# 293T8MDSC# and# B168MDSC# cultures.# This# represents# the# cell# growth#
rate.#On#the#right,#dead#cell#staining#with#fixable#viability#stain#(FVS)#of#M8MDSC#and#G8
MDSC# cultures.# The# proportion# of# viable# cells# is# shown# in# the# legend.# (D)# Bar# graphs#
represent#Ki67#expression#within#G8MDSC#and#M8MDSC#subsets#from#B168MDSC#cultures,#
as# indicated.# Left# graph# represents# the# proportion# of# Ki678expressing# cells# while# the#
graph#on# the# right# represents# Ki67#mean# fluorescent# intensities.# (E)#Day# 5# 293T8MDSC#
cultures#were# incubated# for# three#days#with#either#DC#medium#or#CM293T,#as# indicated.#
Above,# Ly6G8CD11c# profiles# of# 293T8MDSCs# incubated# in# CM293T# (left)# or# DC# medium#
 194&
(right).# Below,# histograms# represent# Ly6G# (left)# and# CD11c# (right)# expression# of# 293T8
MDSCs# incubated# in# CM293T# or# DC# medium,# as# indicated.# Percentages# and# mean#




4.2.7.! EX# VIVO+DIFFERENTIATED! B16+MDSCs! PHENOTYPICALLY! RESEMBLE! IN# VIVO!
MELANOMA+INFILTRATING!MDSCs!!
It&has&become& increasingly&clear& that& tumourFinfiltrating&and&splenic&MDSCs&are&
not&equivalent,&neither&in&phenotype&nor&in&function&(Maenhout,&Van&Lint&et&al.&2013).&As&
the& strategy& described& here&was& to&mimic& the& tumour&microenvironment& through& the&
use&of&CM&from&modified&tumour&cell&lines,&it&was&hypothesized&that&ex#vivo&B16FMDSCs&
would& resemble& B16& tumourFinfiltrating& MDSCs& in# vivo.& Hence,& tumours& and& spleens&
from& B16& melanomaFbearing& mice& were& isolated& and& the& MDSC& phenotype& was&
compared& to& day& 5& ex# vivo& B16FMDSCs& (Fig.& 4.8.AFC).& No& significant& differences& in&
percentage&of&MF&and&GFMDSCs&were& found& in& spleen,& tumour,&or&ex#vivo&MDSCs& (Fig.&
4.8.B).& Several& representative& markers& were& used& to& assess& MDSC& phenotype,& which&







Fig.# 4.8.# Ex# vivo# B16FMDSCs# resemble# tumourFinfiltrating#MDSCs# in# vivo.# (A8C)#Mice#
were#s.c.#inoculated#with#5*105#B16#cells.#When#tumours#reached#sizes#of#circa#100mm2,#
single# cell# suspensions#were# generated# from# tumours# and# spleens.# In# vivo# cells# and# ex#
vivo# day# 5# B168MDSCs# were# simultaneously# stained# with# fluorochrome8conjugated#
antibodies#specific#for#the#indicated#markers#and#analyzed#via#flow#cytometry.#(A)#Gating#
strategy# for# tumour#and# spleen#cells.# Shown#are# representative# flow#cytometry#density#
plots# from# a# tumour# sample.# CD45+# CD11b+# cells#were# gated# as#myeloid# cells.# (B)# Bar#
graph#representing#percentages#of#M8#and#G8MDSCs#in#indicated#samples.#(C)#Bar#graphs#
representing# percentages# of# indicated#markers#within# the# population# of# CD45+# CD11b+#
M8#or#G8MDSCs#of#each#tissue#or#in#vitro#cell#sample.&
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4.2.8.!! EX#VIVO! B16+MDSCs!EXPRESS!MDSC!HALLMARK!PROTEINS! iNOS,!ARG+1,!AND!
TGFβ!
Ex# vivo& B16FMDScs&were&phenotypically& similar& to& tumourFinfiltrating&MDSCs& in&
the& tested& markers.& Further,& the& suppressive& capabilities& of& the& ex# vivo#MDSCs& were&
assessed.&MDSCs&are&known&to&partly&mediate&their&suppressive&functions&by&depleting&
amino& acids& such& as& LFarginine& through& the& expression& of& iNOS& and& ArgF1& (Talmadge&
2007;&Rodriguez,&Ernstoff&et&al.&2009;&Raber,&Thevenot&et&al.&2014).& In&addition,&MDSCs&
recruit& and& expand& Treg& cells& through& secretion& of& TGFβ& and& IL10& (Huang,& Pan& et& al.&
2006;&Filipazzi,&Valenti&et&al.&2007).&The&expression&of&these&proteins&was&assessed&in&ex#
vivo& B16FMDSCs,& control& 293TFMDSCs,& and& immature& conventional& BMFDCs.&
Interestingly,& only& B16FMDSCs& expressed& significant& levels& of& iNOS,& as& assessed& by&
western&blot&as&well&as&intracellular&flow&cytometry&(Fig.&4.9.A).&On&the&other&hand,&ArgF1&
was& expressed& by& all& three&myeloid& cell& types.& Interestingly,& analysis& by& western& blot&






















(A8B)# iNOS# and# Arg81# protein# expression# were# assessed# by# western# blot# (above)# and#
intracellular#flow#cytometry#(below).#(C)#Bioactive#TGFβ#was#assessed#by#culturing#SMAD8







capability.& Firstly,& I& compared& the& capacities&of&MDSCs&and&BMFDCs& to& trigger& a&mixed&
lymphocyte& reaction& (MLR).& In& this& way& it& could& be& tested& whether& the&MDSCs& could&
potentially&act&as& stimulatory&APCs.&While& immature&BMFDCs& from&C57/BL6&mice&were&
capable&of& inducing&BALB/c&CD8&and&CD4&T&cell&proliferation,& this&was&not& the&case& for&
C57/BL6&MDSCs.& This& data& suggested& that& ex# vivo&MDSCs&were& potentially& poor& APCs&
that& were& not& competent& in& priming& or& activating& T& cells& (Fig.& 4.10.A).& This& result&
correlated&with&the&fact&that&ex#vivo&MDSCs&expressed&low&MHC&I/II&and&coFstimulatory&
molecules&(Fig.&4.5).&However,&this&assay&could&not&answer&the&question&whether&these&
ex# vivo& differentiated& MDSCs& could& suppress& activated& T& cells.& Thus,& standard& T& cell&
suppression& assays& were& performed,& to& confirm& their& inhibitory& activities& over& antiF
CD3/CD28Factivated& T& cells.& This& T& cell& suppression& assay& is& widely& used& in& the&MDSC&
field,&as&it&mimics&the&effect&that&MDSCs&have&on&already&activated&lymphocytes.&Hence,&
B16FMDSCs& were& coFcultured& with& antiFCD3/CD28Factivated& CD8& T& cells,& and& their&
proliferation& and& IFNγ& production& was& quantified.& Suppression& activities& of& bulk,&
monocytic,&and&granulocytic&populations&were&assessed.&All&B16FMDSC&subsets&inhibited&
proliferation&and&IFNγ&production&in&activated&CD8&T&cells&within&a&wide&range&of&MDSC:T&
cell& ratios& (Fig.& 4.10.B).& To& further& assess& the&MDSC& suppressive& activity& compared& to&
293TFMDSCs& and& immature& conventional& BMFDCs& Ki67& expression& was& assessed& in&
previously& antiFCD3/CD28Factivated& CD8& T& cells.& In& contrast& to& conventional& BMFDCs,&
which&could&increase&proliferation&of&activated&CD8&T&cells,&both&MDSC&types&significantly&











days.# Splenocytes# from#BALB/c#mice#were# isolated# and# co8cultured#with# day# 5# ex# vivo#
MDSCs# for#72h.# Surface#and# intra8nuclear# staining#with#CD4,#CD8,#and#Ki67#antibodies#
was# performed# and# cultures#were# analysed# by# flow# cytometry.# (B8C)# CD8# T# cells#were#
isolated# from# spleens# of# healthy# C57/bl6# mice# and# activated# with# anti8CD3/CD28#
dynabeads.# Suppression#was# assessed# as# function# of# proliferation# loss.# (B)# CD8# T# cells#
were#incubated#with#CFSE#prior#to#activation#and#co8culture#with#bulk,#M8#or#G8MDSCs#at#
decreasing# ratios.# 72h# later# CFSE# dilution# and# IFNγ# production# were# assessed.# This#
experiment#was#performed#by#Julia#Schwartze#and#Karine#Breckpot.#Pooled#data#from#3#
experiments.#(C)#Similar#to#A,#but#loss#of#T#cell#proliferation#was#assessed#by#intra8nuclear#
Ki67# expression.# Bar# graphs# represent# one# experiment# of# two# similar# repetitions.# All#
samples#in#triplicate.#
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4.2.10.!ADOPTIVE! TRANSFER! OF! EX# VIVO# B16+MDSCs! ENHANCES! MELANOMA!
GROWTH!IN#VIVO!
Ex# vivo& B16FMDSCs&were& capable& of& suppressing& activated& CD8& T& cells& in# vitro.&
Further,& it& was& tested& whether& ex# vivo& B16FMDSCs& would& retain& their& suppressive&
function& in# vivo,& by& enhancing& B16& tumour& growth.& This& would& confirm& the& in# vitro#









this&experiment&all&mice&were&sacrificed&due& to& large& tumour&burden.&Average& tumour&
growth&was&significantly&faster&in&the&B16FMDSC&mouse&group&than&in&control&mice&(Fig.&






activity&at&a& later& timeFpoint&may&give&statistically&significant& results.&Nevertheless,& this&
data& suggested& that& ex# vivo# B16FMDSCs& were& capable& of& enhancing& B16& melanoma&
growth& in#vivo#as&well&as&decreasing&survival&of&B16&melanomaFbearing&mice.&Thus,&the&
newly& developed& ex# vivo# B16FMDSC& differentiation& system& was& capable& of& producing&











Fig.# 4.11.# Ex# vivo# B16FMDSC# suppressive# activity# in# vivo.# (A8D)# C57/Bl6# mice# were#
subcutaneously# inoculated# with# B16#melanoma# cells# in# combination# with# (B16# +# B168
MDSC)# or# without# (B16# only# control)# B168MDSCs.# The# B168MDSC# group# additionally#
received#B168MDSCs#every#587#days.#Tumour#volume#and#time#of#death#were#recorded.#
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average# tumour# sizes# from#experiment#2.#All# B168MDSC#mice#had#established# tumours#
larger#than#150mm2#at#day#19.#Error#bars#correspond#to#SEM.#p8value#represents#column#
factor# from# 28way# anova# analysis.# (D)# Light# emission#within#mice,# dorsal# view# (above,#








promising& results,& I& wondered& whether& the& murine& system& could& be& translated& to& a&
human& setting.& Human& MDSCs& do& not& exhibit& such& a& distinct& phenotype& as& mouse&
MDSCs,& as& there& is& no& homologue& for& GRF1& in& humans.& Human&MDSCs& are& generally&
accepted&to&be&CD11b+/CD33+HLAFDRlow&with&their&main&characteristic&remaining&their&T&
cell& suppressive& activities.& For& this& purpose,& the& human& nonFsmall& cell& lung& carcinoma&
H1299&cell&line&was&transduced&with&lentivectors&coFexpressing&the&huGMFCSF&gene&and&
the& puromycin& resistance& gene.& In& addition,& the& selected& huGMFCSFFexpressing& cells&
were&transduced&with&a&lentivector&containing&the&huILF4&gene&as&well&as&the&blasticidin&
resistance&gene.& It& is&wellFknown&that&MDSCs&express& the& IL4&receptor& (IL4Rα)&on&their&
surface&and!aptamerFmediated&blockade&of&IL4Rα&induces&mouse&MDSC&apoptosis&in#vivo&
and& limits& tumour&progression& (Roth,&De& La& Fuente& et& al.& 2012).& Conditioning&medium&
was& collected& and& termed& CMH1299.& CM293T& conditioning& control& medium& was&
simultaneously& produced&by& expressing& the&huGMFCSF& and&huILF4& genes& in& 293T& cells.&
The&monocytic& adherent& fraction& of& PBMCs&was& incubated&with& CMH1299& for& 3F5& days,&
after&which& cell& viability& began& to& decrease.& A& preliminary& assessment& of&myeloid& cell&
phenotype& with& increasing& concentrations& of& CM& was& undertaken& (Fig.& 4.12.A).& 10%&
CMH1299&was& selected&as& a& suitable& culture& concentration&as& cells& in& this& condition&had&
proliferated&more&than&in&other&conditions&(data&not&shown)&and&exhibited&a&phenotype&
consistent&with&MDSCs;& CD33high& CD14F& CD83low&DCFSIGNlow.& In& addition,& on&day& 5& cells&
differentiated& in& 10%& CM& exhibited& higher& expression& of& CD33.& Accordingly,& CD33&
expression& was& highest& in& myeloid& cells& differentiated& in& the& presence& of& CMH1299,& as&
compared&to&CM293T&and&RPMI&only&(Fig.&4.12.BFC).&While&DCFSIGN&expression&was&low&in&
all& myeloid& cell& types,& markers& CD14& and& CD83& were& lower& in& CMH1299& and& CM293T&
conditions.&Importantly,&on&day&3&myeloid&cells&in&CMH1299&were&HLAFDRF.&Differentiated&
cells&in&CM293T&medium&were&HLAFDRlow&,&and&in&RPMI&only&the&cells&were&HLAFDRhigh&(Fig.&
4.12.D).& This& data& suggested& that& myeloid& cell& culture& in& CMH1299& yielded& immature&
myeloid& cells,& which& could& be& H1299FMDSCs.& Further,& it& was& tested& whether& these&
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immature& myeloid& cells& possessed& T& cell& suppressing& capacities.& To& this& purpose& the&
lymphocyte& fraction& of& PBMCs& was& activated& with& antiFCD3/CD28& activation& beads&
before&coFculture&with&H1299FMDSCs.&H1299FMDSCs&significantly&inhibited&human&CD8&T&
cell&proliferation,&as&measured&by&decreased&nuclear&Ki67&expression&(Fig.&4.12.E).&While&
H1299FMDSCs& seemed& to& inhibit& CD4& T& cell& responses,& this& was& not& found& to& be&
significant.&Somewhat&surprisingly,&H1299FMDSCs&were&more&suppressive& in&conditions&














immunosuppressive# capabilities.# (A8D)# The#monocytic# fraction# of# human# PBMCs#were#
cultured# in# CMH1299# for# 385# days# before# flow# cytometric# analysis.# (A)#Graphs# represent#
percentages#of#indicated#surface#markers#in#myeloid#cells#for#different#concentrations#of#
CMH1299#on#day#3#(left)#and#day#5#(right)#of#culture.#No,#indicates#myeloid#cells#cultured#in#
RPMI# only.# (B8C)# Flow# cytometry# density# plots# representing# the# expression# of# the#
indicated#markers#in#myeloid#cells#conditioned#with#RPMI#only,#10%#CM293T#and#CMH1299#
on# day# 3# of# culture.# (D)# Histogram# representing# HLA8DR# expression# in# myeloid# cells#
conditioned# with# RPMI# only,# 10%# CM293T# and# CMH1299# on# day# 3# of# culture.# (E)#
Lymphocytes# from#human#PBMCs#were#activated#with#anti8CD3/CD28#activation#beads#






The& tumour& microF& and& macroenvironment& affects& the& accumulation,&
differentiation,& and& function& of& many& cell& types,& including&myeloid& cells.&MDSCs& have&
recently&become&prominent&as&one&of&the&main&tumourFinduced&suppressive&cell&types,&
hampering&cancer& immunotherapy&approaches.&Hence,& it&would&be&beneficial& to&assess&
immunostimulatory&treatments&on&such&suppressive&cell&types&as&MDSCs.&The&isolation,&
culture,& and& ex# vivo& differentiation& of& mouse& tumourFinfiltrating& MDSCs& remains&




Huber& et& al.& 2006;& Youn,& Nagaraj& et& al.& 2008;& Highfill,& Rodriguez& et& al.& 2010;&Marigo,&
Bosio&et&al.&2010;&Morales,&Kmieciak&et&al.&2010;&Michels,&Shurin&et&al.&2012;&Kurkó,&Vida&
et&al.&2014),&correlating&its&importance&for&in#vivo&MDSC&mobilization&in&tumourFbearing&
hosts& (Bayne,& Beatty& et& al.& 2012).& Recombinant& cytokines& such& as& GMFCSF& are& usually&
produced& by& bacteria& and& thus& exhibit& different& postFtranslational& modifications& as&
proteins&produced& in&eukaryotic& cells.& I&hypothesized& that&endogenous&mouse&GMFCSF&
expression& by& lentivector& transduction& could& increase& the& efficiency& of& MDSC&
differentiation.&High& levels&of&endogenous&GMFCSF&were&produced& in&this&way&(2.9±0.2&
µg/ml,&Fig.&4.2.B),&which&was&delivered&to&mouse&BM&cells&in&combination&with&other&B16&
melanomaFderived& factors,& simulating& altered&myelopoiesis& in& a& tumourFbearing& host.&
Using&this&method&large&numbers&of&immature&myeloid&cells&were&obtained,&which&were&
equivalent& to& MDSCs& in& phenotype& and& suppressive& function.& Addition& of& high&
concentrations& of& recombinant& GMFCSF& alone& was& not& as& effective& at& inducing& pure&
MDSC&cultures&(Fig.&4.4.C)&and&neither&was&addition&of&293T&supernatant&in&combination&









GFMDSC&populations& of& B16FMDSCs& in& this& thesis,&we& showed& that& the&morphology&of&
sorted& MF& and& GF& CT26FMDSCs& was& consistent& with& monocytic& and&
polymorphonuclear/granulocytic& morphologies,& respectively& (Dufait,& Schwarze& et& al.&
2015).& In& most& tumour& models,& the& GFMDSC& population& preferentially& expands,&




analysing& MDSCs& isolated& from& B16& tumourFbearing& mice& no& significant& differences&
between& the& percentage& of& the& two& MDSC& subpopulations& were& found& at& different&
locations.& Nonetheless,& the& predominant& type& within& the& tumour& seemed& to& be& MF
MDSCs&while& in& the&spleen& it&was&GFMDSCs& (Fig.&4.8).&The&ex#vivo&MDSCs&used& for& this&
experiment&were&from&day&5&of&culture,&thus&representing&equal&numbers&of&MF&and&GF
MDSCs.& MDSCs& were& isolated& from& tumours& when& they& reached& an& average& size& of&
90mm2.&Considering&the&accumulation&of&GFMDSCs&over&time&it&would&be&interesting&to&
assess& whether& the& GFMDSC& population& increases& in& tumours& from& mice& with& larger&
tumour& burden.& Using& a& 4T1& breast& tumour& model,& it& was& shown& that&MDSCs& within&
tumours& are& derived& from& splenic& extraFmedullary& haematopoiesis& (EMH)& before&
infiltrating& tumours.&The&spleen&acted&as&a& reservoir& for&GFMDSCs& that&could& leave& the&
spleen& and& circulate& rapidly& (Younos,& Dafferner& et& al.& 2012).& Hence,& it& is& tempting& to&
hypothesize& that& the&GFMDSCs&within& the& spleen&will& be& recruited& to& the& tumour&over&
time,&leading&to&a&reduction&in&the&GFMDSC&population&in&the&spleen&and&an&increase&of&
the&GFMDSC&population&within&the&tumour.&Nevertheless,&the&frequency&of&MF&versus&GF
MDSCs& in& various& organs& differs& in& various& tumour& models& and& also& depends& on&
progression&of&disease.&It&has&to&be&stressed&that&in&this&PhD&study&I&demonstrated&that&
GFMDSCs&are&differentiated& from&MFMDSCs,&and& thus,&both&populations&should&not&be&
considered& as& independent.& This& consideration& is& not& taken& in&many& of& the& published&
works.& Data& from& a& recent& study& working& with& collaborators& in& the& colorectal& cancer&
model&did&not&find&that&implanting&GMFCSFFexpressing&CT26&tumour&cells&led&to&different&
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role& of& GMFCSF& for& mobilizing& large& amounts& of& myeloid& cells& within& tumourFbearing&
hosts.&






could& act& as& precursors& to& GFMDSCs& (Ugel,& Peranzoni& et& al.& 2012;& Youn,& Kumar& et& al.&
2013).&I&showed&that&in&our&system,&purified&MFMDSCs&could&serve&as&precursors&for&GF
MDSCs.& Moreover,& this& differentiation& process& was& accompanied& by& a& loss& of& both&











at& various& differentiation& stages& is& advantageous& to& study&MDSC& targeting& for& therapy&
and& also& MDSC& biology.& How& do&MDSCs& differentiate?&Which& tumourFderived& factors&
induce& changes& in&myeloid& differentiation?& Are& there& different& precursors& in# vivo& or& a&
single& common& precursor?& What& causes& the& switch& from& splenic& MDSCs& to& tumourF









in#vivo.&Nevertheless,& isolation&of&CD11c+&cells& in&MDSC&cultures&will&be&of&value& in&the&
future.&In&addition,&MDSCs&are&highly&heterogenic&and&there&are&several&researchers&that&
claim& that& MDSCs& can& also& be& CD11c+& or& CD11clow/interm& (Umemura,& Saio& et& al.& 2008;&
Norian,&Rodriguez&et&al.&2009;&Zoso,&Mazza&et&al.&2014).&On&the&other&hand,&transferring&
these&CD11c+&cells&to&a&nonFtumour&environment&could&induce&DC&differentiation,&which&
has&been&prevented& so& far& in& the& tumour&environment.& This& seems& likely&as& culture&of&
tumourFinfiltrating&MDSCs&without&tumourFderived&factors&drives&their&differentiation&to&
DCs& and&macrophages.& Similarly,& transfer& of& tumourFinfiltrating&MDSCs& to& tumourFfree&
mice&results& in&DC&and&macrophage&differentiation&(Li,&Pan&et&al.&2004;&Gabrilovich&and&
Nagaraj& 2009;&Narita,&Wakita&et& al.& 2009;&Gabrilovich,&OstrandFRosenberg&et& al.& 2012).&
Our&group&and&other&researchers&(Huang,&Pan&et&al.&2006)&found&that&MDSCs&express&the&
MFCSF& receptor& (CD115,& Fig.& 4.6),& suggesting& that& they& have& the& potential& of&
differentiating&into&macrophages&upon&MFCSF&ligation.&Thus,&MDSCs&are&not&committed&
to& development& into& immunosuppressive& myeloid& cells& but& can& differentiate& into&
immunostimulatory&myeloid&cells&or&immunosuppressive&myeloid&cells&according&to&the&
specific&signals&they&receive&(Narita,&Wakita&et&al.&2009).&
Importantly,& ex# vivo& B16FMDSCs& phenotypically& resembled& in# vivo& tumourF
infiltrating& MDSCs& induced& by& the& same& tumour& type& (B16& melanoma)& as& used& for&
mimicking&the&tumour&environment&in#vitro&(Fig.&4.8).&In&contrast,&splenic&MDSCs&isolated&
from&B16&tumourFbearing&mice&exhibited&a&different&phenotype&from&tumourFinfiltrating&
and&ex# vivo& B16FMDSCs.& This& is& particularly& important& considering& that& peripheral& and&
tumourFinfiltrating& MDSCs& are& not& equivalent& (Abe,& Dafferner& et& al.& 2010;& Corzo,&
Condamine&et&al.&2010;&Maenhout,&Van&Lint&et&al.&2013;&Noman,&Desantis&et&al.&2014).&
PDFL1& and&ArgF1& expression&were& lower& in& splenic&MDSCs& than& in& tumour& and&ex# vivo&
B16FMDSCs.& Adapting& our& ex# vivo& MDSC& differentiation& system& to& colorectal& cancer&
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during&a&collaboration&with&Prof.&Karine&Breckpot´s&group,&it&was&confirmed&that&ex#vivo&
CT26FMDSCs& resembled& tumourFinfiltrating& MDSCs& rather& than& splenic& subsets.&
Analogous&to&B16FMDSCs,&tumourFinfiltrating&and&ex#vivo&CT26FMDSCs&expressed&higher&
levels&of&PDFL1,&ArgF1,&and&MHC&II&than&splenic&MDSCs&(Dufait,&Schwarze&et&al.&2015).&This&
data& agreed&with& a& study&using& several&murine& tumour&models,&where& tumour&MDSCs&
exhibited& enhanced& PDFL1& expression.& Interestingly,& hypoxia& could& induce& PDFL1&
expression& in& splenic& MDSCs.& In& addition,& the& authors& did& not& observe& differential&
expression&of&CD86,&which&is&in&contrast&to&the&data&presented&here&(Noman,&Desantis&et&
al.& 2014).& Of& note,& MDSC& phenotypic& differences& may& be& caused& by& differences& in&
tumour&model&or&stage&of&tumour&progression.&In&addition&to&hypoxia&there&are&several&
other& tumourFderived& factors& that& can& induce& PDFL1& expression& on& myeloid& cells& in&
cancer&patients.&IL10&and&VEGF,&for&example,&have&been&shown&to&induce&expression&of&
PDFL1& in& monocyteFderived& DCs& and& PDFL1& blockade& enhanced& their& T& cell& activation&
capabilities&(Curiel,&Wei&et&al.&2003).&Similarly,&the&tumour&environment&can&drive&the&upF
regulation&of&ArgF1&expression& in& splenic&MDSCs& (Corzo,&Condamine&et&al.&2010).&Thus,&
splenic& MDSCs& seem& to& be& activated& by& the& tumour& environment,& through& hypoxiaF
mediated& and& tumourFsecreted& factors,& thus& acquiring& further& suppressive& functions.&
Splenic& MDSCs& from& tumourFbearing& mice& were& shown& to& exhibit& an& intermediate&
phenotype& in& transcription& levels&between&tumour&MDSCs&and& immature&myeloid&cells&
from&tumourFfree&mice.&The&authors&found&increased&transcription&of&ArgF1,&iNOS,&Flt3L,&
and&VEGFFA&in&tumourFinfiltrating&MDSCs&(Abe,&Dafferner&et&al.&2010).&This&suggests&that&
splenic& MDSCs& are& an& intermediate& stage& between& immature& myeloid& cells& and&
pathologically&activated&MDSCs&within&the&tumour.&Nevertheless,&as&MDSCs&in&the&spleen&





various& phenotypes& and& functions& according& to& tumour& type& (Poschke& and& Kiessling&
2012;&Solito,&Marigo&et&al.&2014).& In&fact,&Dufait&et&al.&have&already&successfully&applied&
this& system& to& the& study& of& colorectal& cancer,& in& collaboration& with& our& group.& In&






al.& 2008;& Gabrilovich,& OstrandFRosenberg& et& al.& 2012;& Raber,& Thevenot& et& al.& 2014)&












of& the& two& enzymes,& which& share& the& same& substrate.& iNOS& activity& in& cells& where& LF




IL10&secretion&could&not&be&detected& (Fig.&4.9).&Both&cytokines&are& implicated& in&MDSC&
suppressive& activities.& However,& while& TGFβ& is& constitutively& secreted& by&MDSCs,& IL10&
secretion&is&induced&upon&IFNγ&stimulation&(Huang,&Pan&et&al.&2006).&TGFβ&secretion&and&
iNOS&activity&can&be&further&enhanced&by&IFNγ&stimulation&from&activated&T&cells&(Huang,&




immature& DCs& on& the& other& hand& leads& to& DC& maturation,& IL12& production,& immune&
stimulation,& and& antiFtumour& activities& (Cisco,& AbdelFWahab& et& al.& 2004;& BekeredjianF
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Ding,& Roth& et& al.& 2006;& Apetoh,& Ghiringhelli& et& al.& 2007;& Breckpot& and& Escors& 2009;&
Liechtenstein,& Dufait& et& al.& 2012).& Treatment& with& LPS,& a& ligand& of& TLR4,& led& to& a&
phenotypic&maturation& of& immature& BMFDCs& but& not& of& ex# vivo#differentiated&MDSCs&
(Fig.&4.4).&The&only&marker& that&was&upFregulated& in&ex#vivo#MDSCs&but&not& in&BMFDCs&
was& Ly6G.& Interestingly,& this& result&may& suggest& that& TLR4& signalling& in&ex# vivo#MDSCs&
may&enhance&GFMDSC&differentiation.&&
&Importantly,&ex#vivo&MDSCs&did&not&activate&T&cells& in&a&MLR& in#vitro#(Fig.&4.10).&
Low& MHCI/II& and& coFstimulatory& molecule& expression& in& MDSCs& thus& correlated& with&
poor& APC& capabilities.& As& poor& antigen& presentation& is& not& an& indication& of& immune&
suppression,&MDSCs&were&further&assessed&in&suppression&assays,&where&they&inhibited&
activated& CD8& T& cell& proliferation.& Transferring& ex# vivo& B16FMDSCs& together& with& B16&
melanoma& cells& enhanced& tumour& growth& and& decreased& survival& in& mice& (Fig.& 4.11).&
Thus,& it& is& clear& that& ex# vivo& differentiated& B16FMDSCs& exhibit& T& cell& suppressive& and&
tumourFpromoting&activities,&mirroring&their&function&in#vivo.&
In& this& PhD& study,& some&preliminary& results&on& the&establishment&of& an&ex# vivo&
human& MDSC& differentiation& system& were& presented.& PBMCs& differentiated& with& CM&
from&transduced&H1299&lung&cancer&cells&exhibited&an&immature&myeloid&cell&type&(Fig.&
4.12.AFD).& Importantly,& human& ex# vivo& H1299FMDSCs& could& suppress& activated& CD8&
lymphocyte& proliferation& in# vitro.& In& this& experiment& H1299FMDSCs& were& more&
suppressive&when&present&at&lower&ratios&(Fig.&4.12.E).&Several&explanations&for&this&data&
come&to&mind.&One&reason&could&be&that&MDSCs&proliferate&and&activate&in&the&presence&
of& activated& T& cells& (Nagaraj,& Youn& et& al.& 2013).& Supporting& this& hypothesis,& I& have&
observed&enhanced&mouse&ex#vivo&MDSC&proliferation&(Ki67&expression)&in&the&presence&
of& activated& T& cells& (data& not& shown).& Alternatively,& MDSCs& at& large& quantities& could&
suppress& each& other,& thus& leading& to& reduced& suppressive& function.& The& simplest&
explanation&would& be& due& to& human& error,& for& example& in& labelling& of& FACS& tubes& or&
culture&plates.&Although&H1299FMDSCs&were&suppressive,& further&work& to& improve& the&
human&system&is&needed&and&inclusion&of&further&cytokines&will&be&of&value.&So&far,&CM&
containing& human& GMFCSF& and& IL4& was& used.& Several& groups& found& that& IL6& and& IL13&
favour&MDSC&development& (Highfill,& Rodriguez& et& al.& 2010;&Marigo,& Bosio& et& al.& 2010).&




of& tumourFinfiltrating& MDSCs& was& established.& The& MDSCs& were& extensively& studied&
according&to&what&is&generally&accepted&in&the&literature,&and&compared&to&their& in#vivo&
counterparts.& B16FMDSCs& effectively& suppressed& T& cell& proliferation& in# vitro& and&
enhanced&tumour&growth&in#vivo.&Importantly,&this&ex#vivo&MDSC&differentiation&system&
has& already& been& validated& by& other& researchers& in& collaboration& with& our& group.&
Treatment&of&ex#vivo&differentiated&B16FMDSCs&predicted&therapeutic&efficacy&of&an&antiF
tumour& mRNA& strategy& (Van& der& Jeught,& Joe& et& al.& 2014).& Further,& our& system& was&
translated&for&the&study&of&colorectal&cancer,&by&transducing&a&colorectal&cancer&cell&line&




CHAPTER! 5:&USE!OF! EX# VIVO#MDSCs! IN! IN# VITRO! ASSAYS! AND!
HIGH+THROUGHPUT! STUDIES! FOR! THE! IDENTIFICATION! OF!
THERAPEUTIC!TARGETS!
5.1.!! INTRODUCTION!
In& the& last& chapter& an& efficient& ex# vivo# MDSC& differentiation& system& was&




were& found& to& be& equivalent& to& B16& tumourFinfiltrating& MDSCs,& they& were& used& to&
further& test&whether& the& lentivector&vaccines&generated& in&Chapter&3&could&counteract&





intervention& requires& a& deep& understanding& of& the& pathways& that& regulate& MDSC&
differentiation,& expansion& and& suppressive& activities.& In& this& introduction& I& will& briefly&
summarise&what&is&known&about&MDSC&intracellular&pathways&and&their&exploitation&as&
therapeutic&targets.&
As& tumours& grow& they& establish& a&microenvironment& characterized&by& hypoxia,&
inflammation,&low&extraFcellular&pH,&and&presence&of&high&amounts&of&ROS,&RNS,&growth&
factors,&and&other&tumour&metabolites.&I&already&discussed&tumourFsecreted&factors&such&
as& VEGF,& IL6,& IL13,& IL4,& IL10,& IFNγ,& GMFCSF,& and& GFCSF,& which& influence& myeloid&
differentiation&and&MDSC&accumulation.&These&tumourFmediated&effects&activate&several&
intracellular& signalling& pathways& within& MDSCs,& thus& mediating& MDSC& accumulation,&
differentiation,& and& function.& Several& intracellular& pathways& are& of& importance& in& this&
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regard& and& include& STAT1,& STAT3,& STAT6,& NFκB,& PI3K/Akt,& and& ERK.& Some& of& these&
pathways& could& be& inhibited& using& selected& drugs& for& therapeutic& purposes.& Signal&
transducer& and& activator& of& transcription& 3& (STAT3)& is& one& of& the& bestFcharacterized&
MDSC&signalling&molecules.&STAT3&is&activated&in&a&variety&of&tumour&cells&and&tumourF
associated& immune& cells& (Yu,& Kortylewski& et& al.& 2007;& Xin,& Zhang& et& al.& 2009).& Many&
tumourFsecreted&factors,& including&GMFCSF,&GFCSF,& IL6,& IL10,&and& IL1β& induce&signalling&
routes& that& use& the& Jak/STAT3& pathway,& in& this& way& enhancing& MDSC& development,&
accumulation,&and&function&(Nefedova&and&Gabrilovich&2007;&Corzo,&Cotter&et&al.&2009;&
Condamine& and& Gabrilovich& 2011)& (Gabrilovich& and& Nagaraj& 2009)& (Fig.& 5.1).& TumourF





signalling& is& also& involved& in& MDSC& differentiation& by& inducing& abnormal& myeloid&
differentiation&in&cancerFbearing&hosts&(Gabrilovich&2004;&Nefedova,&Huang&et&al.&2004).&
GFCSF& activates& STAT3,& which& induces& the& expression& of& C/EBPβ,& leading& to& myeloid&
progenitor& proliferation& and& differentiation& to& functional&MDSCs& (Marigo,& Bosio& et& al.&
2010;& Zhang,& NguyenFJackson& et& al.& 2010).& Further& STAT3Ftarget& genes& include& BclFxL,&
Cyclin&D1,&Survivin,&cFmyc.&These&proteins&have&antiFapoptotic&and&proliferative&functions&
while& blocking&myeloid& differentiation& (Nefedova& and& Gabrilovich& 2007).& STAT3Ftarget&
genes& implicated& in&MDSC& expansion& include& the& S100A8& and& S100A9& proteins,&which&
inhibit& DC& differentiation& and& favour& MDSC& accumulation.& S100A8/S100A9& was&
suggested&to&help& in&the&formation&of&NADPH&oxidase,&which&produces&ROS& in&myeloid&
cells&and&in&this&way&prevents&myeloid&differentiation.&S100A8/A9&heterodimers&facilitate&
the& accumulation& of& MDSCs& through& blocking& differentiation& of& myeloid& precursors&
(STAT3Fdependent)& and&MDSC& chemoattraction& to& tumour& (NFFκBFdependent)& (Cheng,&
Corzo& et& al.& 2008;& Sinha,& Okoro& et& al.& 2008;& OstrandFRosenberg& and& Sinha& 2009).&
Interestingly,& S100A9&overFexpression& can& induce&MDSC&accumulation& in&mice&without&





in& DC& differentiation,& thus& its& inhibition& favours& MDSC& development& by& preventing&
progenitor& differentiation& (Condamine& and& Gabrilovich& 2011).& Taken& together,&
constitutive& STAT3& activation& prevents& differentiation& of& myeloid& cells.& In& fact,& STAT3&
signalling&enhances&proliferation&and&survival&of&myeloid&progenitors,& leading& to&MDSC&
accumulation& (Corzo,& Cotter& et& al.& 2009).& In& addition,& STAT3& signalling& plays& a& role& in&
inducing& suppressive& functions& in&MDSCs.& STAT3& signalling& in& human&MDSCs& regulates&
ArgF1& activity& (VasquezFDunddel,& Pan& et& al.& 2013)& and& induces& IDOFmediated&
immunosuppression& through& the& activation& of& the& nonFcanonical& NFFκB& pathway& (Yu,&
Wang& et& al.& 2014).& Further,& STAT3& signalling& upFregulates& the& expression& of& NADPH&
subunits& (Nox2)& in&MDSCs.& This& mechanism& facilitates& increased& release& of& ROS& upon&
contact&with& other& cells& (Corzo,& Cotter& et& al.& 2009).& It& could& therefore& be& argued& that&
STAT3& is& one& of& the& main& transcription& factors& leading& to& MDSC& differentiation,&
accumulation,& tumour& infiltration,& and& suppressive& function& in& tumourFbearing& hosts&
(Corzo,&Cotter&et&al.&2009)&(Fig.&5.1).&&
Cytokines&IFNγ&and&IL1β&primarily&signal&through&the&STAT1&transcription&factor,&
while& IL13& and& IL4& primarily& signal& through& STAT6& (Condamine& and& Gabrilovich& 2011)&
(Fig.& 5.1).& STAT1Fmediated& IFNγ& signalling& induces& iNOS& expression& (Huang,& Pan& et& al.&
2006;&Movahedi,&Guilliams& et& al.& 2008)& and& is& implicated& in&ArgF1& activity& (Condamine&
and& Gabrilovich& 2011),& both& used& by& MDSCs& for& T& cell& suppression.& Blocking& IFNγ&
overcomes& MDSCFmediated& immune& suppression& by& inhibiting& iNOS& upregulation&
(Kusmartsev& and& Gabrilovich& 2005).& In& addition,& STAT1& activation& by& IFNγ& induces& the&
expression&of&Bcl2a1,& leading&to&GFMDSC&survival& (MedinaFEcheverz,&Haile&et&al.&2014).&
TumourFsecreted&IFNγ&further&causes&induction&or&increased&secretion&of&IL10,&iNOS,&and&
TGFβ& (Huang,&Pan&et& al.& 2006).& STAT6&activation&by& IL13&or& IL4& causes& increased&ArgF1&
activity& and& TGFβ& production& by& MDSCs& (Condamine& and& Gabrilovich& 2011).& The&
IL4Rα/STAT6& signalling& pathway& is& considered& to& be& important& for& MDSC& survival& as&
aptamerFmediated& blockade& of& IL4Rα& triggers& apoptosis& of& MDSCs& and& limits& tumour&
progression& in& a& 4T1& mammary& carcinoma& mouse& model& (Roth,& De& La& Fuente& et& al.&
2012).& On& the& other& hand,& a& study& using& IFNγF,& IFNγRF,& and& IL4RαFdeficient& mice&
suggested& that& MDSC& accumulation& and& function& do& not& depend& on& IFNγF& or& IL4RαF
mediated&signaling&(Sinha,&Parker&et&al.&2012).&&&&
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In&MDSCs,& TLR& signalling& and&hypoxia& can& activate& the&NFκB&pathway,&which& in&
turn&activates&proFinflammatory&proteins&Cox2&and&PGE2&(Eruslanov,&Daurkin&et&al.&2010;&
Gabrilovich,& OstrandFRosenberg& et& al.& 2012)& (Fig.& 5.1).& Inhibiting& Cox2& prevents& the&
differentiation& from&BM&precursors& to&MDSCs& (Eruslanov,&Daurkin&et&al.& 2010).&PGE2& is&
widely&described&in&relation&to&MDSCs&and&is&believed&to&regulate&ArgF1&and&iNOS&activity&







Phosphoinositide& 3Fkinase& (PI3K)& signalling& is& known& to& regulate& chemotaxis,&
phagocytosis,& ROS& production,& and& apoptosis& in&macrophages& and& neutrophils& (Trikha&
and& Carson& 2014).& Defective& PI3K/Protein& kinase& B& (Akt)& signalling& has& recently& been&
linked& to& accumulation& of& immunosuppressive& immature& myeloid& cells& in& aging& mice&











production& of& bioactive& TGFβ& (Escors,& Lopes& et& al.& 2008;& Arce,& Breckpot& et& al.& 2011).&
Others&have&also&shown&the&regulatory&role&of&Erk,&leading&to&inhibition&of&DC&maturation&





of& these& pathways& was& the& observation& that& STAT3,& p38/MAPK& (mitogenFactivated&
protein& kinase),& Erk1/2,& and& NFFκB& exhibited& increased& phosphorylation& and& thus&
activation& in&MDSCs& in# vivo# (Wu,& Yan& et& al.& 2012).& However,& the& importance& of& these&
pathways& may& not& be& universal& in& MDSCs& as& tumourFassociated& myeloid& cells& differ&
between&tumour&types&(Elpkek,&Cremasco&et&al.&2014).&
HypoxiaFmediated& MDSC& accumulation,& differentiation,& and& function& was&
recently&linked&with&MAPK,&PI3K/Akt,&and&NFFκB&signalling&(Zhu,&Tang&et&al.&2014),&linking&
these& signalling& pathways& to& MDSC& activity& and& hypoxia.& & Thus,& Gabrilovich& and& his&
colleagues& have& proposed& a& twoFstage& model& of& MDSC& involvement& in& cancer&
progression& (Condamine& and& Gabrilovich& 2011;& Gabrilovich,& OstrandFRosenberg& et& al.&
2012).& The& first& stage& is& represented&by& altered&myelopoiesis,&which&prevents&myeloid&
differentiation&and&mobilizes&large&amounts&of&immature&myeloid&cells.&Tumours&secrete&
factors& (such& as& GMFCSF,& GFCSF,& IL6,& and& VEGF)& that& signal& through& STAT3& and& other&
transcription& factors,&mobilizing& and& recruiting& immature&myeloid& cells& to& the& tumour&
tissue& (Fig.& 5.1).& The& second& stage& is& initiated& within& the& tumour& microenvironment.&
There,&proFinflammatory&molecules&such&as&IFNγ,&IL1β,&IL13,&and&tollFlike&receptor&ligands&
(TLRLs)& bind& their& receptors&on&MDSCs,& initiating& regulatory&networks& that& lead& to& the&
acquisition&of&immunosuppressive&activities.&Alternatively,&MDSCs&can&differentiate&into&
TAMs,& TANs,& and& tolerogenic&DCs.& In& addition,& hypoxia& and& other& tumour&metabolites&
influence& the& second& stage& of& MDSC& development& (Gottfried,& Kreutz& et& al.& 2008;&
Gabrilovich,& OstrandFRosenberg& et& al.& 2012;& Husain,& Huang& et& al.& 2013).& NFκB,& STAT1,&
and& STAT6& activation,& for& example,& lead& to& upFregulation& of& iNOS,& ArgF1,& NO& (nitric&
oxide),& and& other& immunosuppressive& cytokines& (Condamine& and& Gabrilovich& 2011;&
Gabrilovich,&OstrandFRosenberg&et&al.&2012).&Importantly,& immunosuppressive&activities&





Fig.# 5.1.# Intracellular# regulatory# pathways# within# MDSCs.# Scheme# represents# the#
regulatory#pathways#and#its#effects#on#MDSC#differentiation,#accumulation,#and#function.#










Corzo,& Cotter& et& al.& 2009).& ROS& include& the& superoxide& anion& (O2F),& hydrogen&peroxide&
(H2O2),& and& the& hydroxyl& radical& (OH).& Superoxide& anion& is& either& generated& by&
mitochondrial&electron&leakage&or&NADPH&oxidases&(Kang,&Lee&et&al.&2015).&In&leukocytes,&
the& primary& source& of& ROS& in& response& to& stimuli& is& NADPH& oxidase& (Nox2)& assembly,&
which& consists& of& two& membrane& proteins& and& three& cytosolic& subunits,& which& are&
associated& with& Rac& (Rho& family& GTPase)& (Groemping& and& Rittinger& 2005).& NADPH&
catalyzes& the&one&electron&reduction&of&oxygen&to&superoxide&anion.&The&electrons&are&
supplied&by&NADPH&(Corzo,&Cotter&et&al.&2009).&In&murine&tumourFinfiltrating&MDSCs&two&





(NO)& to& produce& peroxynitrite& (ONOOF),& a& RNS& (Alvarez& and& Radi& 2003).& Superoxide&
anions&can&also&be&converted&to&H2O2&by&a&free&electron&or&superoxide&dismutase&(SOD)&
activity.& H2O2& can& be& converted& to& OH,&which& is& detrimental& to& cells& as& it& is& the&most&
reactive& ROS.& The& OH& radical& attacks& proteins,& DNA,& and& membrane& lipids,& inducing&
irreversible&changes.&Superoxide&anion&and&H2O2&are&milder&as&they&cause&reversible&DNA&
and& protein& oxidation.& To& protect& themselves& from& ROS& damage,& cells& contain&
peroxidase& enzymes& (such& as& peroxiredoxin,& glutathione& peroxidase,& and& catalase)& to&
reduce&H2O2& to&water& before& it& can& be& converted& to&OH& radicals.& Peroxidase& enzymes&
obtain& the&reducing&power& from&NADPH.&Thus,&NADPH& is&needed& for&ROS&homeostasis&
and&is&supplied&by&energy&metabolic&pathways&such&as&the&pentose&phosphate&pathway&
(PPP)&(Kang,&Lee&et&al.&2015).&&
It& is& well& established& that& ROS& (such& as& H2O2)& and& RNS& (such& as& NO)& exert&
detrimental& effects& on&NK& and& T& cells& (Mougiakakos,& Johansson& et& al.& 2009),& and& that&
MDSCs& from& cancer& patients& and& tumourFbearing&mice& suppress& T& cells& through& these&
reactive& molecules& (Talmadge& 2007;& Kusmartsev,& Su& et& al.& 2008;& Youn,& Nagaraj& et& al.&
2008;&Gabrilovich&and&Nagaraj&2009).&NADPH&oxidase,&ArgF1,&and&iNOS&work& in&concert&
to& produce& peroxynitrite& and& H2O2& to& induce& T& cell& blockage& (Gabrilovich,& OstrandF
Rosenberg& et& al.& 2012).& Peroxynitrite& indirectly& nitrates& tyrosine& residues& but& also&
directly& reacts& with& tryptophan,& methionine,& and& cysteine& residues& (Alvarez& and& Radi&
2003).& H2O2,& superoxide& anion,& NO,& and& peroxynitrite& can& oxidize& cysteine& thiols& on&
proteins,&which&causes&structural&changes&and&thus&controls&protein&activity&(Kang,&Lee&et&
al.& 2015).& As& ROS& and& peroxynitrite& are& highly& reactive& they& are& shortFlived,& and& their&
action& is& hence& limited& to& short& distances.& It& has& therefore& been& suggested& that& the&
immunological&synapse&during&antigen&presentation&may&be&a&good&environment&for&the&
action&of& such&molecules& (Nagaraj,&Gupta&et&al.& 2007).&There&are& three&main&ROSF&and&
RNSFmediated&molecular&blocks&acting&on&T&cell&activity.&First,&nitration&(by&peroxynitrite)&
of&the&CD8&TCR&induces&a&conformational&change,&thus&preventing&its&recognition&of&MHC&
peptides.& This& process& negatively& regulates& antigenFspecific& CD8& T& cell& activity.&




production& (Schmielau& and& Finn& 2001).& Third,& NO& activity& can& block& IL2RFmediated&
signalling,&thus&limiting&T&cell&proliferation&(Mazzoni,&Bronte&et&al.&2002).&
5.1.3.!! THE!ROLE!OF!HYPOXIA!IN!MDSC!BIOLOGY!
Hypoxia& alters& the&energy&metabolism& in& cells/MDSCs& (Corzo,&Condamine&et& al.&
2010;& Liu,&Bi&et&al.&2014),& leading& to&abnormal& respiratory&metabolic&pathways.&This& in&
turn& influences& the& energy& balance& and& hence& ROS& balance& in& cells& (Kang,& Lee& et& al.&
2015).& But& hypoxia& affects& MDSCs& in& additional& ways.& The& hypoxic& tumour&
microenvironment& recruits& and& activates&MDSCs& (Corzo,& Condamine& et& al.& 2010;& Zhu,&
Tang& et& al.& 2014).& The& interaction& between& HIFFα/MIF& (Hypoxia& inducible&
factor/Macrophage&migration& inhibitory& factor)&and&NFFκB/IL6&axes&plays&an& important&
role&in&the&hypoxiaFinduced&accumulation&of&MDSCs&and&tumour&growth&in&HNSCC&(head&
and& neck& squamous& cell& carcinoma)& (Zhu,& Tang& et& al.& 2014).& Further,& hypoxia& upF
regulates& COXF2,& which& leads& to& production& of& PGE2.& PGE2& inhibits& DC& maturation,&
expression& of& coFstimulatory& molecules,& IL12& secretion& or& it& can& skew& their&
differentiation& to& tolerogenic& DCs.& In& addition,& PGE2& can& stimulate& MDSC&
immunosuppressive& functions& (such& as& ArgF1& expression)& by& binding& to& the& EPF4&
(Prostaglandin&E&receptor&4)&receptor.&PGE2&secretion&by&MDSCs&affects&the&capacity&of&
CD8& T& cells& to& recognize& antigen& on& tumour& cells& and& prevents& tumour& cell& apoptosis&
(Rodriguez,&Hernandez&et&al.&2005;&Sinha,&Clements&et&al.&2007;&Serafini&2010;&Chouaib,&
Messai&et&al.&2012).&&
Hypoxia&within& the& tumour& can& further&affect& the&activity&of&MDSCs,&enhancing&





capability& unto& splenic& MDSCs.& In& addition,& the& hypoxic& tumour& microenvironment&
caused&the&upFregulation&of& iNOS&and&ArgF1& in&splenic&MDSCs&(Corzo,&Condamine&et&al.&
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2010).& MDSCs& were& also& shown& to& differentiate& into& TAMs& under& hypoxic& conditions&






et& al.& 2009;& Steding,& Wu& et& al.& 2011).& While& the& effect& of& IL12& on& T& cells& is& wellF
characterized&it& is& less&so&on&myeloid&cells.&An&analysis&of&the&B16&tumour&environment&
showed& that&myeloid& cells& formed& the&majority& of& cells& that& could& respond& to& IL12& by&
expressing&the&IL12RF2β&(Kerkar,&Goldszmid&et&al.&2011).&Mice&deficient&for&IL12&produce&
macrophages&that&have&a&bias& toward&the&M2&phenotype,&suggesting&a& role& for& IL12& in&
macrophage& polarization& (Bastos,& Alvarez& et& al.& 2002).& IL12& provided& in& microspheres&
altered& the& function&of& tumourFinfiltrating&macrophages.&This&was&exhibited&by&a& rapid&
reduction& of& tumourFsupporting& molecules& such& as& IL10,& MCPF1& (monocyte&
chemoattractant& protein& 1),&MIF& (migration& inhibitory& factor),& and& TGFβ.& At& the& same&
time&enhanced&production&of&TNFα,&IL15,&and&IL18&was&observed&(Watkins,&Egilmez&et&al.&
2007).&However,& it& has& to&be&noted& that& the&authors&purified&macrophages&by&CD11b+&
expression,& indicating& that& this& population& did& not& only& consist& of& macrophages& but&
possibly&all&myeloid&cells&within&the&tumour.& Inducible&IL12&in&adoptive&CARFT&cells&also&
led& to& an& increase& in& tumourFinfiltrating& macrophages,& which& together& with& TNFα&
induction,&was&crucial&to&the&antiFtumour&response.&Importantly,&this&treatment&was&also&
effective& against& tumours& that& had& lost& TAA& expression& (Chmielewski,& Kopecky& et& al.&
2011).& An& increase& in& myeloid& cell& tumour& infiltration& is& only& positive& if& these& cells&
possess& antiFtumour& cytotoxic& activities.& IL12& released& by& tumourFspecific& T& cells& was&
found& to& act& directly& on& BMFderived& cells& within& the& tumour& and& convert& tumourF
infiltrating& myeloid& cells& into& functional& APCs.& The& authors& demonstrated& enhanced&
expression& of& genes& associated& with& antigen& presentation& in& bulk& tumourFinfiltrating&
myeloid& cells& exposed& to& IL12Fsecreting& T& cells.& Myeloid& cells& purified& from& tumours&
treated&with&IL12Fsecreting&T&cells&could&stimulate&T&cell&proliferation&ex#vivo,&while&cells&
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the& collapse& of& the& tumour& stroma& and& infiltration& of& CTLs& and& memory& CD8& T& cells&
(Kerkar,& Leonardi& et& al.& 2013).& Other& researchers& recently& showed& that& adenoviralF




IL12& on& MDSCs& are& poorly& known,& and& it& therefore& remains& an& interesting& area& to&
research.&Importantly,&IL12&exerts&not&only&positive&effects&on&T&cells&but&also&on&myeloid&










cell& lymphoma& patients.& The& authors& performed& immunohistochemistry& studies& and&
classified&macrophages&as&CD68+& cells& (Chen,&Chapuy&et& al.& 2013).& Interestingly,& in& this&
thesis,& both&ex# vivo&murine&macrophages& and&MDSCs& expressed& CD68.& PDFL1&was& upF
regulated& on& tumourFassociated& blood&monocyteFderived&myeloid& dendritic& cells& from&
ovarian& carcinoma& patients& (tissue& and& draining& lymph& nodes).& And& PDFL1&mediated& T&
cell&suppression,&as&PDFL1&blockade&partially&reversed&T&cell&suppression&(Curiel,&Wei&et&
al.& 2003).& In& contrast,&other& studies&did&not&encounter&differences& in&PDFL1&expression&
between&MDSCs& from& tumourFbearing& patients& and&mice,& and& immature&myeloid& cells&
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from&healthy&counterparts&(Youn,&Nagaraj&et&al.&2008;&Zhang,&Wang&et&al.&2013).&Of&note,&
these& studies&were&performed&on& circulating&or& spleen&MDSCs& and& thus&had&not&been&
further& activated& by& the& tumour& environment.& Data& from& other& researchers& and& data&
presented&in&this&thesis&has&shown&that&tumourFinfiltrating&MDSCs&express&higher&levels&
of&surface&PDFL1&than&splenic&MDSCs&(Noman,&Desantis&et&al.&2014).&The&importance&of&
PDFL1& for&MDSCFmediated& immune& suppression& varies.& Some& studies& show& that& PDFL1&
blockade& in&MDSCs&can&overcome&their&suppressive&activities& (Chikamatsu,&Sakakura&et&




role& in& their& antiFtumour& efficacy.& Many& of& these& chemotherapeutic& drugs& can& upF
regulate& maturation& and& function& of& mouse& and& human& DCs& at& nonFcytotoxic& doses,&
including& vincristine,& vinblastine,& paclitaxel,& doxorubicin,& methotrexate,& mitomycin& C,&
and& 5FazaF2Fdeoxycytidine& (Kaneno,& Shurin& et& al.& 2009).& Interestingly,& this& maturation&
was& dependent& on& IL12& in& the& case& of& paclitaxel,& methotrexate,& doxorubicin,& and&
vinblastine.&In&addition,&they&regulate&signal&transduction&pathways&in&DCs&and&increase&
tumour&recognition&by&DCs&and&CTLs&(Shurin,&Tourkova&et&al.&2008;&Shurin,&Tourkova&et&
al.& 2009;& Kaneno,& Shurin& et& al.& 2011;& Michels,& Shurin& et& al.& 2012).& Paclitaxel& at& nonF
cytotoxic& concentrations& suppresses& the& induction& of& tumourFmediated& regulatory& DC&
differentiation&in#vitro&and&in#vivo.&Interestingly,&regulatory&DC&induction&was&assessed&by&
a& downFregulation& of& CD11c& and& upFregulation& of& CD11b,& which& does& not& necessarily&
correlate& with& immunostimulatory& activity& (Zhong,& Gutkin& et& al.& 2014).& Nevertheless,&
paclitaxel& has& been& shown& to& promote& the& differentiation& of&MDSCs& into& DCs& in# vitro#
(Michels,& Shurin& et& al.& 2012)& and& was& shown& to& decrease& accumulation& of& tumourF
infiltrating& MDSCs& in& melanomaFbearing& mice,& without& alterations& in& BM&
haematopoiesis.& Interestingly,& this& effect& was& associated&with& inhibition& of& p38&MAPK&
activity,& S100A9& expression,& and& TNFα& production,&which& restored& CD8& T& cell& effector&
functions&and& led&to& increased&survival&and&diminished&tumour&burden&(Sevko,&Michels&
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et& al.& 2013).& Similarly,& docetaxel& induces& the& upFregulation& of& several& maturation&
markers&in&MDSCs&(MHCII,&CD11c,&CD86)&(Kodumudi,&Woan&et&al.&2010).&&
Certain& chemotherapeutic& treatments& at& cytotoxic& concentrations& selectively&
inhibit&or&target&MDSCs,&which&significantly&enhances&their&efficacy&(Suzuki,&Kapoor&et&al.&
2005;& Vincent,& Mignot& et& al.& 2010;& Sevko,& Michels& et& al.& 2013).& 5Ffluorouracil& (5FFU)&
induces&MDSC&apoptosis&in#vitro#and&in#vivo,&enhancing&tumourFinfiltrating&CTL&and&antiF
tumour& responses& (Vincent,&Mignot&et&al.&2010).&Gemcitabine&at&clinical&doses& reduces&
splenic& MDSC& numbers& in& tumourFbearing& mice& and& increases& CD8& and& NK& mediated&
antiFtumour& immune& responses.& Interestingly,& other& immune& cells& such& as& CD4/8,& NK,&
macrophages,&and&B&cells&were&unaffected&by&this&treatment&(Suzuki,&Kapoor&et&al.&2005).&
Certain& chemotherapeutic& agents& deplete&MDSCs& and& inhibit&MDSC& differentiation& by&
triggering&cell&death&in&MDSCs&or&their&precursors,&including&gemcitabine,&5Ffluorouracil,&
docetaxel,& and& doxorubicin& (Suzuki,& Kapoor& et& al.& 2005;& Kodumudi,&Woan& et& al.& 2010;&
Vincent,&Mignot&et&al.&2010;&Alizadeh&and&Larmonier&2014;&Alizadeh,&Trad&et&al.&2014).&
Doxorubicin& selectively& eliminated& MDSCs& in& blood,& spleen,& and& tumour& of& mice&
(mammary& cancer& model)& and& the& remaining& MDSCs& were& impaired& in& suppressive&
activities.& MDSCs& from& patients& (bearing& a& variety& of& tumour& types)& were& killed& by&
doxorubicin& in#vitro&(Alizadeh,&Trad&et&al.&2014).&Importantly,&certain&chemotherapeutic&




In& the& previous& chapter,& ex# vivo& MDSCs& were& phenotypically& and& functionally&
studied& and& found& to& be& equivalent& to& tumourFinfiltrating& MDSCs.& The& aim& of& this&
chapter&is&the&establishment&of&protocols&using&the&newly&developed&ex#vivo&MDSCs&for&
discovery& of& novel& antiFcancer& therapeutic& targets& that& inhibit& MDSC& suppressive&
function.& First,& the& lentivector& vaccines& from& chapter& 3,& particularly& the& IL12Fbased&
lentivectors,& will& be& evaluated& to& characterise& their& effects& on& MDSCs.& Further,& highF
throughput&mass&spectrometry&based&proteomic&analysis&of&ex#vivo&MDSCs&is&presented,&
followed&by&validation&of&P450R&expression&as&a&novel&MDSCFspecific&therapeutic&target&
for& chemotherapy& drugs.& In& this& chapter,& the& applicability& of& ex# vivo& differentiated&








cells& and& proFinflammatory& cytokines& can& convert& MDSCs& into& efficient& APCs& (Bronte,&
Apolloni& et& al.& 2000;& Bronte,& Serafini& et& al.& 2001;& Kerkar,& Goldszmid& et& al.& 2011).&
Consequently,& it& was& assessed& whether& transduction& of& MDSCs& with& the& lentivectors&
developed& in& chapter& 3& could& inhibit&MDSCFmediated& T& cell& suppression& and& enhance&
their& antigen& presenting& capacities.& For& this& purpose&MDSCs&were& transduced& in# vitro&
before&their&use&in&MLRs&or&in&OVAFspecific&coFculture&assays.&For&MLRs&C57/BL6&MDSCs&
were& transduced& with& lentivectors& expressing& the& GFP& reporter& gene& and& coFcultured&
with& BALB/c& splenocytes.& Interestingly,& the& MDSCs& were& only& capable& of& inducing&
significant& Th1& and& CTL& responses& when& transduced& with& IL12Fp1FGFP& (Fig.& 5.2.A).&
Further,&a&coFculture&assay&using&OVAFspecific&CD4&and&CD8&T&cells& from&OTFII&and&OTFI&
mice& was& performed,& respectively,& as& responder& cells.& MDSCs& were& transduced& with&
lentivectors& containing& the&model& antigen& OVA& before& coFculture& with& OVAFspecific& T&
cells& at& a& ratio& of& 1:10.& Similar& to& the& results& in&MLRs,& only& IL12Fp1Fbased& lentivectors&
were& capable& of& significantly& enhancing& CTL& activation& above& control.& While& IL12Fp1F
based& lentivectors&were& also& effective& at& inducing& Th1& responses,& no& significance&was&
achieved&when&pooling&two&independent&experiments&(Fig.&5.2.BFC).& It&could&be&argued&
that& IL12& secretion& by& transduced& MDSCs& could& have& autocrine& effects& and& cause&
proliferation& and& maturation& of& DC& precursors,& instead& of& causing& a& change& within&
MDSCs.&To&test&this,&day&5&B16FMDSCs&were&treated&with&recombinant& IL12&and&tested&










change& in& these&markers&was& found& (Fig.&5.2.D).&Further,& it&was&assessed&whether& IL12&
provided& in# cis& by& lentivectorFtransduction& would& have& an& effect& on& the& MDSC&
phenotype.&Ex# vivo& B16FMDSCs&were& transduced&with& lentivectors& expressing& selected&
cytokines& (IL12,& IFNγ,& and& IL10)& and& p1.& Constructs& coFexpressing& GFP& were& used& for&
these&experiments&to&study&the&MDSC&phenotype&of&GFP+&transduced&cells.&A&lentivector&
encoding&only&GFP&was&used&as&control.&Transduction&efficiencies& ranged& from&10F45%&
(Fig.& 5.2.E).& The&expression&of&maturation&markers& in& transduced& (GFP+)&MDSCs& versus&
nonFtransduced& (GFPF)& MDSCs& within& the& same& cultures& was& compared.& Interestingly,&
IL12F,& IL10F& and&especially& IFNγFcontaining& lentivectors&upFregulated&CD11c,& CD86,& and&
MHC&II&within&transduced&MDSC&populations&(Fig.&5.2.F).&In&these&experiments,&none&of&
the& surface&marker& changes& in& response& to& IL12Fbased& lentivectors& reached& statistical&
significance.& Ly6G& expression& on& the& other& hand& was& not& affected& by& lentivector&
transduction.&&
Taken&together,&these&data&suggested&that&ex#vivo#MDSCs&can&be&transduced&by&
lentivectors& and& that& IL12Fp1Fbased& lentivectors& induce& antigenFpresenting& capacities.&
Importantly,& enhanced& T& cell& activation& does& not& necessarily& correlate& with& increased&









Fig.# 5.2.# Lentivectors# expressing# IL12# and#microRNA# p1# convert# ex# vivo#MDSCs# into#
APCs.# (A)# Bar# graphs# represent# percentages# of# Th1# and# CTL# responses# in# response# to#
transduced#ex#vivo#MDSCs#in#a#MLR.#Briefly,#BM#cells#from#C57/BL6#mice#were#cultured#
with# CMB16# for# 5# days,# and# MDSCs# were# transduced# with# the# indicated# lentivectors.#
Splenocytes#from#BALB/c#mice#were#isolated#and#co8cultured#with#transduced#MDSCs#for#
72h.# Surface# and# intracellular# staining# was# performed# with# CD4,# CD8,# and# IFN8γ#
antibodies# and# cultures# were# analysed# by# flow# cytometry.# Pooled# data# from# two#
independent#experiments.#(B)#Bar#graphs#represent#percentages#of#OVA8specific#Th1#and#
CTL#responses#in#response#to#transduced#ex#vivo#MDSCs.#Briefly,#MDSCs#were#transduced#
on# day# 5# of# culture# with# IiOVA8containing# indicated# lentivectors.# Splenocytes# were#
isolated# from# OT8II# and# OT8I# mice# and# co8cultured# with# transduced# MDSCs# for# 72h.#
Surface#and#intracellular#staining#was#performed#with#CD4,#CD8,#and#IFNγ#antibodies#and#
cultures# were# analysed# by# flow# cytometry.# Pooled# data# from# two# independent#
experiments.#(C)#Flow#cytometry#density#plots#show#CD8#T#cell#responses#in#response#to#
MDSCs# transduced# with# indicated# lentivectors.# Percentages# of# GrzB# and# IFNγ8positive#
 239&
cells#are#indicated#within#the#dotplots.#Grz#B,#Granzyme#B.#(D)#Flow#cytometry#histograms#
representing# expression# of# indicated# markers# in# B168MDSCs# on# day# 8# of# culture,#
untreated# or# treated# with# recombinant# IL12# for# 72# hours.# Percentages# and# MFI# are#
indicated# within# the# histograms.# Rec# IL12,# recombinant# IL12.# (E8F)# B168MDSCs# were#
transduced# on# day# 5# of# culture# with# indicated# GFP8expressing# lentivectors# and# flow#
cytometry# was# performed# 72# hours# later.# UT,# untransduced# cells.# (E)# Bar# graphs#
represent# percentages# of# GFP+# cells# within# transduced# MDSC# cultures# on# day# 8# of#
culture.# Pooled# data# from# two# independent# experiments.# (F)# Bar# graphs# represent#
percentages# of# indicated# surface#markers#within# transduced# (GFP+)# and# untransduced#





&Lentivector& transduction& of& MDSCs& could& convert& them& into& APCs,& capable& of&
priming& naïve& T& cells.& IL12& and& the& microRNA& p1& were& provided& in# cis& in& these&
experiments.&While&priming&of&naïve&T&cells&will&be&important&in&prophylactic&vaccination,&
this&may&not&be&the&case&during&therapeutic& intraFtumour&administration.&T&cells& found&




whether&direct& transduction&of&MDSCs& in& the&tumour&would&be&required&to&counteract&
their&activities&over&activated&T&cells.&For&this&purpose,&standard&suppression&assays&with&
antiFCD3/antiFCD28Factivated& CD8& T& cells& were& performed,& in& which& cultures& were&
treated&with&soluble&IL12,&antiFPD1&antibody,&and&antiFCTLAF4&antibody.&Soluble&IL12&was&
obtained&from&293T&cells&that&were&previously&modified&with&lentivectors&to&express&the&
IL12&gene&(2.5ng/mL& IL12& in&supernatant).&Supernatant& from&293T&cells&expressing&GFP&
was&used&as&a&control,&while& isotype&antibodies&were&used&as&a&control& for&CTLAF4&and&
PDF1&blocking&antibodies.& Soluble& IL12& could&overcome&MDSC& inhibitory&activities&over&
activated&CD8&T&cells&(Fig.&5.3.A,B).&In&contrast&to&soluble&IL12,&CTLAF4&or&PDF1&antibodies&
alone& did& not& significantly& increase& CD8& T& cell/MDSC& ratios.& A& consistent& synergistic&
effect&was&observed&when&PDF1&antibody&was&added&together&with&soluble& IL12,&albeit&
without& significance& in& these&particular&experiments& (Fig.&5.3.A).&Addition&of&MDSCs& to&
activated&T&cell&cultures&completely&inhibited&secretion&of&IFNγ,&while&addition&of&soluble&
IL12& reversed& this&process& and& strongly& increased& IFNγ& secretion& (Fig.& 5.3.B).& This&data&
suggested& that& MDSCs& did& not& have& to& be& directly& transduced& with& IL12Fbased&
lentivectors& to& overcome& their& immunosuppressive& function.& However,& direct&
transduction&with&PDFL1&silencing&microRNA&may&still&be&beneficial.&MDSCs&secrete&TGFβ&
to& dampen& the& immune& response& and& ex# vivo& MDSCs& secrete& large& amounts& of& this&
cytokine&(Fig&4.9.C).&As&TGFβ&impairs&the&ability&of&macrophages&to&produce&and&secrete&
IL12&(Takeuchi,&Alard&et&al.&1998),&and&IL12&inhibits&TGFβ&production&by&TAMs&(Watkins,&






Taken& together,& IL12& (a& known& effective& antiFtumour& agent)& induction& and&
inhibition&of&PDFL1/PDF1&interaction&in#vitro#overcomes&MDSC&suppressive&activities&over&
naïve&and&effector&T&cells.&Although&these&ex#vivo&assays&are&good&indicators&of&the&effect&







Fig.# 5.3.# Soluble# IL12# can# overcome# MDSC# inhibitory# activities.# (A8B)# Standard#
suppression# assays#were# performed,# in#which# ex# vivo#MDSCs#were# added# to# activated#
CD8# T# cells# in# indicated# conditions# at# a# ratio# of# 1:1.# –b,# no# anti8CD3/CD28# activatory#
beads#were#added;#+b,#anti8CD3/CD28#activatory#beads#were#added;#No,#indicates#T#cell8
MDSC# co8cultures# with# no# added# condition;# IC,# Isotype# control# was# added;# CTLA4# Ab,#
CTLA84#antibody#was#added;#PD81#Ab,#PD81#antibody#was#added;#GFP,#supernatant#from#
293T8GFP#cells#was#added;#IL12,#supernatant#from#293T8IL12#cells#was#added;#IL12#PD81#
Ab,#supernatants# from#293T8IL12#cells# together#with#PD81#antibody#was#added.# (A)#Bar#
graphs#represent#the#ratio#of#CD8#T#cells#over#MDSCs#within#the#co8cultures.#After#72h#of#
co8culture#cells#were#stained#with#anti8CD8#and#anti8CD11b#antibodies#and#analysed#by#
flow# cytometry.# (B)# Bar# graphs# represent# the# amount# of# secreted# IFN8# antibody# was#
added.#(A)#Bar#graphs#represent#concentration#in#supernatants#was#measured#by#ELISA.#
(C)# Bar# graphs# represent# secreted# bioactive# TGFβ# in# B168MDSCs.# B168MDSCs# were#
treated# with# recombinant# IL12# (10ng/mL)# for# 24# hours.# Supernatants# were# then#
transferred# to# and# quantified# with# a# TGFβ8reporter# cell# line.# Standard# deviations# are#
represented#as#error#bars.#
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5.2.3.!! EX# VIVO! MDSCs! DIFFER! FROM! IMMATURE! BM+DCs! IN! KEY! METABOLIC!
PATHWAYS!
The&data&presented& in&this& thesis&so& far&suggested&that& the&newly&developed&ex#
vivo&MDSCs&are&phenotypically&and&functionally&equivalent&to&tumourFinfiltrating&MDSCs,&
and& that& they& can& be& used& to& predict& therapeutic& outcomes& in& the&melanoma&mouse&
model.& It& was& therefore& reasoned& that& ex# vivo& MDSCs& may& be& used& to& address&
mechanistic& studies& of& MDSC& behaviour.& To& validate& our& ex# vivo& MDSCs& as& well& as&
identify&MDSC&differential& intracellular&pathways&and&specific&therapeutic&targets,&highF
throughput& analytical& techniques& were& applied.& This& could& be& possible& as& the& ex# vivo&
MDSC&differentiation&protocol&yields&high&numbers&of&MDSCs&(in&contrast&to&purification&
of& in# vivo& tumourFinfiltrating&MDSCs).&B16FMDSCs&were& compared&with& immature&BMF
DCs& by& unbiased& quantitative& proteomic& analyses& and& hence& differentially& activated&
pathways&in&the&two&myeloid&cell&types&could&be&identified.&Relative&protein&expression&
levels& were& quantified& using& iTRAQ& isobaric& tags& coupled& to& 2D& nanoFliquid&
chromatography& tandem& mass& spectrometry.& The& myeloid& proteome& of& conventional&
immature&BMFDCs&was&first&compared&with&that&of&B16FMDSCs,&using&triplicates&of&each&
cell& type.& Further,& the& proteomic& differences& within& MDSCs& caused& by& the& tumourF
environment& were& evaluated.& For& this& purpose& nonFneoplastic& 293TFMDSCs& were&
compared& with& melanoma& B16FMDSCs.& The& dataset& files& were& processed& using&
ProteinPilotTM& 4.5& software& from& AB& Sciex.& ProteinPilotTM& 4.5& uses& the& algorithm&
Paragon™&(v.4.0.0.0)&(Shilov,&Seymour&et&al.&2007)&for&database&search&and&ProgroupTM&
for& data& grouping.& As& described& in& Chapter& 2,& each& MS/MS& spectrum& was& searched&
against&a&database&of&murine&protein&sequences&(Uniprot&complete&mouse&proteome).&In&
this&way,&3002&proteins&were&detected&in&the&two&myeloid&cell&types&(B16FMDSC&and&BMF
DC)& with& a& false& recovery& rate& (FDR)& of& 1%.& 64& (2%& of& overall& identified& proteins)&
differentially& expressed& proteins& were& identified,& using& stringent& cutFoff& conditions.&





















































! ! ! ! ! ! ! ! ! ! ! !
Clec10a! CFtype&lectin&
domain&family&10&
member&A&& 1.14& 1.26& 1.69& 1.71& 1.60& 0.19& 0.21& 0.01& 0.01& 0.02& 51.1& 9&
Sod2! Superoxide&
dismutase&[Mn],&
mitochondrial&& 0.99& 0.84& 1.75& 1.87& 2.00& 0.46& 0.43& 0.05& 0.02& 0.01& 58.1& 16&
Gatm! Glycine&
amidinotransfera
se,&mitochondrial&& 0.93& 1.22& 1.77& 2.01& 1.67& 0.84& 0.36& 0.01& 0.03& 0.03& 49.4& 24&
Irg1! CisFaconitate&















polypeptide&& 0.89& 1.14& 2.07& 1.85& 1.79& 0.58& 0.84& 0.00& 0.01& 0.05& 27.1& 14&
Apobr! Apolipoprotein&B&






protein&A&& 1.18& 0.90& 2.19& 2.17& 2.31& 0.08& 0.52& 0.00& 0.00& 0.00& 67.8& 14&
Oat! Ornithine&amino&
transferase,&
mitochondrial&& 0.99& 1.17& 2.21& 2.19& 2.17& 0.63& 0.75& 0.01& 0.01& 0.00& 65.4& 34&
Actn4! AlphaFactininF4&& 0.87& 0.82& 2.54& 2.54& 2.58& 0.82& 0.98& 0.00& 0.00& 0.00& 68& 44&
Clta! Clathrin&light&
chain&A&& 1.06& 0.97& 3.28& 2.15& 2.83& 0.87& 0.99& 0.01& 0.04& 0.03& 37.1& 11&
Chi3l3! ChitinaseF3Flike&
protein&3&& 0.82& 0.80& 3.31& 3.66& 3.10& 0.22& 0.32& 0.00& 0.00& 0.00& 67.8& 34&
Thbs1! Thrombospondin&
1&& 1.13& 1.07& 3.44& 4.41& 4.02& 0.88& 0.59& 0.00& 0.00& 0.00& 22.1& 30&




& & & & & & & & & & & &
CD180! CD180&antigen& 1.01& 1.18& 1.47& 1.66& 1.39& 0.94& 0.57& 0.05& 0.02& 0.16& 22.4& 12&
Plin3! PerilipinF3&& 0.88& 0.86& 2.27& 1.80& 1.56& 0.58& 0.65& 0.01& 0.02& 0.12& 34.1& 11&
Hmox2! Heme&oxygenase&
2&& 1.22& 0.79& 1.32& 1.63& 1.98& 0.28& 0.15& 0.16& 0.03& 0.01& 42.2& 17&
Fbl! rRNA&2'FOF
methyltransferas
e&fibrillarin&& 1.21& 0.95& 1.33& 1.79& 1.64& 0.60& 0.83& 0.37& 0.03& 0.04& 50.7& 15&
Nsf! VesicleFfusing&








protein&59&& 0.96& 0.81& 1.79& 2.78& 2.70& 0.35& 0.10& 0.35& 0.00& 0.00& 40.7& 18&
Prkcsh! Glucosidase&2&
subunit&beta&& 0.98& 1.21& 2.17& 2.63& 2.88& 0.36& 0.80& 0.28& 0.04& 0.03& 38.2& 23&
Ephx1! Epoxide&
hydrolase&1&& 0.89& 0.82& 1.32& 1.60& 1.39& 0.85& 0.50& 0.18& 0.01& 0.07& 45.2& 23&
Snap23! SynaptosomalF
associated&






B1&& 1.09& 0.99& 1.53& 2.49& 2.07& 0.73& 0.13& 0.35& 0.01& 0.16& 45.3& 21&
Sf3a3! Splicing&factor&3A&
subunit&3&& 1.20& 1.04& 1.96& 2.17& 2.96& 0.84& 0.80& 0.49& 0.02& 0.09& 20.1& 14&


















































! ! ! ! ! ! ! ! ! ! ! !
Anxa5! Annexin&A5&& 0.80& 0.90& 0.08& 0.10& 0.10& 0.79& 0.44& 0.00& 0.00& 0.00& 88& 36&
Mfge8!! Lactadherin& 1.07& 0.92& 0.17& 0.15& 0.18& 0.94& 0.09& 0.00& 0.00& 0.00& 40& 19&
Dpysl2!! Dihydropyrimidi
naseFrelated&





d&2&& 0.94& 0.80& 0.30& 0.43& 0.36& 0.52& 0.13& 0.00& 0.00& 0.00& 36.5& 15&
Anpep!! Aminopeptidase&





protein&& 1.07& 1.09& 0.35& 0.43& 0.36& 0.60& 0.74& 0.04& 0.00& 0.00& 55.5& 35&
Acox3!! Peroxisomal&
acylFcoenzyme&A&
oxidase&3&& 0.86& 0.82& 0.40& 0.70& 0.55& 0.48& 0.21& 0.00& 0.05& 0.01& 47.7& 29&
Emc1!! ER&membrane&
protein&complex&






n&A/B&& 1.19& 1.10& 0.52& 0.56& 0.46& 0.57& 0.56& 0.01& 0.01& 0.00& 27.7& 15&
Alox5!! Arachidonate&5F
lipoxygenase&& 0.99& 0.87& 0.54& 0.53& 0.59& 0.46& 0.10& 0.00& 0.00& 0.00& 28.2& 27&
Pygl! Glycogen&
phosphorylase,&
liver&form&& 0.80& 0.94& 0.58& 0.56& 0.62& 0.22& 0.21& 0.00& 0.00& 0.00& 37,2& 44&
Gdi2!! Rab&GDP&
dissociation&
inhibitor&beta&& 0.89& 0.93& 0.59& 0.48& 0.70& 0.64& 0.45& 0.01& 0.00& 0.04& 58.2& 26&
Ndufv1!! NADH&
dehydrogenase&










homolog& 0.82& 0.86& 0.67& 0.55& 0.58& 0.15& 0.39& 0.01& 0.01& 0.01& 63.3& 24&
Cndp2!! Cytosolic&nonF
specific&









mitochondrial& 1.09& 0.88& 0.47& 0.63& 0.61& 0.69& 0.56& 0.02& 0.05& 0.08& 50.7& 28&
Npc1!
NiemannFPick&C1&
protein&& 1.10& 0.96& 0.47& 0.57& 0.75& 0.43& 0.37& 0.00& 0.01& 0.10& 5.4& 10&
Copb1!
Coatomer&


























isoform&& 1.05& 0.86& 0.52& 0.60& 0.59& 0.82& 0.45& 0.02& 0.12& 0.03& 16.7& 18&
Ptgs1!
Prostaglandin&





mitochondrial&& 0.85& 0.86& 0.65& 0.71& 0.55& 0.24& 0.33& 0.05& 0.10& 0.03& 34.1& 15&













sulfatase&& 0.82& 0.97& 0.50& 0.42& 0.37& 0.33& 0.83& 0.13& 0.03& 0.04& 18.7& 11&













protein&2&& 0.96& 0.96& 0.46& 0.67& 0.36& 0.64& 0.88& 0.14& 0.17& 0.01& 11.7& 11&
Pgm1!
Phosphoglucomu
taseF1&& 0.79& 0.87& 0.66& 0.72& 0.53& 0.52& 0.57& 0.38& 0.23& 0.02& 12.1& 12&
Table#5.1.#Differentially#expressed#proteins# from# immature#BMFDCs#and#ex#vivo#B16F
MDSCs.# iTRAQ# isobaric# tags# coupled# to# 2D# nano8liquid# chromatography# tandem#mass#
spectrometry#was#used# to# identify# the#proteomes#of# the# two#myeloid#cell# types.#Tables#
indicate#the#abundance#of#the#indicated#proteins#from#B168MDSCs,#relative#to#immature#
BM8DCs.#All#proteins#were# identified#with#>99%#confidence# (corresponding# to#a#protein#
score#cutoff#>2.0).#DC1,#DC2,#and#DC3#together#with#B1681,#B1682,#and#B1683#correspond#
to# the# three# independent# biological# replicates# from# BM8DCs# and# B168MDSCs,#
respectively.# The# ratio# of# protein# expression# levels# between# DCs# and# B168MDSCs# are#
indicated# and# correspond# to# the# protein# reporter# ion# intensity# originating# from# DC2#
(Tag114),# DC3# (Tag115),# B1681(Tag116),# B1682(Tag117),# B1683(Tag118)# relative# to#
DC1(Tag113).#Proteins#were#considered#to#show#a#significant#upward#or#downward#trend#




Relative& abundance& determined& differential& protein& identification& (Fig.& 5.4.A).&
The&proportion&of&nuclear&proteins&decreased&twoFfold&in&B16FMDSCs,&while&membraneF
associated&proteins&increased&twoFfold&in&B16FMDSCs&relative&to&immature&BMFDCs&(Fig.&
5.4.B).& Further,& programmes& STRING& 9.1,& DAVID& Bioinformatics& resources& 6.7,& and&
PANTHER& were& used& to& perform& molecular& network& and& pathways& analyses& of& the&
differentially& expressed&proteins.& In& this&way,& insight&was& gained& into& the&differentially&
activated& and& deactivated& intracellular& pathways& of& MDSCs,& compared& to& DCs.& This&
systems& biology& approach& allowed& the& grouping& of& upFregulated& proteins& within& B16F
MDSCs& into& several& localized& groups&within& the& cell& (Fig.& 5.4.C).&A& range&of&membrane&
receptors& were& shown& to& be& upFregulated& within& B16FMDSCs,& including& cFtype& lectin&
receptors,& adhesion& molecules,& and& TLRFassociated& molecules& (Chi3l3,& Clec10a,& Mgl2,&




have&been&recently& found&to&be&specific& targets& for&MDSC&depletion& in#vivo& in& tumourF
bearing& mice& (Cheng,& Corzo& et& al.& 2008;& Qin,& Lerman& et& al.& 2014).& In& addition,& these&
molecules& were& linked& to& phagocyte& migration& to& sites& of& inflammation,& chemotaxis,&
immune&regulation,&clathrinFdependent&endocytosis,&and&Src&signalling.&The&Src&signalling&
pathway&is&linked&to&cell&motility&and&division.&CD180&was&linked&to&TLR&signalling,&while&
thrombospondin& 1& (Thbs1)& was& associated& to& integrin& family& proteins,& negative&
regulation&of&DCs,&and&responses&to&hypoxia.&Response&to&hypoxia&is&important&in&MDSC&
biology& as& MDSCs& are& known& to& function& and& even& differentiate& in& hypoxic& tumour&
environments& (Corzo,&Condamine&et&al.&2010).&Enhanced&protein&expression&of&clathrin&
light& chain&A& (Clta),& alphaFactininF4& (Actn4),& vesicleFfusing&ATPase& (Nsf),& synaptosomalF
associated& protein& (Snap& 23),& and& vesicleFassociated& membrane& proteinFassociated&
protein& A& (VAPA)& in& B16FMDSCs& indicated& further& involvement& of& endocytosis,& vesicle&
trafficking,&and&fusion&in&MDSC&function.&STRING&analyses&of&these&proteins&(Fig.&5.4.D,E)&
showed& association& with& intracellular& signalling& pathways& SRC,& Grb2& (Growth& factor&
receptorFbound&protein&2),&Ras,&Stat3,&NFFκB&and&MAPKs,&all&of&which&are&known&to&be&
active& in& MDSCs& (Gabrilovich,& OstrandFRosenberg& et& al.& 2012).& Some& SRC& family&
members& such& as& Fyn& kinase& have& been& recently& predicted& to& play& a& role& in& MDSCs&
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(Aliper,& FriedenFKorovkina& et& al.& 2014).& STAT3,& for& example,& is& a& known& melanoma&
MDSCFspecific& target& (Emeagi,& Maenhout& et& al.& 2013).& RNA& helicase& Ddx3x,& splicing&
factor& 3A& (Sf3a1),& Lrrc59& (mRNA& splicing),& lamin& B2& (Lmnb2),& fibrillarin& (Fbl),& and&
glucosidase& II& subunit& β& (Prkcsh)& are& associated& with& transcription,& splicing,& and&
translation.& Enhanced& expression&of& these& proteins& suggested& that&ex# vivo& B16FMDSCs&
were&not&quiescent&and&could&function&under&hypoxic&conditions.& In&addition,&enzymes&
associated& with& aerobic& cellular& respiration& and& glycogen/glucose& metabolism& were&
downFregulated& in& B16FMDSCs,& compared& to& BMFDCs.& This& was& represented& by& a&
decrease& in& expression& of& coenzyme& Q10& (ubiquinone),& NADH& dehydrogenase&
flavoprotein& 2& (Ndufv2),& creatine& kinase& (Ckb),& glycogen& phosphorylase& (Pygl)& and&
phosphoglucomutaseF1& (Pgm1)& (Table& 5.1).& Not& only& did& B16FMDSCs& downFmodulate&
proteins& linked&to&glycogen/glucose&metabolism&but&also&showed&enhanced&expression&
of& proteins& associated& with& lipid& metabolism,& indicating& a& shift& in& energy& production&
within& this& cell& type.& Enhanced& expression& of& ApoB& receptor& (lipoprotein& endocytosis)&
and& peripilinF3& (Plin3,& lipid& storage,& hydrolysis& and& metabolism)& were& linked& to& lipid&
metabolism.& In& addition,& mitochondrial& proteins& associated& to& lipid& metabolism& and&
amino& acid& synthesis,& such& as& aldehyde& dehydrogenase& (Aldh3),& glycine&
amidinotransferase& (Gatm),& ornithine& aminotransferase& (Oat),& cisFaconitic& acid&
decarboxylase& (IRGF1)& and& methylenetetrahydrofolate& dehydrogenase& (Mtfhd2),& were&
found&to&be&increased&in&B16FMDSCs.&Lysosomal&enzymes&were&also&downFmodulated&in&
B16FMDSCs,& as&well& as& enzymes& involved& in& βFoxydation& (Table& 5.1.B).& These& included&
peroxysomal& acylFCoA& oxidase& (Acox3),& trifunctional& enzyme& subunit& β& (Hadhb),& and&
carnitine&OFpalmitoyltransferase&(Cpt1a).&
Very& interestingly,& it& was& found& that& MDSCs& upFregulated& a& group& of& ROS&
scavenger&proteins&and&detoxifying&enzymes,&such&as&cytochrome&p450&reductase&(Por&or&
P450R),& epoxide& hydrolase& 1& (EphxF1),& heme& oxygenase& 2& (Hmox2)& and& superoxide&
dismutase&2& (Sod2).& These&enzymes& can&be& linked& to&ROS&production,&protection& from&
oxidative& damage,& and& in& NADP/NADPHFdependent&metabolism.& This& is& important& for&
MDSCs,&to&counteract&the&generation&of&highly&toxic&metabolites&generated&by&NOS&and&
ROS&production&as&well&as&lipid&metabolism&(Fig.&5.4.E).&
Further,& the&proteome&of&B16FMDSCs&was&compared& to& the&proteome&of&293TF
MDSCs& (Table& 5.2).& The& percentage& of& identified& differentially& expressed& proteins&
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between&B16FMDSCs&and&DCs&was&2%.&This&percentage&was&further&reduced&to&0.4%&(11&
of& 3100& identified& proteins)& when& quantitatively& comparing& the& two& different& ex# vivo&
MDSC& cell& types.&While& 3& proteins&were&upFregulated,& 9&were&downFregulated& in& B16F
MDSCs& (Table& 5.2& and& Fig.& 5.4.G).& UpFregulated& proteins& in& B16FMDSCs& possessed&
antioxidant& properties,& such& as& peroxiredoxin& 6& (Prdx6)& and& superoxide& dismutase& 1&
(Sod1).&These&proteins&play&a&role&in&protection&of&cells&from&oxidative&stress.&In&addition,&
DF3Fphosphoglycerate& dehydrogenase& exhibited& enhanced& protein& expression& in& B16F
MDSCs,&which&is&a&known&regulator&of&amino&acid&synthesis.&Interestingly,&similar&to&the&






































































dehydrogenase&& 0.79& 0.79& 0.57& 0.60& 0.53& 0.30& 0.07& 0.00& 0.00& 0.00& &18.95& 10&
! Tendency!to!up+
regulation!in!
B16+MDSCs& & & & & & & & & & & & &




Zn]&& 0.83& 0.78& 0.62& 0.63& 0.62& 0.49& 0.21& 0.01& 0.00& 0.06& &46.1& 9&
! Down+regulated!
proteins!in!B16+
MDSCs& & & & & & & & & & & & &
Slc2a6! Protein&Slc2a6&& 1.03& 1.01& 1.84& 1.68& 1.32& 0.76& 0.93& 0.00& 0.08& 0.40& &10.46& 5&
Cd38!
ADPFribosyl&





mitochondrial&& 0.89& 0.83& 1.33& 1.50& 1.31& 0.31& 0.39& 0.02& 0.00& 0.03& &34.08& 22&
Vim! Vimentin&& 0.83& 1.00& 1.72& 1.69& 1.40& 0.06& 0.99& 0.00& 0.00& 0.02& &83.26& 56&
Arg1! ArginaseF1&& 0.85& 0.88& 2.47& 2.52& 2.63& 0.18& 0.71& 0.01& 0.00& 0.00& &43.96& 15&
! Tendency!to!
down+regulation!
in!B16+MDSCs& & & & & & & & & & & & &








homolog&& 0.98& 0.00& 1.67& 1.37& 1.31& 0.69& 0.91& 0.03& 0.01& 0.22& &26.29& 7&





hydrolase&25&& 0.99& 1.05& 1.59& 1.35& 1.46& 0.94& 0.70& 0.03& 0.08& 0.14& &1.232& 3&
#
Table#5.2.#Differentially#expressed#proteins#from#ex#vivo#B16FMDSCs#and#293TFMDSCs.#
iTRAQ# isobaric# tags# coupled# to# 2D# nano8liquid# chromatography# tandem# mass#
spectrometry#was# used# to# identify# the# proteomes# of# the# two#myeloid# cell# types.# Table#
indicates# the# abundance# of# the# indicated# proteins# from# 293T8MDSCs,# relative# to# B168
MDSCs.# All# proteins#were# identified#with# >99%# confidence# (corresponding# to# a# protein#
score# cutoff# >2.0).# 293T.1,# 293T.2,# and# 293T.3# together# with# B16.1,# B16.2,# and# B16.3#
correspond# to# the# three# independent# biological# replicates# from# 293T8MDSCs# and# B168
MDSCs,#respectively.#The#ratio#of#protein#expression#levels#between#the#two#cell#types#are#
indicated# and# correspond# to# the# protein# reporter# ion# intensity# originating# from# B16.2#
(Tag114),# B16.3# (Tag115),# 293T.1(Tag116),# 293T.2(Tag117),# 293T.3(Tag118)# relative# to#
B16.1(Tag113).# Proteins# were# considered# to# show# a# significant# upward# or# downward#














MDSCs.# (B)# Bar# graphs# represent# the# ratio# between# the# percentage# of# differentially8
expressed# proteins# between# B168MDSCs# and# BM8DCs# over# the# total# detected# myeloid#
proteins,# grouped# according# to# cell# location.# Highest# relative# changes# in# protein#
expression# are# indicated# by# arrows.# (C)# Schematic# representation# of# B168MDSC# up8
regulated#proteins,#according#to#cellular#location,#biological#relationships,#and#pathways.#
String# 9.1,# DAVID,# and# Panther# programs# were# used# to# assess# differential# protein#
relationships.# Direct# pathways# between# indicated# protein# groups# are# indicated# by#
arrows.#Detoxifying# enzymes#are# indicated# in# red.#Green#boxes# indicate#pathways# that#
are# predicted# to# be# activated,# according# to# biological# reactions# between# up8regulated#
proteins.# (D8E)# String#9.1#networks#are# represented,#using# the# confidence#view.#Thicker#
lines# connecting# proteins# indicate# a# higher# confidence# of# protein# interaction.# Up8
regulated# B168MDSC# proteins# are# indicated# with# arrows# and# represent# nodes# of#
interactions.# Proteins# that# are# predicted# to# interact# with# up8regulated# proteins# are#
grouped#according#to# interaction#and# function.# (F)#Same#as# in#C,#but# representing#B168
MDSC# up8regulated# proteins,# as# compared# to# non8neoplastic# control# 293T8MDSC#
proteome.#
5.2.4.!! P450! REDUCTASE,! UNCOVERED! BY! QUANTITATIVE! PROTEOMICS,! ACTS! AS! A!
MDSC+SPECIFIC!CHEMOTHERAPY!TARGET!!
Quantitative& proteomics& comparing& B16FMDSCs&with& BMFDCs& and& 293TFMDSCs&
confirmed& and& highlighted& several& MDSCFassociated& pathways.& Further,& I& strove& to&
validate&newly& identified&proteins&through&this&method.&P450R&(or&Por)&expression&was&
highly& upFregulated& in& MDSCs,& relative& to& conventional& immature& BMFDCs,& and& was&
selected& for& further& analysis& as& a& potential& MDSCFspecific& target& (Table& 5.1& and& Fig.&
5.5.A.).& First,& enhanced& P450R& expression& in& MDSCs& was& confirmed& by& western& blot&
analysis&(Fig.&5.6.B).&P450R&was&selected&as&a&candidate&of&interest&as&it&plays&a&role&in&the&
activation/metabolism&of& chemotherapeutic& proFdrugs,& leading& to& cytotoxicity& and& cell&
growth& arrest& of& tumour& cells& (Kivisto,& Kroemer& et& al.& 1995;&Martinez,&Williams& et& al.&
2008).& In& addition,& some& chemotherapeutic& agents& have& been& found& to& selectively&
diminish&MDSC&populations&in&experimental&animals&(Suzuki,&Kapoor&et&al.&2005;&Vincent,&
Mignot&et&al.&2010;&Sevko,&Michels&et&al.&2013).&As& the&mechanism& for&MDSC&selective&
cytotoxicity& by& certain& chemotherapeutic& drugs& is& unkown,& the& hypothesis& that&
differential& P450R& expression& was& crucial& in& this& process,& was& tested.& Paclitaxel,&
Docetaxel,& and& Irinotecan& are& chemotherapeutic& agents& with& differing& therapeutic&
efficacies& in&melanoma& patients.& Importantly,& P450R& acts& differentially& on& these& three&
chemotherapeutic& agents.& P450/P450R& convert& the& proFdrug& Paclitaxel& into& its& toxic&
form&and& it& is&an&effective&antiFmelanoma&agent& that&also&depletes&MDSCs& (RodriguezF
Antona&and& IngelmanFSundberg&2006;&Sevko,&Michels&et&al.&2013).&On& the&other&hand,&
Docetaxel&is&not&effective&in&melanoma&patients&and&not&processed&in&the&same&way&as&
Paclitaxel& by& P450& cytochromes& (Tas,& Camlica& et& al.& 2003;& Vaclavikova,& Soucek& et& al.&
2004;& RodriguezFAntona& and& IngelmanFSundberg& 2006).& Irinotecan& is& neutralized& by&
P450R&and&activated&by&carboxylesterases&and&could&thus&serve&as&a&control&(Wu,&Yan&et&
al.& 2002).& MDSCs& and& conventional& immature& BMFDCs& were& treated& with& the& three&
chemotherapeutic& agents& and& the& effect& on& viability& was& tested& and& compared.&
Published& cytotoxic& concentrations& over& cancer& cell& lines& of& each& chemotherapeutic&
agent&were&used&and&viability&was&assessed&after&24&hours&of&treatment&by&trypan&blue&
staining.&Interestingly,&Paclitaxel&(200nM)&was&selectively&cytotoxic&to&MDSCs&while&BMF
DCs& remained& viable.& In& contrast,& Docetaxel& (50nM)& and& Irinotecan& (32μM)& did& not&
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exhibit& a& significantly& different& effect& on& the& two&myeloid& cell& populations& (Fig.& 5.5.C).&
Hence,&Docetaxel&and&Irinotecan&affected&BMFDCs&and&MDSCs&similarly,&while&Paclitaxel&
selectively&killed&MDSCs.&
As& Paclitaxel& is& activated& by& P450R& into& its& toxic& form,& it& was& tempting& to&
hypothesize& that& P450R& expression& is& crucial& to& its& MDSCFselective& cytotoxicity.& To&
confirm&that&indeed&P450R&expression&within&target&cells&conferred&selective&PaclitaxelF
mediated& cytotoxicity& towards&MDSCs,& P450R& expression&was& silenced&within&myeloid&
cell&populations.&For&this&purpose&a&lentivector&encoding&a&shRNA&specific&for&P450R&was&
constructed&(Fig.&5.5.D).&BM&cells&were&transduced,&followed&by&differentiation&towards&




the& cytotoxic& effect& of& Irinotecan.& Taken& together,& this& data& suggested& that& P450R&
expression& was& enhanced& in& MDSCs& and& that& it& causes& the& selective& cytotoxicity& of&









Fig.# 5.5.# High# expression# of# P450R# renders# B16FMDSCs# susceptible# to# Paclitaxel.# (A)#
String#9.1#network#depicting#P450R#and#its#interactions.#(B)#Western#Blot#performed#with#
anti8P450R#antibody# in#BM8DCs,#293T8MDSCs,#and#B168MDSCs.#GADPH#expression#was#
used# as# a# control# as# it# was# expressed# at# same# levels# according# to# quantitative# mass#
spectrometry.# P450R#was# therefore# very#highly# expressed# in#MDSCs,# compared# to#BM8
DCs.#(C)#Myeloid#cells#were#treated#overnight#with#indicated#chemotherapeutic#drugs,#at#
known# cancer# cell# cytotoxic# concentrations.# Bar# graphs# represent# the# ratio# of# drug8
treated#over#untreated#myeloid#cells#as#a#percentage.#Error#bars#correspond#to#standard#
deviations.# (D)# Above,# schematic# representation# of# the# lentivector# construct# used# to#
deliver# P450R8silencing# shRNAs.# Below,# detection#of# P450R#or#GADPH#by#Western#Blot#
after# transduction# of# B16# cells# with# P450R8silencing# lentivectors.# Three# shRNAs# were#
tested# and# P450R8shRNA# 2# (indicated# with# an# asterisk)# was# selected# for# myeloid# cell#











survival& in& a& rapidly& growing& B16& tumour& model.& IL12& exerts& multiple& effects& over& a&
variety&of& cell& types&within& the& tumour.& It& is&becoming& increasingly&clear& that& IL12&also&
affects& immature& and& suppressive&myeloid& cells&within& the& tumour& environment,& thus&
contributing&to&tumour&regression&(Kerkar,&Goldszmid&et&al.&2011).&As&MDSCs&comprise&
about& 5%& of& cells& within& B16& tumours& (data& not& shown),& purification& of& sufficient&
tumourFinfiltrating&MDSCs& for& functional& experiments&with& a& high& number& of& different&
treatment& conditions& is& highly& impractical.& Therefore,& a& novel& system& to& assess& antiF
cancer&treatments&ex#vivo&on&MDSCs&was&developed&during&the&course&of&this&PhD&thesis&
(Chapter&4).&Using&ex#vivo&differentiated&B16FMDSCs,&it&was&found&that&the&IL12Fp1Fbased&
lentivector& could& confer& T& cell& stimulatory& activities& upon& this& immunosuppressive& cell&
type& (Fig.& 5.2).& Lentivectors& containing& cytokines& IFNγ,& IL10,& or& TGFβ& did& not& induce&
significant&changes& in&T&cell&activation.&While&transduction&of&B16FMDSCs&with& IL12Fp1F
IiOVA& lentivectors& triggered& T& cell& responses& to& OVAFpresenting&MDSCs,& this& was& not&
accompanied&by&significant&phenotypic&myeloid&maturation.&Nevertheless,&it&was&shown&
that& transduction& with& the& IL12Fp1Fbased& lentivector& could& confer& antigen& presenting&
capabilities&upon&B16FMDSCs,&correlating&with&antiFtumour&activities&of&this&lentivector.&&
Further,& IL12& did& not& have& to& be& produced& by&MDSCs& themselves& to& overcome&
MDSC&suppressive&activities&(Fig.&5.3).&This&is&important&for&application&in&the&therapeutic&
experimental&setting,&as&the&majority&of&cells&transduced&during&intraFtumour&lentivector&
injection& are& tumour& cells& (about& 80%)& (Emeagi,& Thielemans& et& al.& 2012).& In& standard&
suppression&assays& (using&CD3/CD28&activated&CD8&T& cells),& addition&of& IL12& to& culture&
medium&led&to&an&increase&in&the&percentage&of&activated&CD8&T&cells&over&MDSCs&and&an&
increase& in& IFNγ& secretion& (Fig.& 5.3).& It& is& well& established& that& IL12& stimulates&
proliferation&of&activated&T&cells&while&resting&T&cells&do&not&proliferate&in&the&presence&of&
IL12.& In& addition,& IL12& induces& IFNγ& production& by& NK& cells,& CD4& and& CD8& T& cells& and&
polarizes&naïve&T&cells&into&Th1.&(Bertagnolli,&Lin&et&al.&1992;&Lee,&Suen&et&al.&1998).&Thus,&





of&activated&CD8&T&cells& in&this&experiment.&What&the&direct&effect&of& IL12&on&MDSCs& is&
remains&to&be&elucidated,&but&it& is&clear&that&IL12&retains&its&stimulatory&effects&even&in&
the&presence&of&highly&suppressive&MDSCs.&&
Nevertheless,& other& researchers& showed& that& preFtreatment& of& tumourF




Steding&et&al.& found&an& increase& in&surface&markers&MHC& II&and&F4/80&but&not&CD80&or&
CD86& on& tumourFinfiltrating& MDSCs& following& IL12& treatment& in# vitro.& Interestingly&
splenic&MDSCs& from&tumourFbearing&mice&upFregulated&CD80,&CD86,&MHCII,&and&F4/80&
expression& in& response& to& IL12,& indicating& significant& differences& between& spleen& and&
tumour&MDSCs.&On&the&other&hand,&adenovirusFmediated&IL12&led&to&upFregulation&of&all&




adenoviral& vectors& encoding& IL12,& representing& a& possible&mechanism& for& overcoming&
MDSC&suppressive&activity& (Steding,&Wu&et&al.&2011).&Studies& transferring&engineered&T&
cells& secreting& IL12& have& similarly& shown& effects& on& tumourFinfiltrating& myeloid& cells.&
Myeloid& cells& from& treated&mice& could& stimulate& CD8& proliferation& in# vitro& while& cells&
from&mockFtreated&mice& did& not& (Kerkar,& Goldszmid& et& al.& 2011).& Taken& together,& the&
data&from&this&thesis&and&other&studies&suggests&that&IL12&has&direct&immunostimulatory&
effects& on& tumourFinfiltrating& MDSCs,& overcoming& their& suppressive& functions& and&
converting& them& into& efficient& APCs& with& potential& antiFtumour& activities.& Aiding& this&
effect& may& be& the& positive& feedback& loop& of& IL12,& as& IL12Fmediated& IFNγ& induction&
induces&myeloid&cells&to&produce&more&IL12&(Yoshida,&Koide&et&al.&1994).&
Addition&of&PDF1&blocking&antibodies& to& suppression&assays&did&not& significantly&
enhance& the& stimulatory& activity& of& IL12& (Fig.& 5.3).& In# vivo& there& were& significant&
synergistic& effects& of& IL12& expression& and& PDFL1& silencing,& especially& in& prophylactic&
vaccinations& (Fig.&3.7).&Blocking&of&PDFL1&has&been& shown& to& impair&MDSC&suppressive&
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activity& (Chikamatsu,& Sakakura& et& al.& 2012;& Noman,& Desantis& et& al.& 2014).& It& could& be&
hypothesized& that& IL12& may& mask& the& adjuvant& effect& of& PDF1& blocking& in& the&
experiments&performed& in& this& thesis.& Importantly,& functional& assays& involving& two&cell&
types&do&not&reflect& the&complexity&of& the& in#vivo& situation&since&they&do&not&take& into&
account& various& other& cell& types& and& molecules& present& within& the& tumour&
microenvironment.& Accordingly,& it& was& shown& that& PDFL1& silencing& in& cells& of& nonF
haematopoietic& origin& at& the& injection& site& confers& adjuvant& effects& in# vivo,& leading& to&
enhanced&T&cell&responses&(Fig.&3.10).&
Taking& advantage& of& the& newly& developed& MDSC& differentiation& system& two&
quantitative& proteomic& experiments& were& performed,& comparing& BMFDCs& and& B16F
MDSCs&as&well&as&MDSCs&from&different&“environments”.&In&this&way&the&changes&elicited&
in& the& twoFstep& development& of& MDSCs& were& dissected,& the& first& step& being& the&
mobilization&of&immature&myeloid&cells&and&the&second&step&being&further&acquisition&of&
MDSCFassociated& characteristics& depending& on& the& tumour& environment& (Talmadge&
2007;& Gabrilovich,& OstrandFRosenberg& et& al.& 2012).& The& proteomic& data& and& analyses&
highlighted&several&important&changes&between&MDSCs&and&DCs.&MDSCs&upFregulated&a&
range& of& membrane& receptors,& which& could& be& linked& to& TLR& signalling,& phagocyte&
migration& to& inflammatory& sites,& immune& regulation,& and& blocking& of& myeloid&
differentiation& and&maturation.& This& data& revealed& that&MDSCs& are&not& quiescent& cells&
but& are& involved& in& cell& cycle& progression,& growth,& proliferation,& active& movement,&
transcription,& splicing,& translation,&and&protein& transport.&These&processes& require&high&




as& P450R,&Hmox2,& and& Sod2&were& elevated& in&MDSCs& (Table& 5.1& and& Fig.& 5.4).& Sod2& is&
elevated& in& TAMs& and& tumour& cells,& thus& representing& a& potential& TAM/MDSCFspecific&
therapeutic& target& (Hartmann,& Tousseyn& et& al.& 2013).& S100& family& proteins& represent&
known&and&important&MDSC&targets&(Cheng,&Corzo&et&al.&2008;&Sinha,&Okoro&et&al.&2008;&
Qin,&Lerman&et&al.&2014)&and&they&could&be&linked&to&upFregulated&proteins&in&B16FMDSCs&
(Fig.& 5.4.D).& This& data& correlates& with& the& S100& autocrine& feedback& loop& in& tumourF
bearing& hosts,& causing& enhanced& MDSC& accumulation& (Sinha,& Okoro& et& al.& 2008).&
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Similarly,& a& connection& to& hallmark& MDSC& enzymes& iNOS& and& ArgF1& as& well& as&
transcription&factor&STAT3&could&be&established&(Fig.&5.4.D,E).&STAT3&is&one&of&the&main&
transcription&factors&leading&to&MDSC&differentiation,&accumulation,&tumour&infiltration,&
and&suppressive& function& in& tumourFbearing&hosts& (Corzo,&Cotter&et&al.&2009)& (Fig.&5.1).&
After& finishing& this& PhD& thesis,& further& inFdepth& proteomic& studies& were& performed,&
which& highlighted& mitochondrial& dysfunction& and& MHC& II& downFmodulation,& together&
with& other& proteins& involved& in& chemotaxis,& immune& cell& trafficking,& intracellular&
signalling,&and&reduced&antigen&presenting&capacities&(data&not&shown).&&
As&expected,&comparing&the&proteomes&of&293TF&and&B16FMDSCs&resulted&in&the&
identification& of& fewer& differentially& expressed& proteins.& Particularly& important& were&
changes& in& energy& metabolism& and& proteins& involved& in& the& generation& and&
neutralization&of&ROS&and&RNS.&The&B16FMDSC&proteome&”emphasized”&on&detoxifying&
processes,& while& 293TFMDSCs& upFregulated& proteins& involved& in& the& mitochondrial&
electron& transport& chain& and& NADPH& oxidase& activities.& Again,& after& finishing& this& PhD&
thesis,&further&inFdepth&analyses&were&carried&out&which&linked&ROS&production&and&the&
regulation& of& energy& metabolism& by& driving& the& carbohydrate& flux& to& the& pentose&
phosphate& pathway& (PPP)(data& not& shown).& Interestingly,& ArgF1& expression& was&
enhanced& in& 293TFMDSCs& as& detected& by& proteomics& (Table& 5.2).& Differential& ArgF1&
expression&supports&the&theory&that&MDSCs&acquire&further&suppressive&activities&upon&
tumour&infiltration.&&
Important& intracellular& signalling& molecules& that& were& linked& to& MDSC&
development& shown& during& the& analyses& of& all& the& proteomic& data& included& STAT3,&
MAPK/ERK,&PKC,&SRC,&NFFκB,&Ras,&Grb2,&mTOR,&and&Akt&(Fig.&5.4,&Fig.&5.5,&and&data&not&
shown).&Further,&proteomic&analyses&uncovered&major&changes&in&the&mitochondria.&On&
one& hand& these& changes& produce&more& ROS& species& and& on& the& other& they& neutralize&
ROS&species.&Interestingly,&similar&processes&have&been&observed&in&cancer&cells.&Cancer&
cells&exhibit&mitochondrial&metabolic& reprogramming&and&higher&ROS& levels& than&other&
cells.&And&much&of&cellular&glucose&is&metabolized&through&the&PPP&in&cancer&cells&(Kang,&
Lee& et& al.& 2015).& The& detrimental& effects& of& ROS& and& RNS& on& NK& and& T& cells& are& well&




Differentially& expressed& proteins& and& conclusions& from& the& proteomic& analyses&
were& confirmed& by& published& results.& Nevertheless,& P450R& was& selected& to& further&
validate& the& proteomic& data,& due& to& its& role& in& the& activation/metabolism& of&
chemotherapeutic& proFdrugs.& B16FMDSCs& showed& enhanced& P405R& expression,& which&
conferred& selective& cytotoxicity& of& the& chemotherapeutic& agent& paclitaxel.& In& contrast,&
docetaxel&and& irinotecan&did&not&selectively&deplete&MDSCs&(Fig.&5.5.B,C).& Interestingly,&
docetaxel& and& irinotecan& alone& or& in& combination& do& not& appear& to& be& effective& in&
melanoma&patients&(Tas,&Camlica&et&al.&2003).&Importantly,&silencing&of&P450R&in&MDSCs&
abolished& the& selective& cytotoxicity& of& paclitaxel& (Fig.& 5.5.D,E).& This& mechanistically&
explains&for&the&first&time&why&the&proFdrug&paclitaxel&selectively&depletes&MDSCs&in#vivo,&
which& is& thought& to& contribute& to& improved& antiFmelanoma& efficacy& in& patients&
compared&to&other&chemotherapeutic&treatments.&
The& effect& of& paclitaxel& on&MDSCs& may& be& tumourFtype& dependent.& In& an& EL4&
thymoma& mouse& model& several& chemotherapeutic& agents& (including& paclitaxel)& were&
compared&for&their&effect&on&MDSC&levels&within&spleen&and&tumour&beds.&Interestingly,&
in&this&study,&the&only&agents&significantly&depleting&MDSCs&in#vivo&were&gemcitabine&and&
5Ffluorouracil.& Paclitaxel& on& the& other& hand& did& not& lead& to& a& significant& reduction& in&
MDSC&levels&(Vincent,&Mignot&et&al.&2010).&It&would&be&of&interest&to&assess&whether&EL4F
MDSCs&express&high&levels&of&P450R.&Other&researchers&showed&that&paclitaxel&prolongs&
survival& and& reduces& tumour& burden& in& a& ret& transgenic& melanoma& mouse& model.&
Paclitaxel&administration&in&this&spontaneous&melanoma&model&reduced&the&number&of&
tumourFinfiltrating& MDSCs& as& well& as& their& T& cell& suppressive& activities.& Interestingly,&
MDSC& NO& production& and& STAT3& activation& but& not&MDSC& numbers& were& reduced& in&
metastatic& lymph& nodes.& Importantly,& paclitaxel& did& not& affect& DC& or& macrophage&
populations&within& tumours.&Thus,&paclitaxel&mediated& its&effect& in#vivo& in&a& tissue&and&
cell& type& specific& manner.& TumourFinfiltrating& MDSCs& exhibited& reduced& p38& MAPK&
activity,&TNFα&production,&and&S100A9&expression,&following&paclitaxel&treatment&(Sevko,&
Michels& et& al.& 2013).& As& previously& discussed,& STAT3& and& S100A9& are& important&
molecules& in& MDSC& biology& and& p38& MAPK& activation& in& myeloid& cells& reduces& DC&




As& the& authors& previously& published& in# vitro& data& showing& paclitaxelFmediated& MDSC&
differentiation&to&functional&conventional&DCs,&it&was&suggested&that&the&in#vivo&decrease&
of&MDSCs&could&be&due&to&differentiation&(Michels,&Shurin&et&al.&2012;&Sevko,&Michels&et&
al.& 2013).& Although& MDSC& and& DC& markers& were& not& assessed& following& paclitaxel&
treatments& in& this& thesis& it&was&clear& that&paclitaxel&mediated&selective&cytotoxicity.&Of&
note,& Sevko& et& al.& used& nonFcytotoxic& concentrations& while& cytotoxic& concentrations&
were& used& in& this& thesis.& It& would& be& of& interest& to& assess& the& B16FMDSC& phenotype&
following&paclitaxel&treatment&at&cytotoxic&concentrations.&&
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modulating& coFstimulation& during& antigen& presentation.& This& project& developed& from&
previous& results& of& our& laboratory.& Karwacz& et& al.& found& that& PDFL1& silencing& inhibited&
TCR&downFmodulation&during&antigen&presentation&in#vitro&and&in#vivo.&T&cells&activated&
by& PDFL1Fsilenced& DCs& exhibited& enhanced& proliferation& and& produced& increased& IFNγ&
and&IL17.&These&T&cells&thus&represented&a&hyperFactivated&T&cell&population&with&a&proF
inflammatory&phenotype.&Therapeutic& transfer&of&PDFL1&silenced&DCs& in&an&EG7&mouse&
lymphoma& model& (with& OVA& surrogate& tumour& antigen& expression)& led& to& reduced&
tumour&growth&and&an&increase&in&life&span.&However,&overall&survival&after&one&month&
remained& the& same& and& PDFL1& silencing& had& to& be& combined& with& DC& molecular&
activators& to& increase& therapeutic& efficacy.& Thus,& it& was& suggested& that& while& PDFL1&
silencing&in&DCs&may&speed&up&T&cell&expansion&and&cytokine&secretion,&additional&factors&
were&needed&to&convey&effector&functionality&to&activated&T&cells&(Karwacz,&Bricogne&et&
al.& 2011).& I& therefore& set& out& to& construct& and& test& lentivectors& that& would& not& only&
deliver&an&antigen& in&combination&with&PDFL1&silencing&but&would&also&ensure&cytokine&
signalling& to& confer& acquisition& of& effector& T& cell& capacities.& Lentivector& constructs&
containing& a&wide& range& of& T& cell& polarizing& cytokines&were& constructed& and& tested& in#
vitro&in&antigen&presenting&assays&and&in#vivo&in&healthy&and&tumourFbearing&mice.&&
While& early& efforts& in& cancer& immunotherapy& approaches&were&mainly& focused&
on&enhancing&the&number&of&tumourFspecific&immune&effector&cells,&little&attention&was&
paid& to& the& effect& these& treatments& could& have& on& the& immunosuppressive& tumour&
microF& or& macroFenvironments.& The& crucial& question& to& ask& is& whether& stimulated&
immune& effector& cells& would& be& able& to& eliminate& cancer& cells& within& the&
immunosuppressive& tumour& environment.& The& immunosuppressive& mechanisms& are&
manifold& and& include& amongst& others,& the& recruitment& and& differentiation& of&
immunosuppressive& cell& types& and& the& upFregulation& of& negative& coFstimulatory&
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molecules& by& cancer& cells& and& immune& cells.& Lentivector& vaccination& can& lead& to&
increased& PDFL1& expression& on& tumour& cells& and& tumourFinfiltrating& leukocytes,& which&
can&be&counteracted&by&blocking&of&PDFL1&signalling,&thus&leading&to&a&partial&recovery&of&
T&cell&effector&functions&and&enhanced&lentivector&efficacy&(Zhou,&Xiao&et&al.&2010).&Thus,&
the& lentivectors& constructed& in& this& thesis,& by& silencing& PDFL1& in& transduced& cells,&
counteracted&this&route&of&immune&suppression.&While&immunosuppressive&cells&use&PDF







lack&of&clinical&efficacy&of& immunotherapeutic&approaches& is&now&generally&believed& to&
be& due& to& immunosuppression,& for&which&MDSCs& are& largely& responsible.& Thus,&MDSC&
biology& has& become& of& increasing& interest& in& the& fields& of& experimental& and& clinical&
cancer& immunology& (Escors,& Liechtenstein& et& al.& 2013;& Iclozan,& Antonia& et& al.& 2013).&
Considering&these& issues& I& realized&the& importance&of&cancer& immunotherapy&regimens&
to& contain&elements& initiating&TAAFspecific& responses&while& at& the& same& time&ensuring&
that& these&approaches&can&overcome& the& immunosuppressive&elements&of& the& tumour&
environment,&especially&those&of&MDSCs.&Thus,&an&ex#vivo&MDSC&differentiation&protocol&
was& developed& to& test& antiFcancer& immunotherapeutic& treatments& in# vitro,&
circumventing&the&need&to&purify&tumourFinfiltrating&MDSCs&from&a&significant&number&of&
tumourFbearing&mice.&The&ex#vivo&MDSC&differentiation&system&produces&large&numbers&







activation& of& T& cells& but& not& effective& antiFtumour& activities.& It& was& hypothesized& that&
additional& signals& needed& to& be& conveyed& in# cis& to& T& cells& and& thus& lentivectors&
containing& cytokine& transgenes& were& constructed.& In& this& context,& the& most& effective&
cytokine& was& IL12,& which& could& be& predicted& by& the& DCFT& cell& as& well& as&MDSCFT& cell&
assays.& This& suggested& that& there& is& an& advantage& of& using& both& these& assays& for& the&
preclinical&assessment&of& cancer& treatments.& Further,& vaccination&of&healthy&mice&with&
lentivectors& encoding&OVA& transgenes& as&well& as& using& tumour&models&with& surrogate&
antigen& OVA& expression& had& limited& predictability.& A& B16& melanoma& model& without&
surrogate&antigens&was&therefore&used,&which&revealed&the&beneficial&effects&of&the&IL12F
p1Fbased& lentivectors.& In& this& experimental& model,& induction& of& antiFcancer& immune&
responses& is& more& challenging,& making& it& a& more& realistic& and& more& relevant& tumour&
model.& Cancer& cells& express& either&mutated&or& altered& levels& of& selfFantigens& and& thus&
cancer& immunotherapy& treatments& need& to& overcome& the& natural& tolerance& towards&
these&antigens.& In& addition,&mice&were& vaccinated&only&once,&both& in&prophylactic& and&






resident& myeloid& cells,& IL12& delivery& counteracts& the& skewing& of& the& tumour&
microenvironment.& IL12& has& antiFtumour& as& well& as& immunostimulatory& properties,&
allowing& for& a&multitude&of& antiFtumour&mechanisms&within& the& tumour.& Initially& I&was&
somewhat&surprised&that&the&IFNγFp1Fbased&lentivectors&did&not&exhibit&antiFmelanoma&
protective&effects&as& IFNγ& is&central& to&the&endogenous&antiFtumour& immune&response.&
Due&to&the&intensified&study&of&the&immunosuppressive&mechanisms&it&is&now&becoming&





For&any&successful& cancer& immunotherapy&strategy,& to&achieve&an&effective&and&
potent& TAA& presentation& to& effector& cytotoxic& T& cells& is& crucial,& especially& CD8& T& cells&
(Bodey,& Bodey& et& al.& 2000;& Escors,& Liechtenstein& et& al.& 2013).& Additionally,& it& is&
fundamental& to& ensure& that& these& effector& cells& will& not& be& inactivated& within& the&
tumour.&PDFL1&is&upFregulated&on&tumour&cells&of&various&cancer&types&and&on&tumourF
infiltrating& myeloid& cells.& PDFL1& upFregulation& is& caused& by& tumourFderived& factors& as&
well&as&the&hypoxic&tumour&environment&(Curiel,&Wei&et&al.&2003;&Noman,&Desantis&et&al.&
2014).& This& suggests& that& therapies& targeting&PDFL1& should&be&beneficial,&which& in& fact&
they&are&(Zhou,&Xiao&et&al.&2010;&Brahmer,&Tykodi&et&al.&2012).&PDFL1&acts&at&two&levels.&
PDFL1&plays&a&role&first&during&antigen&presentation&by&APCs&to&T&cells.&Secondly,&during&
antigen& recognition& on& target& cells& by& effector& cells.& Thus& the& prophylactic& and&
therapeutic& vaccination& regimens& have& to& be& viewed& from& different& angles& and& need&
different& requirements.& In& the& prophylactic& setting,& transduced& cells& with&
haematopoietic&and&nonFhaematopoietic&origins&present&TRP1&in&the&context&of&reduced&
PDFL1& ligation& but& increased& IL12& secretion.& This& may& lead& to& hyperFactivated& TRP1F
specific&T&cells&with&effector&capacities&conveyed&by&IL12.&Thus&tolerance&to&TRP1&can&be&
broken,& which& induces& CD4& and& CD8& T& cells& that& secrete& IFNγ& in& response& to& TRP1F
presenting&DCs.&It&was&shown&that&transduction&of&cells&of&nonFhaematopoietic&origin&at&
the& injection& site& plays& a& crucial& role& for& enhancing& antigenFspecific& T& cell& responses.&
Once& B16& tumours& are& transferred& to& vaccinated& mice,& TRP1Fspecific& effector& T& cells&
recognize& and& eliminate& B16& tumour& cells.& Nevertheless,& in& the& end& most& tumours&
escaped,& apart& from& one& exception& in& which& a& mouse& exhibited& efficacious& recall&
responses&5&months&later.&In&the&therapeutic&experimental&protocol&mainly&tumour&cells&
are& transduced& during& intraFtumour& lentivector& injection.& The& recognition& and&
elimination&of&tumour&cells&by&TAAFspecific&T&cells&is&facilitated&through&inhibition&of&PDF
L1& in& transduced& tumour&cells.& In&addition,&a&number&of& tumourFresident&myeloid&cells&
and& stroma&cells& are& transduced,& assuring& that&CTLs&will& not&be&deactivated&once& they&
reach& the& tumour.& In# vitro& assays& using& ex# vivo& B16FMDSCs& suggested& that& once&
transduced,& tumourFinfiltrating& MDSCs& would& be& capable& of& activating& TAAFspecific&
effector&T&cell&responses.&Taken&together&the&data&presented&in&this&thesis&showed&that&
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the& engineered& lentivectors& could& break& tolerance& to& the& endogenous& TAA& TRP1& and&
prolong&survival&in&prophylactic&and&therapeutic&experimental&protocols.&&&
To& further& elucidate& the& mechanisms& and& effects& of& the& IL12Fp1Fbased&
lentivectors& not& only& their& immunostimulatory& effects& were& assessed& but& also& their&
efficacy& to& overcome& the& effects& of& immunosuppressive&MDSCs.& During& the& course& of&
this& thesis,& an& easy& and& reproducible& system& was& developed& for& the& ex# vivo&
differentiation&of&MDSCs&resembling&in#vivo&cancerFspecific&immunosuppressive&tumourF
infiltrating& subsets.& Importantly,& this&ex# vivo& differentiation& system& included& immature&
stages& of&myeloid& cells,&which& conserved& high& proliferative& capacities& and& plasticity& of&
differentiation.&Ex#vivo&B16FMDSCs&were&highly& immunosuppressive& in#vitro#and& in#vivo&
and&their&responses&to&treatments&could&predict&the&antiFtumour&efficacy&of&the&IL12Fp1F





in&MDSC& biology.& This& strategy& uncovered& that& P450R& is& responsible& for& the& selective&








effects& on& a&wide& range& of& immune& cells.& Due& to& high& toxicity& following& systemic& IL12&
administration& several& groups& have& established& protocols& to& locally& administer& IL12& to&
the& tumour.&Strategies& involve& the& transfer&of& transduced&DCs& (Zhao,&Bose&et&al.&2011)&
and& T& cells& (Chmielewski,& Kopecky& et& al.& 2011;& Kerkar,& Goldszmid& et& al.& 2011;& Kerkar,&
Leonardi&et&al.&2013)&or&direct&vector&injection&(Steding,&Wu&et&al.&2011;&Thaci,&Ahmed&et&
al.& 2014)& and&microsphere& administration& (Watkins,& Egilmez& et& al.& 2007).& An& approach&
similar&to&the&one&described&in&this&thesis&was&the&adoptive&transfer&of&DCs&engineered&to&
secrete& IL12.& This& strategy& slowed& down& B16& tumour& growth& in# vivo& in& mice& through&
priming&of&CD8&T&cell&responses&(Zhao,&Bose&et&al.&2011).&However,&I&propose&that&direct&
intraFtumour&vaccination&may&be&more&beneficial& than& infusion&of&transduced&DCs&as& it&
ensures& that& cancer,& tumour& stroma,& and& infiltrating& myeloid& cells& present& TAAs& in& a&
positive& coFstimulatory& context.& This& proposition& is& further& supported& by& a& recently&
submitted& study& by& Goyvaerts& et& al.,& where& vaccines& specifically& targeting& APCs& were&
inferior& to& broad& tropism& lentivector& vaccines! (Goyvaerts,& Lienenklaus& et& al.& 2015).& In&
addition,& intraFtumour& vaccination& is& cheaper& than& autologous& DC& therapy& and& thus&
more&amenable&to&translation&to&the&clinic.&While&there&are&several&strategies&combining&
TAAFspecificity& and& IL12& production& by& engineered& T& cells,& so& far& no& approach& has&
combined& PDFL1& silencing,& IL12& induction,& and& TAA& presentation& in& a& single& delivery&














through& a& more& rational& approach& (Liechtenstein,& Dufait& et& al.& 2012;& Escors,&
Liechtenstein& et& al.& 2013;& Liechtenstein,& PerezFJanices& et& al.& 2013).& As& DCs& can& be&
genetically& modified& with& various& gene& carrier& systems,& including& viral& vectors,& their&
maturation&status&can&be&modified,&thus&affecting&their&polarization&of&adaptive&immune&
responses& (Dullaers,& Breckpot& et& al.& 2004;& Breckpot& and& Escors& 2009).& Nowadays,&
immunotherapeutic&strategies&are&frequently&assessed&in&in#vitro/ex#vivo&DCFT&cell&assays&
before&their&use&in&in#vivo&experimental&models&(Gruber,&KanFMitchell&et&al.&2000;&Dyall,&
Latouche& et& al.& 2001;& Arrighi,& Pion& et& al.& 2004;& Yu,& Kovacs& et& al.& 2004;& Escors,&
Liechtenstein& et& al.& 2013).& Increasing& knowledge&of&DCFbased&mechanisms& led& to& their&
use& in& antiFcancer& immunotherapeutic& strategies& (Klein,& Bueler& et& al.& 2000;& Akazawa,&
Shingai&et&al.&2007;&Escors,&Lopes&et&al.&2008;&Breckpot,&AertsFToegaert&et&al.&2009;&Hu,&
Dai& et& al.& 2010;& Chiang,& Hagemann& et& al.& 2011;& Karwacz,& Bricogne& et& al.& 2011)& with&
promising& results& in& preFclinical& models& (Schnurr,& Galambos& et& al.& 2001;& Hegmans,&
Hemmes& et& al.& 2005;& Liu,& Shivakumar& et& al.& 2008).& However,& promising& therapeutic&
activities& could& not& always& be& translated& into& clinical& success& (Gitlitz,& Belldegrun& et& al.&
2003;&Zarour&and&Kirkwood&2003;&Escors,&Liechtenstein&et&al.&2013).!
What& are& the& reasons& for& the& apparent& discrepancy& between& preFclinical& and&
clinical&efficacy?&One&reason&is&that#in#vitro#models&do&not&reflect&the&in#vivo&context&and&
many& factors& influencing& immune& responses&are&disregarded.&The& second& reason& likely&
reflects&the&major&cause&for&this&discrepancy.&DCs&loaded&with&TAAs&and/or&modified&to&
mature& must& counteract& strong& and& systemic& immunosuppressive& activities& once&
transferred&to&cancer&patients.&Nevertheless,&the&possibility&of&differentiating&DCs&ex#vivo&
had& a& huge& impact& on& cancer& immunology& (Steinman& and& Banchereau& 2007;& Escors,&
Liechtenstein&et&al.&2013).&Here&I&propose&that&we&need&to&go&a&step&further&and&establish&
reproducible& ex# vivo& MDSC& differentiation& protocols& to& model& a& strong&
immunosuppressive& factor& in& vaccine& evaluation.& The& use& of& ex# vivo& differentiated&





increasing,&as&reflected&by&the& increase& in&the&number&of&publications&on&these&cells& in&
recent& years& (Escors,& Liechtenstein& et& al.& 2013)& (Fig.& 6.1).& Thus,& in& this& PhD& thesis& I&
proposed&that& the&establishment&and&use&of&MDSCFT&cell&assays&could&compliment& the&
use&of&DCFT&cell&assays&for&the&assessment&of&antiFcancer&treatments.&This&would&ensure&
that& antiFcancer& regimens& could& overcome& immunosuppressive& characteristics& of&
MDSCs,& making& it& a& more& faithful& model& in& cancer& immunotherapy& research.& This&
approach& could& save& resources,& time,& and& effort,& as& it& would& prevent& the& further&
development&of&treatments&that&are&inhibited&by&MDSC&activities.&In&fact,&it&is&becoming&
clear& that& certain& immunotherapeutic& and& chemotherapeutic& treatments& partially& owe&
their& efficacy& to& their& inhibition& of&MDSC& expansion& (Serafini,&Meckel& et& al.& 2006;& Xin,&
Zhang&et&al.&2009;&Iclozan,&Antonia&et&al.&2013).&Of&significance,&here&it&is&shown&that&ex#
vivo&MDSCs&were& amenable& to& lentivector&modification,& acquiring& APC& characteristics,&
leading&to&stimulation&of&antigenFspecific&immune&responses.&Our&group&and&others&have&
shown& that& splenic& and& tumourFinfiltrating&MDSCs& are&not& equivalent& (Maenhout,&Van&
Lint& et& al.& 2013;& Aliper,& FriedenFKorovkina& et& al.& 2014;& Dufait,& Schwarze& et& al.& 2015),&
highlighting& the& advantages& of& this& novel& ex# vivo& MDSC& differentiation& system.&
Importantly,&the&ex#vivo#MDSC&differentiation&system&has&already&been&used&by&our&close&
collaborators.&The&use&of&ex#vivo&B16FMDSCs&predicted&the&therapeutic&antiFmelanoma&




study& confirmed& that& the& ex# vivo& MDSC& differentiation& system& developed& in& this& PhD&
thesis& renders& a& high&MDSC& differentiation& efficiency& and& produces& large& numbers& of&
immunosuppressive&MDSCs&with&high&proliferative&potential.&The&study&by&Dufait&et&al.&
further& showed& that& the& novel&ex# vivo&MDSC&differentiation& system& can& be& applied& to&
different& tumour& models,& facilitating& MDSC& research& in& a& tumourFrelevant& manner&
(Dufait,&Schwarze&et&al.&2015).&
Several& studies& have& analysed&MDSCs& using& highFthroughput& methods& such& as&
proteome& characterization& by&mass& spectrometry.& These& studies& used&MDSCs& purified&
from&spleens&or&blood&of&tumourFbearing&mice,&thus&not&representing&tumourFinfiltrating&




the& differences& between& circulating& and& tumourFinfiltrating& MDSCs& have& become&
prominent,& researchers& have& started& using& purified& tumourFinfiltrating& MDSCs& in&
proteomic& studies.&A& recent& study&compared&splenic&and& tumourFinfiltrating&MDSCs&by&
gene&arrays,&further&emphasizing&the&difference&between&these&MDSC&populations.&This&
study& predicted& key& transcription& factors,& kinases,& and& proteases& within& the& MDSC&




throughput& studies.&Due& to& the& laborious&nature&of&using& tumourFinfiltrating&MDSCs& in&
studies&requiring&large&numbers&of&sample,&their&use&in&this&setting&has&been&limited.&Use&
of&MDSCs&in&highFthroughput&studies&will&aid&in&clarifying&several&issues&in&MDSC&biology&
as&well& as& facilitate& the&discovery&of&MDSCFspecific& targets.&A&main& challenge& in&MDSC&
biology& remains& their&heterogeneity,&making& it&difficult& to&distinguish& them&from&other&
myeloid&cell&types.&Thus&the&use&of&ex#vivo&MDSCs&alongFside&other&myeloid&cell&types&will&
be& able& to& clarify& fundamental& differences.& This& approach& was& used& in& this& thesis& to&
identify& differential& protein& expression& between& immature& BMFDCs& and& ex# vivo& B16F
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While& limited& efficacy& in& preventing& tumour& establishment& in& the& prophylactic&
setting&(a&single&survivor&mouse)&and&no&cure&rates&were&achieved&here,&it&was&proposed&
that& these& stringent& conditions& allow& for& a& more& realistic& and& practical& vaccination&
protocol.&I&strictly&implemented&a&single&vaccination&regimen&in&a&rapidly&growing&tumour&
model&lacking&surrogate&tumour&antigens.&The&use&of&OVA&antigen&is&a&convenient&way&of&
assessing& antigen& presentation& but& its& use& in# vivo& obscures& the& efficacy& of& antiFcancer&





A& significant& amount& of& time& and& resources& could& be& saved& if& antiFcancer& treatments&
would&be&assessed&in&more&realistic&preFclinical&assays.&Thus,&MDSCFT&cells&assays&using&
ex# vivo&MDSCs&were&performed& in& this& thesis,& showing& that& IL12Fp1Fbased& lentivectors&
could& overcome& the& immunosuppressive& functions& of& these& cells.& While& these& assays&
take& into& account& the& immunosuppressive& effect& of& MDSCs,& they& remain& another&
approximation& to& reality.& Additional& cell& types& and& immunosuppressive& mechanisms&
exist&in&the&tumour&that&may&prevent&MDSCs&acquiring&APC&activities.&All&in#vitro&assays&
are& undertaken& in& a& highly& controlled& environment.&While& this& is& important& to& dissect&
effects&from&an&experimental&point&of&view,&it&does&not&reflect&the&in#vivo&situation&within&
tumourFbearing&hosts.&&
It&was&not&possible& to& further& improve& the&human&MDSC&ex#vivo&differentiation&
protocol&within& the& time& frame&of& this& PhD& thesis.& Human&models& are& generally&more&
complicated&to&establish&and&this&holds&true&also&for&DC&ex#vivo&differentiation&protocols.&
Human& DCs& are& differentiated& from& PBMCs,& in& this& way& limiting& the& initial& supply& of&
immature& myeloid& precursors& and& making& the& system& less& efficient.& Nevertheless,& it&
remains& a& good& DC& differentiation& protocol& of& key& clinical& relevance& (Escors,&
Liechtenstein& et& al.& 2013).& Addition& of& several& endogenously& produced& growth& factors&
and& cytokines& will& surely& improve& the& human& ex# vivo& MDSC& differentiation& system&
presented& in& this& thesis.&An& improved&ex#vivo&human&MDSC&differentiation& system&will&
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represent&a&significant&step&forward.&Once&this&system&is&fully&developed,&human&MDSCs&
can& be& generated& by& patientFspecific& tumour& cells.& The& patientFspecific& ex# vivo&
differentiated& human& MDSCs& could& then& be& tested& in& mouse& models& with& patientF
derived&xenografts.&
The& first&successful&cancer& immunotherapy&clinical& trials&using& lentivectors&have&
recently& been& published& (Kalos,& Levine& et& al.& 2011;& Porter,& Levine& et& al.& 2011;&Maude,&
Frey& et& al.& 2014).& It& is& evident& that& the& use& of& lentivectorFbased& treatments& in& cancer&
patients&is&feasible,&effective,&and&possibly&safe,&although&a&number&of&issues&need&to&be&
taken& into& account.& Translation& of& lentivector& constructs& for& use& in& clinical& practice&
entails& elaborate& production& and& purification& procedures,& safety& measures,& and& high&
costs.&Thus,&ensuring&GMP&(good&manufacturing&practice)Fgrade& lentivector&production&
remains& a& barrier& to& lentivectorFbased& treatments.& Lentivector& production& systems&
should& be& improved,& as& the& establishment& of& stable& producer& cell& lines& remains& a&
challenge.& Stable& producer& cells& lines& would& decrease& production& costs& and& lead& to&
higher&quality&and&safer&vector&particles.&Significant&steps&forward&have&been&undertaken&
very& recently& to& implement& such& an& efficient& GMP& lentivector& production& system&
(Sanber,& Knight& et& al.& 2015).& In& this& way,& lentivectors& can& be& continuously& produced&
without& the& need& of& transiently& transfecting& the& transfer,& packaging,& and& envelope&
plasmids.& Safety&measures& need& to& ensure& that& no& replication& competent& retroviruses&
can& arise& in& treated& patients& and& that& no& insertional& mutagenesis& or& other& genotoxic&
events& are& initiated& by& these& treatments& (Liechtenstein,& PerezFJanices& et& al.& 2013).&
Nevertheless,&improvement&of&lentivector&production&is&a&worthy&pursuit&to&facilitate&the&
application&of&lentivectorFbased&treatments&in&human&gene&therapy.&
Gene& therapy& techniques& have& become&more& efficient& and& safer& over& the& last&
decade&and&a&milestone& in&cancer& immunotherapy&using& lentiviral& vectors&has& recently&
been& achieved.& Clinical& trials& with& CAR& T& cells& have& shown& highly& promising& clinical&
responses& and& have& emphasized& the& viability& of& cancer& immunotherapeutic& strategies&
using&lentivectors&(Kalos,&Levine&et&al.&2011;&Porter,&Levine&et&al.&2011;&Maude,&Frey&et&al.&
2014).& As& cancer& immunotherapy& has& been& largely& ineffective& in& the& last& decades,& the&




of& tumourFinfiltrating& MDSCs& is& expensive,& timeFconsuming& and& inefficient.& The&
development&of& this& novel&ex# vivo&MDSC&differentiation& system& facilitates& research&on&
MDSC& biology& and& identification& of& targets& for& therapy.& Using& these& cells& an& MDSCF
specific& target& was& identified& by& quantitative& proteomics,& P450R.& Currently& our&
laboratory&is&continuing&the&work&initiated&in&this&PhD&thesis&by&silencing&other&proteins&
identified&by& this&proteomic&study,&especially& the&ones& involved& in&ROS&generation&and&
protection&against&oxidative&damage.&These&studies&of&MDSC&biology&are&possible&as&ex#
vivo# MDSCs& and& their& precursors& can& be& transduced& by& lentivectors.& By& silencing& or&
activating&genes&of&interest&we&will&gain&enhanced&insight&into&MDSC&biology&and&identify&
further&MDSCFspecific&targets.&&
Characterization& of& MDSCs& will& in& turn& facilitate& the& discovery& of& MDSC&
therapeutic& targets,& which& remains& the& most& prominent& application& of& MDSC& ex# vivo&
differentiation& systems.& Several& strategies& are& being& developed& to& target& MDSCs& for&
cancer& immunotherapy.& These& strategies& include& MDSC& differentiation/maturation,&
MDSC&depletion,&MDSC& inhibition,&and& inhibition&of&MDSC&recruitment& (Albeituni,&Ding&
et&al.&2013;&Jiang,&Guo&et&al.&2014).&Further,&MDSCs&could&be&used&as&vehicles&to&deliver&
cancerFtargeting&molecules&to&the&tumour&site&(Chandra&and&Gravekamp&2013;&Chandra,&
Jahangir& et& al.& 2013).& The& wide& variety& of& MDSCFtargeting& therapies& and& the& issue& of&
cancerFspecific&MDSC&phenotypes&require& large&numbers&of& tumourFspecific&MDSCs& for&
highFthroughput& drug& testing.&Moreover,&MDSC& biology& can& equally& be& applied& to& the&
fight&against&pathogenic& infections&or& in&the&field&of&autoimmune&diseases.&An&efficient&
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